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Résumé 
Le virus de l’hépatite C (VHC) infecte ~185 millions d’individus dans le monde. 
Malgré le développement des nouvelles thérapies dirigées contre le VHC, on compte  deux 
millions de nouvelles infections chaque année, en particulier dans les pays sous-développés et 
les populations marginalisées. Comme pour la plupart des virus à infection chronique, le 
développement d’un vaccin prophylactique efficace est limité par le manque  de 
caractérisation des déterminants de la mémoire immunitaire protectrice lors des épisodes de 
réinfection naturelle chez les êtres humains. Le VHC représente un modèle unique au sein des 
virus à infection chronique pour étudier l’immunité protectrice. En effet ~30% des patients 
infectés par le VHC peuvent être guéris suite à un premier épisode d’infection spontanément. 
Dans cette thèse, nous avons étudié l’immunité protectrice contre le VHC dans une 
cohorte d’utilisateurs de drogues par injection qui sont à risque d’être infectés ou réinfectés. 
Notre hypothèse est que la majorité des patients qui ont résolu une première infection par le 
VHC sont protégés contre le développement d’une infection chronique s’ils sont réexposés. 
Cette immunité protectrice est associée à la présence des cellules T CD4 et CD8 
polyfonctionnelles qui possèdent des fréquences, magnitudes et avidités  élevées. La capacité 
protectrice des cellules T mémoire contre les séquences variables du VHC est dépendante de 
la diversité et flexibilité du répertoire de leurs récepteurs de cellules T (TCR), qui 
reconnaissent les séquences variables des épitopes ciblés. 
Notre premier objectif était de définir et détailler les déterminants de l’immunité 
protectrice conférée par les cellules T spécifiques du VHC. Nos résultats ont montré que la 
protection pendant l’épisode de réinfection était associée à une augmentation de la magnitude 
et du spectre des réponses spécifiques par les cellules T CD4 et CD8 polyfonctionnelles, ainsi 
que par l’apparition d’une population de cellules T tétramère+ CD8+  effectrices qui 
expriment faiblement le marqueur CD127 (CD127lo) lors du pic de la réponse. Chez les 
patients qui ont développé une infection chronique pendant l’épisode de réinfection, nous 
avons observé une expansion très limitée des cellules T CD4 et CD8. Le séquençage des 
épitopes ciblés par les cellules T CD8 chez ces patients qui sont non-protégés a montré que les 
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séquences de ces épitopes sont différentes des séquences de référence qui étaient utilisées pour 
tous les essais immunologiques de cette étude.    
Le deuxième objectif était d’analyser la dynamique du répertoire des TCRs des cellules 
T CD8 spécifiques chez les patients protégés versus les patients non-protégés. Nos résultats 
ont montré que le répertoire des cellules T CD8 spécifiques est plus focalisé que chez les 
patients protégés. En plus, nous avons observé que les clonotypes qui forment le répertoire 
chez les patients protégés sont distincts de ceux chez les patients non-protégés. Ces clonotypes 
chez les patients protégés ont montré de plus grandes avidité et polyfonctionnalité que leurs 
homologues chez les patients non-protégés.  
En conclusion, nos résultats suggèrent que la protection contre le développement d’une 
infection chronique pendant l’épisode de réinfection par le VHC est associée à une 
augmentation de la magnitude, du spectre et de la fonctionnalité des réponses des cellules T 
spécifiques, ainsi qu’à un répertoire des TCRs plus focalisé composé des clonotypes distincts 
qui possèdent de plus grandes avidité et polyfonctionnalité que chez les patients non-protégés. 
L’homologie des séquences des souches virales entre les différents épisodes de l’infection est 
un déterminant majeur de l’établissement d’une protection efficace.  Ces résultats ont donc des 
implications très importantes pour le développement d’un vaccin prophylactique contre le 
VHC et d’autres virus à infection chronique.    
 
Mots-clés : Virus de l’hépatite C (VHC) – Mémoire immunitaire – Réinfection par le VHC – 
Immunité protectrice – Répertoire des cellules T 
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Abstract 
Hepatitis C virus (HCV) currently infects ~185 million individuals worldwide. Despite 
the development of new effective antivirals against HCV, it is estimated that two million new 
infections occur annually, especially among marginalized populations and in developing 
countries. As with many chronic viral infections, the development of an effective prophylactic 
vaccine is hampered by the limited knowledge of determinants of a protective immune 
response in humans upon natural exposure to the virus. HCV represents a unique model to 
study protective immunity in chronic viruses, since ~30% of the patients are able to clear the 
primary infection spontaneously. 
In this thesis, we proceeded to study protective immunity against HCV in cohorts of 
injection drug users (IDUs) who are continuously at risk of infection and reinfection by HCV. 
We hypothesized that the majority of spontaneous resolvers of a primary HCV infection are 
protected against chronicity of infection upon re-exposure. Protective immunity would likely 
be associated with the highest breadth, frequency and functional avidity of HCV-specific 
polyfunctional CD4 and CD8 memory T cells. The protective capacity of memory T cells 
upon infection with novel HCV variants will depend on the diversity and flexibility of the T 
cell repertoire that can recognize these viral variants and/or the capacity to generate de novo T 
cell responses specific for these variants.  
The first aim of the project was to define and dissect correlates of protective immunity 
conferred by HCV-specific T cells in reinfected individuals. Our results showed that 
protection from chronicity upon reinfection was associated with an increased magnitude and 
breadth of the HCV-specific polyfunctional CD4 and CD8 T-cell responses, as well as the 
appearance of a CD127lo tetramer+ CD8+ effector T-cell population at the peak of the 
response. Individuals who developed persistent viremia upon HCV reinfection demonstrated 
very limited or no expansion of HCV-specific T cells. Sequencing of the cytotoxic T-
lymphocyte (CTL) epitopes targeted by the memory immune response in unprotected 
individuals revealed that the sequence of the autologous reinfecting virus was different from 
the reference sequence used in our immunological assays.  
The second aim was to analyse the dynamics of the T-cell receptor (TCR) repertoire of 
HCV-specific CD8 T-cells in protected versus unprotected patients and in relation to infection 
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with variant viral sequences. Our results demonstrate that for epitope-specific CD8 T cells a 
more focused TCR-repertoire of distinct clonotypes was associated with protection. These T-
cell populations showed higher functional avidity and polyfunctionality compared to their 
counterparts in non-protected patients. The clonotypes forming the effector T-cell population 
during reinfection were recruited from the memory pool, rather being de novo responses 
generated from the naïve pool. 
In conclusion, our results suggest that protection from persistence upon HCV 
reinfection is associated with an enhanced magnitude, breadth and quality of the HCV-specific 
T-cell response, as well as a more focused TCR-repertoire of distinct clonotypes with high 
functional avidity. The degree of homology between viral strains causing the consecutive 
episodes of infection is a critical determinant for protection. These findings provide a first 
insight into the correlates of protective immunity against HCV and have important 
implications for the rational design of effective prophylactic vaccines against HCV and other 
chronic viruses.  
 
Keywords:  
Hepatitis C Virus (HCV) – Memory immune response – HCV reinfection – Protective 
immunity – T-cell receptor (TCR) repertoire 
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CHAPTER 1: 
INTRODUCTION 
 
(Parts of this introduction were used in the review article  
“Protective Immunity against Hepatitis C: Many Shades of Gray”,  
Frontiers in Immunology, 2014) 
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The rational design of prophylactic vaccines against chronic viral infections 
necessitates dissection of the correlates of protective immunity that remain undefined to date. 
Hepatitis C virus (HCV) represents a unique model among chronic viruses where two 
dichotomous outcomes of infection are observed: spontaneous resolution or chronic infection. 
Thus it represents an ideal model for understanding determinants of the memory immune 
response that can confer protection upon re-exposure to the virus in a human cohort. 
This introduction discusses what is known about primary and memory immune 
responses against chronic viral infections, followed by a more specific review of the literature 
about the primary and memory immune responses against HCV infection. It also gives a brief 
account of different aspects of HCV; characteristics of the virus, the infection caused by HCV, 
treatment strategies and HCV-vaccine trials.  
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1.1. Immunity against primary viral infection 
The human immune system is composed of two interconnected lines of defence; innate 
immunity and adaptive immunity. Innate immunity is non-specific, as it recognizes common 
motifs shared by interrelated pathogens known as “Pathogen Associated Molecular Patterns” 
(PAMPs), while adaptive immunity is highly specific and recognizes specific pathogen 
derived peptides known as antigens (Ags) or epitopes. Furthermore, adaptive immunity is 
privileged by its ability to generate immunological memory, which has the capacity to respond 
more rapidly to subsequent exposures to an Ag that has been previously encountered (also 
known as, the recall response). 
Innate immunity is the first line of defence triggered by foreign pathogens including 
viruses. Cells of innate immunity include monocytes, natural killer cells (NKs) and dendritic 
cells (DCs) [1]. NKs have direct cytotoxic action and can kill infected cells. In addition, they 
possess antiviral action through secretion of inflammatory cytokines such as interferon-gamma 
(IFN-γ) and tumor necrosis factor-alpha (TNF-α) [2], as well as having the ability to stimulate 
maturation of DCs that represent the link between innate and adaptive immunity (Figure 1) 
[3]. NK cell activity is triggered by reduced expression of the major histocompatibility 
complex (MHC) class I molecules on the surface of infected cells, known as the “missing self” 
hypothesis. The extent of NK cell activation is determined by the balance of interaction 
between the activating and inhibitory receptors on NK cells and their corresponding ligands 
expressed on target cells. These receptors include members of the killer cell immunoglobulin-
like receptors (KIRs) family and the NKG2 family [4, 5]. DCs are the main professional 
antigen presenting cells (APCs) involved in priming naïve adaptive immune cells known as T 
cells [6]. There are two main populations of DCs: myeloid DCs (mDCs) and plasmacytoid 
DCs (pDCs). The mDCs are the major APCs involved in antigen uptake and presentation, 
while pDCs mainly produce IFN-α and act as overall orchestrators of the immune response. 
DCs become activated upon recognition of PAMPs by cell surface and/or intracellular 
receptors [7]. 
Adaptive immunity has two arms that evolved to provide distinct functions; humoral 
immunity and cell-mediated immunity (CMI). The humoral immune response is comprised of 
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B cells that produce antibodies (Abs) that mainly target extracellular microorganisms (e.g. 
bacteria), but also neutralize intracellular pathogens (e.g. viruses) by targeting surface epitopes 
to prevent viral binding and entry into target cells. Abs also help in the destruction of infected 
cells by Ab-dependent cellular cytotoxicity (ADCC), where specific Abs bind to cell surfaces 
using their variable Ag-binding fragment (Fab) recognizing a specific Ag and their constant 
portion (Fc) binds to the Fc-receptors on NK cells and/or monocytes and activates their 
cytotoxic functions [6]. Cell-mediated immunity mainly targets intracellular pathogens (e.g. 
viruses) and abnormal cells like cancer cells, and it is comprised of CD8 T cells, known as 
cytotoxic T lymphocytes (CTLs) and CD4 T cells that act as helper T cells. CD8 T cells 
recognize and kill cancer cells and virus infected cells expressing foreign Ags/epitopes on 
their cell surface in the form of peptides bound to MHC class I molecules. CD8 T 
lymphocytes kill infected/cancerous cells by secreting pore-forming molecules inducing cell 
lysis (granzymes and perforin) or through ligand-mediated initiation of programmed cell death 
(e.g. Fas-FasL interactions). CD8 T cells also secrete cytokines (e.g. IFN-γ and TNF-α) that 
have direct antiviral effects and can activate other effector cells [8]. CD4 T cells, were 
previously divided into two major helper subsets; T helper 1 cells (Th1), that help priming and 
sustaining CTL responses, and Th2 that secrete specific cytokines that help activate B cells and 
promote them to differentiate into plasma cells and produce Abs [9]. More recently other CD4 
T-cell subsets were identified that regulate different aspects of the immune response and 
include Th17 cells that mediate inflammation and response to microbial pathogens, regulatory 
T cells (Tregs) that regulate different immune responses and follicular helper T cells (Tfh) cells 
that regulate formation of germinal centers for the initiation of antibody responses. 
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Figure 1: Innate and adaptive immune responses in humans using hepatitis C virus 
(HCV) as a model. 
Reproduced with the permission of Frontiers scholarly communications: Frontiers in 
Immunology [10], author copyrights 2014. 
Legend: (1) Pathogen entry and replication induces the production type I IFNs that are also 
secreted by pDCs and create a defensive state and stimulate NK cells that kill infected 
hepatocytes. (2) APCs (especially DCs) uptake apoptotic bodies from destroyed infected cells 
and present epitopes to both CD4 and CD8 T cells in the context of MHC class II and MHC 
class I, respectively. (3) The cross-talk between DCs and NKs regulates the function of both 
cells enhancing antigen presentation and priming, as well as NK-mediated killing. (4) CD4 
helper T cells support responses of CD8 T cells and B cells through production of Th1 and 
Th2 cytokine, respectively. (5) Abs produced from B cells could have an essential role in 
pathogen clearance by directly neutralizing the pathogen or by mediating ADCC. Tfh cells 
play an essential role in mediating the selection and survival of B cells. (6) CD8 T cells 
eliminate pathogen-infected cells through direct cytotoxic mechanisms (cytolytic granules, as 
perforin and granzyme) or non-cytolytic mechanisms through secretion of the antiviral 
cytokines IFNγ and TNFα or through ligand-mediated initiation of programmed cell death 
(e.g. Fas-FasL interactions). (7) CD8 T cell functions are sustained and enhanced by IL-21 
mainly produced by Th17 cells. IL-21 is also essential to rescue virus-specific T cells from 
exhaustion caused by persistent exposure to HCV antigens. Reduced IL-21 production or 
Th17 cell numbers results in an increased exhaustion status and expression of exhaustion 
markers like PD-1, Tim-3, CTLA-4, and others. (8) Regulatory T cells might be a cause in the 
failure of the primary immune response by secreting the regulatory cytokines TGFβ and IL-10, 
or secretion of Gal-9 that enhances apoptosis of Tim-3+ CD4 and CD8Tcells. 
ADCC, antibody-dependentcellular cytotoxicity; APC, antigen-presenting cell; CTLA-4, 
cytotoxic T lymphocyte antigen-4; DC, dendritic cell; FcR, receptor for the constant fragment 
of the antibody; Gal-9, galactin-9; Gz, granzyme; HCV, hepatitis C virus; IFN, interferon; IL, 
interleukin; NK, natural killer; PD-1, Programed death-1; pDC, plasmacytoid DC; Tfh, T 
follicular helper cells; TGF, transforming growth factor; Th17, T-helper 17 cell; Tim-3, T cell 
immunoglobulin and mucin domain 3;TNF, tumor necrosis factor;Treg, regulatoryT cell. 
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1.2. Immunological memory and vaccines against viruses 
Immunological memory is the ability to mount a specific accelerated recall response by 
antigen experienced T- and B-lymphocytes against a previously encountered pathogen [11-
13]. The memory immune response is also characterized by the increased frequency of 
antigen-specific lymphocytes with improved recognition and function [14, 15], as well as 
enhanced trafficking, migration and localisation at the site of infection [16, 17]. 
Most of our current knowledge about immunological memory against viruses is based 
on studies of the lymphocytic choriomeningitis virus (LCMV) infection in mouse models. 
LCMV is an excellent infection model, since its different strains have distinct courses of 
infection; where the Armstrong strain causes an acute infection cleared within a few days, as 
opposed to LCMV-clone 13 that leads to chronic infection and serves as a model that would 
correspond to human chronic viral infections (e.g. HIV and HCV) [18]. It is only recently that 
these findings were validated in human viral infections [19].  
1.2.1. Generation of memory immune responses 
Naïve B cells are activated and proliferate when they encounter their specific antigen 
for the first time. Activated B cells either remain in the marginal zone of T cells within lymph 
nodes and differentiate into short-lived plasma cells or migrate to B cell follicles initiating a 
germinal centre (GC) reaction. Within the GC, B cells undergo somatic hypermutation, 
affinity maturation and selection leading to the generation of high affinity memory B cells. 
The GC formation requires help from Tfh CD4 T lymphocytes [20, 21].  
Development of memory T cells (Tmem) includes three phases (Figure 3);  
Phase I (Expansion): activation and expansion of Ag-specific T-cell clones that have 
recognized their specific Ag within the context of MHC molecules, and with adequate 
costimulation these T cells differentiate into effector T cells (Teff).    
Phase II (Contraction): after resolution of infection the majority (~90%) Teff die by apoptosis. 
Phase III (Maintenance): establishment of the Tmem niche (from the remaining ~10% of Ag-
specific T cells) [22]. 
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Two models for the development of Tmem were proposed, the linear/progressive model 
and the asymmetric/bifurcative/stochastic model. Evidence supporting both models is 
equivocal, thus it remains unclear whether the pathway is linear or asymmetric, and whether it 
is one-way or reversible. The linear model proposes that activated naïve T cells develop into 
Teff then a proportion of those Teff differentiate into Tmem that are either effector-memory T 
cells (TEM) or central-memory T cells (TCM) (Figure 2). This was supported by microarray 
analysis of the gene-expression program of T cells in the LCMV model showing that 
acquisition of Tmem cell traits was gradual and was still occurring several weeks after viral 
clearance. This suggests that the 5-10% of the surviving Teff are promoted to Tmem by 
completing a gradual program of differentiation and acquisition of all memory properties [23]. 
An interesting study of SIV-infected monkeys treated with bromodeoxyuridine (BrdU) 
demonstrated the progression of labelled cells, from TCM to TEM and finally to terminally-
differentiated T cells (TEMRA) representing the end-stage of T-cell development [24] (different 
T-cell subsets are explained in detail in section 1.2.4.). These results suggest that memory 
subsets are not independent, but rather share a common differentiation pathway, supporting 
the linear model [25]. On the other hand, the asymmetric model suggests that a single naïve T 
cell once primed gives rise to a heterogeneous population of Ag-specific T cells, and that the 
different populations of T cells of all phases are programmed for their final fate shortly 
following antigenic stimulation [26]. This early imprinting of a specific developmental 
program is reflected in changes in the gene expression that occur shortly after priming of naïve 
T cells [27]. Asymmetric T-lymphocyte division during early steps of initiation of the adaptive 
immune response were demonstrated in a mouse model of Listeria monocytogenes [28]. 
Important issues concerning generation of immunological memory remain to be 
resolved. First, what factors determine which cells would express memory T-cell markers 
versus those that become short-lived effector cells? Second, are those factors intrinsic, 
extrinsic or both? Finally, is it predetermined for CD8 T cells to become Tmem from the earliest 
point of priming or is it a stochastic process occurring later during the activation process? [11]. 
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Figure 2: Possible models for memory T-cell differentiation. 
Reproduced with the permission of Macmillan Ltd: Nature Reviews in Immunology [29], 
author copyrights 2009. 
Legend: (A) The linear model versus (B) the asymmetric model for the generation and 
differentiation of memory T-cell populations.  
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1.2.2. Maintenance of immunological memory  
The Tmem population remains stable at a nearly constant number for many years. BrdU 
labelling of T cells in a mouse model showed that Tmem cells maintain their numbers by 
continuously dividing [30]. Homeostatsis of Tmem is achieved through slow turnover balanced 
by both survival and death [11]. Survival of Tmem will depend on intrinsic properties of T cells, 
but also on the space available in the anatomic niche that is accessible to memory cells [31]. 
The dogma of the space limitation is challenged by a recent study showing that the memory 
niche is subject to expansion [32]. 
Homeostatsis of Tmem is regulated by common γ-chain cytokines as interleukin-7 (IL-
7), IL-15 and IL-21 [33]. IL-7 is essential for the generation and basic survival of Tmem. This 
was partially attributed to its ability to sustain the expression of B-cell lymphoma-2 regulator 
protein (Bcl-2), which is an important anti-apoptotic protein [34, 35]. Expression of the IL-7 
receptor alpha chain (IL-7Rα/CD127) was not sufficient for the formation of a CD8 Tmem 
population during viral infection [36], but it was necessary for Tmem generation and identifies 
T cells that give rise to a long-lived memory population [37]. IL-15 is another important 
cytokine for homeostasis, but mainly for the stage of maintenance of Tmem [38]. This was 
demonstrated in mice deficient in IL-15 or IL-15Rα, since they could still generate LCMV-
specific CD8 Tmem, but they declined in number faster than in normal mice and regained their 
proliferative capacity when transferred to wild-type (WT) mice with intact IL-15/IL-15Rα 
[39-41]. Under steady-state conditions, Tmem slowly turn over, even in the absence of the Ag, 
depending on the constitutive production of IL-7 and IL-15 [42]. IL-21 was also shown to be 
important for maintenance of Tmem by preventing their exhaustion [43]. 
Whether maintenance of B and T cell memory requires continuous Ag stimulation (or 
even intermittent stimulation) is still controversial. In several mouse models it has been shown 
that T cells may persist indefinitely in the absence of Ag [44, 45]. This was confirmed by 
observations in humans, where specific memory was preserved despite lack of exposure to the 
pathogen for many years. Long-term immunological memory was reported for measles on the 
Faroe Islands (where the population was not exposed to the pathogen for 65 years) [46], 
yellow fever in Virginia (75 years) [47], or polio in remote Eskimo villages (40 years) [48]. 
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However, these studies did not specify whether those memory cells would be protective [49, 
50]. In contrast, results from other human studies suggest that the presence of Ag plays a role 
in maintaining memory (reviewed in [13]). Epidemiological studies confirm this concept by 
demonstrating that the levels of memory responses are higher in people who continue to live 
in endemic regions than in individuals who leave those areas [11]. To reconcile those 
seemingly contradicting findings, it was proposed that even in the absence of reinfection and 
re-exposure to Ag there is maintenance of Ag presence on follicular DCs (fDCs) trapped in 
immune complexes in the GCs for months or even years after the resolution of infection [51, 
52]. Another possible mechanism is that lymphocytes might undergo low affinity interactions 
with self-Ags [53]. A third explanation could be that there is periodic re-exposure to the 
antigen(s) due to asymptomatic exposures to the same pathogen (or a closely similar 
pathogen). 
Longevity of memory also depends on inherent properties of the lymphocytes, as their 
division potential. Telomere shortening is an important mechanism for limiting the number of 
cell-divisions, where rapidly dividing cells/populations reach senescence before slowly 
dividing ones [54]. Despite up-regulation of telomerase to limit telomere shortening, it will 
ultimately reach the Hayflick limit and cell division will be arrested [55]. Different 
proliferation rates are required for continuous replenishment of memory pools according to 
their life spans; where TEM have a proliferation rate of 4.7% per day compared to 1.5% for 
TCM [56]. 
1.2.3. Characteristics of a memory immune response 
The memory immune response is characterized by having more rapid kinetics upon re-
exposure to the same Ag. Many studies in animal models reported this finding; for example, 
rechallenging chimpanzees with HCV showed that memory immune cells responded in a 
much shorter time than that required for naïve cells to respond to primary infection [57].  
A second important characteristic of the memory immune response is the increased 
frequency of the specific lymphocytes targeting the Ag. It was shown in the LCMV model that 
CD8 T cell precursors specific for a certain epitope occur at a frequency of about 1 in 105 CD8 
T cells (~100-200 cells). At the peak of the immune response these specific cells expanded to 
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reach ~107 cells. After the resolution of infection, a memory pool of ~ 5x105 cells was present 
[45]. Other reports confirmed that Ag-specific cells are 20- to 1000-fold more prevalent after 
primary exposure than in naïve mice [14]. 
Third, memory immune cells show improved recognition and responsiveness to their 
specific Ags upon re-exposure. The nature and magnitude of stimulatory and co-stimulatory 
signals required for activation of lymphocytes differ between naïve and memory populations. 
Memory B cells were shown to respond more effectively than naïve B cells and to lower 
concentrations of Ag and with less help from helper CD4 T cells [58]. This was suggested to 
be due to somatic mutations of immunoglobulin (Ig) genes that take place upon primary 
exposure [59]. Memory T cells also have enhanced proliferation and more rapid differentiation 
into effectors in response to lower doses of Ag when compared to naïve T cells [15]. Some of 
these changes have been attributed to alterations in T-cell signalling, thus leading to less 
stringent requirements for Ag presentation, costimulation and help [60].  
Fourth, altered trafficking contributes to the accelerated secondary response. Where 
Tmem, TEM in specific, are more predominant in non-lymphoid organs and preferentially 
migrate through different peripheral tissues enabling them to perform surveillance where 
infections usually start and concentrate at the initial site of Ag encounter which is the most 
probable site of reinfection [61]. In contrast, naïve cells mainly circulate the blood and lymph 
nodes (LNs) [62]. This is attributed to lower level of expression of the LN-homing receptors 
such as the C-C motif chemokine receptor type 7 (CCR7) and L-selectin (CD62L) (both 
detailed in section 1.2.4) [16]. 
Fifth, memory T cells were shown to have improved effector functions than naïve 
cells. As naïve cells get primed during the primary immune response they are educated 
through the signals they receive, and as they differentiate into memory cells their gene 
expression is reprogrammed to enable the production of more cytokines. CD4 T cells that are 
able to produce high levels of one cytokine only (IL-2) when they are naïve, gain the capacity 
to produce other cytokines at high levels as they develop into differentiated Tmem, becoming 
polyfunctional rather than monofunctional like their naïve counterparts [17]. Similarly, genes 
encoding IFNγ and cytotoxic proteins are not expressed in naïve CD8 T cells, but 
constitutively expressed in CD8 Tmem [23].  
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Sixth, differences in proliferation kinetics have been observed for Tmem in comparison 
to naïve T cells. This could be attributed to the difference in telomere length, which is shorter 
in Tmem than naïve cells, and is reflected in the more rapid turnover of Tmem and their limited 
number of cell divisions [12]. Nevertheless, heterogeneity of proliferative capacity exists 
among the different subpopulations of both Tmem and naïve T cells [56, 63].   
Finally, the relative contributions of humoral versus cell-mediated immunity 
(antibodies versus CD8 and CD4 T cells) during primary and secondary viral infections seem 
to be different. Using smallpox as a model, it was shown that mice lacking Ab responses had 
comparable rates of viral clearance during primary infection as WT mice indicating that CD8 
T cells had the predominant role [64]. In contrast, in a reinfection setting pre-existing 
neutralizing Abs (nAbs) represented the first line of defense against the virus [50].  
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Figure 3: Generation and maintenance of T-cell memory. 
Reproduced with the permission of Cell Press: Immunity [65], author copyrights 2009. 
Legend: The diagram depicts the dynamics of Ag-specific T cells at various stages after 
priming and boosting the immune response. The total number of T cells (black line) is the sum 
of the effector T cells activated during the primary response (red line) and the memory 
population generated following the clearance of the Ag (green line). Some proposed 
intermediate populations are also represented (yellow and violet lines). 
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1.2.4. Memory T cell subsets 
Memory T cells represent a heterogeneous population. The different subsets of Tmem 
are associated with the expression of specific surface receptors and intracellular 
molecules/transcription factors, and this is linked to their differential requirements for 
stimulation, survival, homing and some effector functions [66].  
These subsets are mainly classified according to the expression of the surface 
molecules involved in homing to lymph nodes; CCR7 and CD62L. CD62L mediates 
attachment and rolling to walls of high endothelial venules (HEVs). CCR7 binds to the C-C 
motif chemokine ligand 19 (CCL19) and CCL21 on endothelial cells causing arrest of 
movement and extravasation [67]. Combined expression of adhesion molecules and 
chemokine receptors allow tissue-specific targeting of T cells [68]. CD62Lhi CCR7hi Tmem 
cells are located predominantly in the lymph nodes and constitute the central memory T 
population. Effector memory T cells are CD62Llo CCR7lo and mainly circulate the blood and 
peripheral tissue [69]. Distinct CD8 T-cell subsets have differential functional profiles, where 
TCM mainly produce IL-2 and TEM produce effector cytokines as IFNγ and TNFα [70]. 
Additional markers better distinguish the different subsets. These include markers 
involved in T-cell activation (e.g. CD45RA or CD45RO), costimulation/maturation markers 
(e.g. CD27 or CD28), regulation markers (e.g. programmed death-1 (PD-1)) and cytokine 
receptors (e.g. CD127/IL-7Rα). General phenotypic profiles emerge within the heterogeneity 
of T-cell population (Figure 4). TCM (CCR7+ CD45RA- CD27+ CD28+) express low levels of 
PD-1, but high levels of CD127 and CD62L, in contrast, to terminally-differentiated cells 
(TEMRA) having an opposite phenotype (CCR7– CD45RA+ CD27– CD28–) [66].  
Ag-specific CD8 T cells display unique profiles depending on their viral specificity; 
where HCV-specific CD8 T cells are predominantly CCR7+ CD27+ CD28+, whereas for 
human immunodeficiency virus (HIV) they are mainly CCR7– CD27+ CD28– and for 
cytomegalovirus (CMV) they are mainly CCR7– CD27– CD28– [71]. Interestingly, the 
phenotypic profiles of CD4 T cells specific for the corresponding viruses are also present with 
similar distributions [64, 72, 73]. This may be related to the nature of the infection (resolved, 
latent or chronic), as well as the site of infection.  
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Figure 4: Different subsets of human T cells and their phenotypic attributes. 
Reproduced with the permission of John Wiley & Sons publications: Cytometry Part A [66], 
author copyrights 2008. 
Legend: Different homing and activation markers that distinguish the various stages of 
differentiation of CD8 T cells (upper half), and the level of expression of these markers, as 
well as markers of activation, co-stimulation and regulation at the different phases of 
differentiation (lower graph). 
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1.2.5. Immunological memory at the clonal level 
Another level of complexity is that Tmem subsets and even T-cell populations specific 
for a single epitope are formed of heterogeneous clones of T cells bearing different T-cell 
receptors (TCRs). It is the additive function of these clones and their differential capacity to 
recognize antigen that would finally determine the efficacy of the memory response [13]. 
However, some Ag-specific CD8 T-cell clones can dominate the total effector CD8 response, 
especially during the initial phase of the response [74-76]. The clonal repertoires of Tmem 
subsets could be different (e.g. the repertoire of TEM could be distinct from the TCM-repertoire) 
[77]. 
1.2.5.1. Generation of TCR diversity 
The adaptive immune system has evolved to generate a large number of T-cell 
clonotypes, each expressing a unique TCR. The TCR is formed of a heterodimer of the α and 
β chains (Figure 5). The variable region of both chains is generated by somatic recombination 
of genes encoded by the variable (V) and junction (J) gene segments, in addition to the 
diversity (D) gene segment for the β chain. Regions of hypervariability are encoded within the 
V gene segments, these are known as complementarity-determining regions (CDRs). CDR3 of 
the β-chain is formed by combinatorial and junctional variation and is characteristic for a 
specific clonotype. During T-cell development, gene segments recombine and are spliced to 
form a unique TCR for each T-cell clone [78]. To add to the diversity, the recombination 
process involves random addition and deletion of nucleotides to/from the ends of V, J and D 
gene segments. Mathematically, this would lead to the generation of a TCR repertoire of > 
1015 different TCRs in humans. However, positive and negative selection in the thymus leaves 
only ~107 T-cell clonotypes with unique TCR amino acid sequences forming the human 
repertoire [79]. 
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Figure 5: Generation of TCR diversity by recombination of TCR gene segments. 
Reproduced with the permission of Macmillan Ltd: Nature Reviews Immunology [78], author 
copyrights 2006. 
Legend: (A) TCRs are formed of heterodimers of both α and β chains. They are generated by 
gene recombination of the V and J gene segment (and for the β-chain, also the D gene 
segment). During T-cell development, genes segments recombine and are spliced together to 
form a single functional αβ TCR unique for each T-cell clonotype (B) Regions of 
hypervariability (CDRs) are encoded in the V gene segments. The diversity of the TCR 
repertoire is further increased due to lack of precision during gene rearrangements. 
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1.2.5.2. Impact of TCR diversity on the viral immune response 
Given the huge number of different T-cell clonotypes with unique TCRs present in the 
repertoire, it would not be expected that the same clonotype could be found in different 
individuals. A rarer event would be that a specific clonotype would be responding to a 
particular epitope in several individuals. Surprisingly, specific T-cell clonotypes were detected 
recurrently in different individuals against the same viral epitopes, referred to as a “public” T-
cell clonotype [79]. Several models and explanations have been proposed to explain this 
phenomenon [80, 81]. A decisive factor in the selection of the clonotype(s) that would 
participate in the initial response against a specific epitope is the TCR fitness measured by its 
functional avidity. Functional avidity is a determinant of T-cell efficacy that reflects the ability 
of specific T-cell clonotypes to recognize peptide-MHC (p-MHC) complexes. Higher avidity 
of a clonotype/TCR would mean the recognition of p-MHC at lower densities on cell surfaces, 
leading to more rapid proliferation and more rapid induction of effector responses. This is 
usually associated with prompt elimination of virus-infected cells [82]. Consequently, these T 
cells with high avidity have a selective advantage over other clonotypes and would proliferate 
more rapidly shaping the dominance of clonotypes in the responding T-cell pool. Thus, despite 
the presence of a great variety of T-cell clonotypes with TCRs that could interact with a 
specific Ag, not all of them would be present in the pool of the responding Teff population 
[81].  
Memory T-cell populations are composed of the clones that expanded during the initial 
exposure to the pathogen. The longevity of specific memory and the stability of the repertoire 
are limited by the senescence of the different clones, which might be still replenished by 
homeostasis. Senescence of the individual clone is governed by a number of factors including: 
avidity to the epitope and competition from other clones. Other general factors include the 
nature of the pathogen and the microenvironment of the clone [13]. Longevity of persistence 
of an individual clone in the memory repertoire was measured in the context of Epstein–Barr 
virus (EBV) infection. Many clones were detected for at least a year and some persisted for 
over 3 years [74, 83], and the overall repertoire was stable for 19 months [77]. Nevertheless, 
some changes could occur due to switch in response towards a different set of Ags [84]. 
Clonal survival is probably shaped by the avidity of each clone to the epitope, so that the 
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largest responses are the ones with high avidity. Nevertheless, dominant clones show the 
highest proportional reduction over time [85], as their accelerated exhaustion was observed in 
mouse models [86]. Another factor affecting clonotype survival is the persistence of the 
corresponding epitope. Persistence of epitopes in the chronic phase of viral infections (e.g. 
HIV, EBV and CMV) can result in deletion of their specific highly reactive clonotypes [18]. 
Antigen decay was associated with dynamic changes in the TCR repertoire and gain of 
function within HIV-specific CD8 T populations attributed to functional improvement of the 
clonotypes originally present and/or recruitment of additional clonotypes with higher 
functionality [87]. 
The lack of consistent correlations between the quantitative parameters of the overall 
specific CD8 T-cell responses and control of viral infection indicated that not all specific T 
cells have equivalent efficacies. Dissecting the responses according to the fittest clonotypes 
provided better correlations with the control of the viral replication, indicating that it is more 
precise [66]. T-cell avidity, diversity and cross-recognition were shown to be crucial for 
superior control of HIV replication by Ag-specific T cells and their polyfunctionality [88]. 
Furthermore, it was shown that both avidity and polyfunctionality are interrelated, since Ag-
sensitivity is a major determinant of CD8 T-cell polyfunctionality and HIV-suppressive 
activity [89]. A study rechallenging chimpanzees with HCV after clearance of a primary 
infection demonstrated that rapid resolution of viremia after rechallenge temporally coincided 
with the expansion of the dominant Tmem clonotype that was associated with the clearance of 
the primary infection [90]. 
Another important difference between T-cell clonotypes is their ability to tolerate 
mutations in the targeted peptides [91]. HIV-positive patients who are long-term non-
progressors (LTNPs) to AIDS (i.e. had better long-term control on the virus) possessed highly 
cross-reactive clonotypes that recognize the different variants of targeted viral epitopes 
efficiently [92]. Studies analysing HCV-specific immune responses at the clonotypic level 
showed that one of the mutations in a specific epitope (NS3-1406) was aimed at exploiting a 
virtual gap or a “hole” in the TCR repertoire, thus avoiding recognition [93]. Rechallenging a 
chimpanzee that spontaneously resolved a primary HCV infection demonstrated that higher 
diversity within the TCR CDR3 region correlated with viral clearance and better control on the 
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evolution of escape mutations within the targeted epitope. Despite preferential expansion of 
the dominant clonotypes at the peak of the immune response to reinfection, the repertoire was 
diverse in the memory phase following primary infection and following clearance of the 
secondary viral infection. This indicates that focusing/narrowing the repertoire at the peak of 
the recall response was only temporary [94]. Altogether, these findings underscore the 
importance of studying the protective memory immune response at the clonal level. 
1.2.6. Immunological memory and vaccination 
Vaccination is the most efficient and cost-effective intervention strategy for 
prophylaxis against pathogens. It represents the main pillar for public health measures to 
contain infectious diseases. The only infectious diseases that were successfully eradicated are 
those against which an effective vaccine was developed and accompanied with successful 
vaccination campaigns worldwide (e.g. Smallpox). Ironically, successful vaccines were 
developed without understanding the molecular basis for protection or immunological 
memory. We realize now that vaccines are an effective and well-controlled alternative to a 
primary infection for inducing immunological memory, without suffering from the high rates 
of morbidity and mortality associated with many pathogens.  
The majority of available antiviral vaccines are protective against lytic viruses causing 
acute infections. The main correlate of protection conferred by these vaccines is the generation 
of nAbs that inhibit viral binding and entry into target cells [95]. Another factor contributing 
to the success of these vaccines is the presence of only a few closely related strains in nature, 
thus the inclusion of few cross-reactive strains in the vaccine provided broad protection 
against the majority of strains (e.g. polio, human papilloma virus (HPV) and rotavirus) [96-
100]. This memory immune response provides sterilizing immunity, where the immune 
response neutralizes the pathogen before establishing an infection. However, for chronic 
viruses the realistic goal would be to have protective immunity that could prevent the 
establishment of persistent infection. 
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1.2.7. Challenges for developing vaccines against chronic viruses 
Early vaccines were the result of an empirical design based on clinical observations of 
patients infected with the corresponding pathogen. However, several challenges impede the 
successful design of vaccines against chronic viruses, since major questions remain 
unanswered. First, how to design a vaccine for viral infections where the CD8 T-cell response 
is the major determinant of viral clearance and protection upon re-exposure? Second, how to 
overcome the high variability of viral-sequences for viruses that continually mutate, as HIV 
and HCV? Third, is the memory immune response always protective in case of chronic 
viruses? The answers to these critical questions are essential for the rational design of an 
effective prophylactic vaccine [101]. But, the most challenging issue remains the definition of 
the characteristics of the protective immune response, specifically, the properties of the Tmem 
that would be protective upon exposure and/or re-exposure to chronic viruses. 
Whether the memory immune responses observed for the different chronic viruses 
would be protective upon re-exposure is debatable, since strong memory responses do not 
necessarily provide protective immunity, as it was shown for different human pathogens [102]. 
The discrepancy between the demonstration of immunological memory and protective 
immunity may reflect the time needed to produce sufficient levels of nAbs or effector T cells 
following exposure to the pathogen versus the incubation period of the pathogen [103]. Thus, 
an important factor for memory immune cells to be protective would be their ability to 
differentiate into effector cells upon re-exposure fast enough to outpace the virus and prevent 
the establishment of persistent infection [104]. It is also difficult to verify whether the memory 
immune response would be protective for some viruses upon re-exposure, since the virus is 
never eliminated from the body of the host after the primary infection due to being chronic or 
latent (e.g. HIV and herpes simplex virus (HSV), respectively). For other viruses as HCV 
(where ~30% of patients do clear the virus spontaneously and with no latency), it has been 
very challenging to study a reinfection setting.  
The setback caused by the STEP trial for developing an HIV vaccine by Merck & co. 
(New Jersey, USA) underscores the importance of defining the correlates of memory immune 
responses, especially for complex chronic viruses like HIV and HCV [105]. This vaccine was 
tested in a population at risk and aimed at inducing CMI to reduce viremia, consequently 
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slowing disease progression and transmission [106]. Despite being immunogenic in 77% of 
the vaccinees, it did not prevent infection or reduce viremia in the vaccinated group, and there 
were even more infection cases in the vaccinated group compared to the placebo group [107, 
108]. 
1.2.8. Protective CMI mechanisms for successful vaccines 
The Food and Drug Administration (FDA) defines a correlate of protection as a 
parameter that has been shown to be associated with protection from clinical disease [109]. 
Deeper understanding of correlates of protection of successful vaccines would ensure better 
design of next-generation vaccines [110]. With the recent advances in flow cytometry, 
genomics, proteomics and other immunology and molecular biology techniques, it is 
inevitable to revise our strategies for vaccine design based on lessons learned from successful 
vaccines on how to trigger an efficient memory CMI response. More important, what are the 
correlates of this memory immune response associated with protection against the different 
pathogens with their varying disease courses and pathologies? 
Early protection provided by most available vaccines has been mainly attributed to the 
presence of nAbs or antibody-dependent mechanisms [95]. The contribution of CMI to the 
long-term protection conferred by those vaccines has not been thoroughly studied [103]. 
Studies using yellow fever (YF) 17D vaccine as a model were able to shed light on some of 
the determinants of protection of CMI. Yellow fever 17D vaccine is an ideal example of a 
successful vaccine where 540 million doses have already been administered [111]. Despite 
existing in seven different genotypes differing by 25% at the nucleotide sequence level, the 
YF 17D vaccine provides effective protection against all of them [111]. The nAb response is a 
correlate of protection, yet, the CD8 T cell response seems to contribute by mediating viral 
clearance. A system-biology approach demonstrated that both innate and adaptive immunity 
collaborate in providing protection. Both humoral and CMI are implicated in the protection 
orchestrated by transcription factors as signal transducer and activator of transcription-1 
(STAT1) and interferon regulatory factor-7 (IRF7) [112]. The vaccine was shown to activate 
multiple DC subsets via several toll-like receptors (TLRs) (specifically, TLR-2, 7, 8 and 9), 
thus stimulating polyvalent immunity [113]. 
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1.2.9. Human models for studying protective immunity against chronic 
viruses 
The LCMV model was invaluable in shaping our knowledge about anti-viral immunity 
against chronic viruses and characteristics of the memory immune response. However, these 
findings require validation in a human model due to caveats of the LCMV model that hinder 
applying this knowledge directly for developing human vaccines. First, the mouse is a short-
lived species when compared to humans, thus, whether a successful memory generated in the 
mouse would be paralleled by a similar memory in humans is questionable. Second, many 
differences exist between the immune system and the cell biology of mice versus humans. 
Third, mice used for these studies are inbred and they do not reflect the genetic diversity found 
in human populations. They are also kept in a restricted semi-sterile environment with limited 
exposure to environmental factors and other pathogens that shape the natural immune 
response. Finally, LCMV causes systemic infection and affects many organs [114, 115]. 
Whether similar findings would be observed for chronic viruses causing localized infections 
needs verification. One example reflecting these discrepancies is the observation of 
experiments for blocking inhibitory receptors. In human HCV infection cytotoxic T 
lymphocyte antigen-4 (CTLA-4) blocking synergized with PD-1 blocking in restoring CD8 T 
cell functions, versus LCMV infection in mice where there was no synergism [116]. 
A better understanding of the mechanisms and correlates of the protective memory 
against chronic viral infections in humans would enable the rational design of a vaccine 
capable of stimulating such protective memory. With more elaborate immunological tools 
available, we need to define these correlates, not only at the cellular level (phenotype and 
function) but also at the molecular level (signalling and transcriptome), and not only at the 
cell-population level but also at the clonotypic level.  
We remain in a quest for a model of a human chronic virus that would permit studying 
the correlates of protective immunity under real-life settings. HCV represents an excellent 
model for studying protective memory immune responses in a natural human infection. First, 
the infection with HCV has the advantage that the natural immune response in humans can 
clear the virus spontaneously [117]. Second, the infection has a clear dichotomous outcome 
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during the acute phase of infection (first 6 months of infection); either clearance or 
persistence. Third, epidemiological studies have reported that in populations at risk, such as 
injection drug users (IDUs), patients who were able to clear the first infection could be 
infected for a second time (reinfected) as they continued their high-risk behaviour. Among 
those reinfected patients, many successfully cleared the second infection [118, 119]. These 
cohorts represent a unique opportunity to study protective memory immune responses in a 
real-life human infection context, where humans (rather than in-bred laboratory animals) are 
infected with variant quasispecies (rather than single reference sequences) and are under 
natural environmental conditions (rather than controlled laboratory conditions). Therefore, 
HCV represents a unique setting for identifying correlates of protective immunity against 
chronic viruses in humans. 
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1.3. Hepatitis C Virus 
HCV is a non-cytopathic hepatotropic virus that infects the liver [120]. HCV was first 
cloned in 1989 in the laboratory of Dr. Michael Houghton at Chiron Corporation (California, 
USA), from a chimpanzee infected with the plasma of a patient infected with non-A, non-B 
(NANB) viral hepatitis [121, 122]. This discovery impacted public health strategies, where 
screening blood for this new virus (given the name hepatitis C) became a regular procedure at 
blood banks since 1992 [123]. 
1.3.1. HCV epidemiology and transmission 
The World Health Organization (WHO) estimates HCV prevalence at 3.1% worldwide 
(~185 million individuals) [124]. The prevalence is higher in developing countries, the highest 
being in Egypt (15-20%) (Figure 6) [125, 126]. In the absence of a prophylactic vaccine, two 
million new HCV infections are estimated to occur every year worldwide [127]. In Canada, 
the prevalence of HCV is 0.8% (~275,000 individuals), of whom 30% are IDUs [128, 129]. 
These numbers might not be representative, since many HCV patients live in secluded areas in 
developing countries or belong to marginalized groups in developed countries. Thus, despite 
the universal distribution of HCV, it is uneven [130].  
The main mode of transmission of HCV is direct exposure to infected blood [131-133]. 
Other modes of transmission account for a small percentage (e.g. the second and third most 
common modes of transmission, perinatal transmission and  sexual transmission, account for 
4% and 1.5% of the cases, respectively) [134-136]. Currently, there are 2 patterns for HCV 
transmission; in the developing world unsafe therapeutic injections and transfusions account 
for ~40% of new cases, while in developed countries, sharing contaminated needles between 
IDUs accounts for ~68% of new cases. In Canada, most new HCV infections occur among 
IDUs and aboriginal populations [126].  
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Figure 6: Prevalence of HCV and genotype distribution worldwide. 
Reproduced with the permission of Macmillan Ltd: Nature [137], author copyrights 2011. 
Legend: World map showing the prevalence of HCV infection in different countries. The 
panel at the bottom shows the distribution of genotypes per continent. 
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1.3.2. HCV genome and proteins 
HCV genome is an uncapped positive single-stranded RNA (+ssRNA) of 
approximately 9.6 kilo base-pairs (kb) [138]. The genome represents an uninterrupted open 
reading frame (ORF) encoding a polyprotein precursor [121] which is processed upon 
translation first by cellular then by viral proteases into ten proteins: three structural proteins 
(Core, E1 and E2), the viroporin (p7) and six non–structural (NS) proteins (NS2, NS3, NS4A, 
NS4B, NS5A and NS5B) (Figure 7). The genome also contains two non-coding regions 
(NCRs) flanking the ORF, the 5’untranslated region (5’UTR) and the 3’UTR [139].  
The core: The core protein amino acid sequence is highly conserved among different 
HCV genotypes [140]. The core is involved in the formation of the HCV nucleocapsid [141] 
and was shown to modulate the host’s intracellular signalling pathways [142].  
The envelope: The two envelope glycoproteins (E1 and E2) form complexes which are 
the building unit of the envelope [143], and are necessary for viral entry [144, 145].  
P7: The P7 protein is a small hydrophobic polypeptide suggested by many reports to 
function as a viroporin or ion channel [146, 147].  
NS2: NS2 is essential for viral replication in vivo [148]. NS2/3 possesses an 
autoprotease activity necessary for the polyprotein processing between NS2 and NS3. This 
activity resides in the C-terminal half of NS2 and the N-terminal third of NS3 [149, 150].  
NS3: NS3 is a complex multi-functional molecule essential for both viral protein 
processing and RNA replication [150], with a serine protease activity located in the N-terminal 
third and RNA helicase/NTPase activity residing in the C-terminal two-thirds of the protein 
[151]. The helicase domain unwinds RNA-RNA substrates in a 3’ to 5’ direction [152]. The 
serine protease catalyses the processing of the polyprotein downstream of the NS3 region 
[140].  
NS4A: NS4A is the co-factor for the NS3 serine protease [153].  
NS4B and NS5A: NS4B and NS5A are poorly characterized and their functions are 
not fully elucidated. However, studies show that NS4B induces the formation of a 
membranous-web compartment where viral replication takes place [154, 155], and cell-culture 
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adaptive mutations mapped to the NS5A enhance RNA replication suggesting its importance 
for viral replication [156-158].  
NS5B: NS5B is the viral RNA-dependant RNA-polymerase (RdRp) responsible for 
HCV-RNA replication [141]. As with other RNA viruses the HCV RdRp enzyme lacks proof-
reading activity and is highly error prone, leading to the emergence of different viral 
populations circulating in the blood of an individual patient as a mosaic of highly related 
sequences termed ‘quasispecies’, that differ in nucleotide sequence by >10% [130].  
The untranslated regions (UTRs): Most of the 5’UTR is occupied by the internal 
ribosome-binding site (IRES) that can direct translation of the downstream reading frame in a 
cap independent manner [159-161]. The 3’UTR is formed of three regions; a short variable 
region of ~30 nucleotides, a poly–U/UC stretch and a highly conserved 98-base sequence 
designated the ‘x-tail’ [162, 163]. The poly–U/UC region is recognized by the retinoic-acid-
inducible gene I (RIG-I) pattern recognition receptor (PRR) [164]. Current evidence suggest 
the importance of 3’UTR in viral replication [165].   
Despite variability of the HCV genome, certain highly conserved regions were 
identified in the core/E1 and NS5B that were used as the basis of HCV genotyping, thus 
classifying HCV into genotypes 1 to 7 which differ from each other by 31–33 % at the 
nucleotide level, and more than 60 different subtypes (e.g. 1a, 1b, 1c, etc.) with 20–25 % 
differences in sequences [166-169]. The different genotypes show marked differences in 
geographic distribution (Figure 6) and response to therapy [170].  
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Figure 7: HCV genome and polyprotein. 
Reproduced with the permission of Frontiers scholarly communications: Frontiers in 
Immunology [10], author copyrights 2014. 
Legend: HCV genome RNA is composed of an ORF flanked by 5′ and 3′ UTRs (blue). IRES-
mediated translation of the ORF leads to the formation of a polyprotein that is processed into 
ten viral proteins. Cleavage of the core protein from E1 involves a cellular signal peptidase, 
which also cleaves E1, E2 and p7 from the polyprotein (pink arrows). In an autocleavage 
mechanism the NS2-NS3 protease cleaves itself (green arrow). The NS3 protease located in 
the first one-third of NS3, assisted by its membrane-bound cofactor, NS4A, cleaves the 
remaining proteins NS3, NS4A, NS4B, NS5A and NS5B (violet arrows). 
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1.3.3. HCV life cycle 
Major advances in our knowledge about the life cycle of HCV were achieved since 
2005, with the development of the first in vitro culture system able to produce complete 
infectious virus particle by Dr.Takaji Wakita using the Japanese fulminant hepatitis-1 (JFH1) 
isolate [171]. 
Receptors involved in binding and entry of a given virus determine its tissue tropism 
and host range [140]. All the receptors and co-receptors that have been discovered for HCV 
are expressed on hepatocytes. The first described receptors for HCV were CD81 [172] and 
scavenger receptor class B type I (SR-BI) [173]. Tight junction (TJ) proteins Claudin-1 
(CLDN1) and occludin (OCLN) have also been identified as receptors/co-receptors for HCV. 
It has recently been reported that epidermal growth factor receptor (EGFR) and ephrin 
receptor type A2 are also required for HCV entry and possibly modulate the interaction 
between CD81 and CLDN1 [174] (Figure 8 – Main panel). Binding is followed by fusion of 
the viral envelope with the cellular membrane by clatherin mediated endocytosis then fusion 
with the endosomal membrane and the viral genome is released into the cytosol [144].  
Translation of the HCV genome (lacking a 5’ cap) depends on the IRES [160], which 
binds the 40s ribosomal subunit directly without the need for pre-initiation factors [175]. The 
major product of HCV ORF translation is a large polyprotein that is subsequently processed 
into mature structural and non-structural proteins. Junctions between structural proteins are 
processed by host signal peptidases from the endoplasmic reticulum. The viral non-structural 
proteins are processed by two proteases encoded by HCV; the NS2/3 autoprotease [140, 141] 
and the NS3/4A serine protease (Figure 7) [176]. 
Replication starts by the NS5B RdRp synthesis of a complementary full-length 
negative strand RNA using the genome as a template, then using this negative strand as a 
template for the production of many copies of the genomic positive strand in a replication 
complex [177, 178] that is associated with lipid-raft based membranes (Figure 8 – Lower left 
then right panels) [179, 180]. 
Data from expression systems show that once an HCV nucleocapsid is formed at the 
cytoplasm-endoplasmic reticulum interface it acquires an envelope as it buds through an 
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intracellular membrane [181-183] producing particles of heterogeneous size (40-70 nm) that 
are released from the cell through the secretary pathway [140]. HCV nucleocapsid is built 
from units of the core protein with RNA, surrounded by a membrane derived from the human-
cell with embedded heterodimers of the envelope glycoproteins (E1 and E2)  [138]. The 
virions associate with low-density and very-low-density lipoproteins (LDL and VLDL) 
forming lipoviroparticles (LVPs) that are pleomorphic (Figure 8 – Upper right panel)  [184]. 
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Figure 8: HCV viral life cycle. 
Reproduced with the permission of Macmillan Ltd: Nature Medicine [185], author copyrights 
2013. 
Legend: Interaction of extracellular HCV LVPs (1) with cellular surface receptors initiates the 
entry process (2), which can also occur by direct cell-to-cell transmission. After fusion and 
uncoating, the incoming HCV genome is translated and the resulting polyprotein processed 
(bottom panel, (3)). Replication takes place in ER-derived membrane spherules (membranous 
web, bottom right panel (4)). In the assembly and release process (top right panel, (5)), core 
protein is transferred from LDs to form nucleocapsids that, assisted by NS5A, are loaded with 
RNA. The p7, NS2 and NS3-NS4A proteins are also involved in coordination of assembly. 
HCV virion morphogenesis is coupled to the VLDL pathway, and particles are produced as 
LVPs. EphA2, ephrin receptor type A2; GAG, glycosaminoglycans; LD, lipid droplet; PL, 
phospholipids; TG, triglycerides.  
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1.3.4. HCV infection and its outcome 
Due to the asymptomatic nature of HCV infection, less than 15% of the infected 
persons worldwide are aware of their carrier status [186], leading to the spread of infection 
and missing the opportunity of early treatment [187, 188]. The majority of acutely infected 
HCV patients (~70%) progress to chronicity [117], and up to 20% of patients with chronic 
viral hepatitis C subsequently develop complications including end-stage cirrhosis, liver 
failure and hepatocellular carcinoma (HCC) [189]. These patients represent a quarter of the 
cirrhosis and HCC cases worldwide [190], making hepatitis C the most common indication for 
liver transplantation (40-50%) [191,  192]. 
Several factors influence the outcome of HCV infection. Ethnicity and accompanying 
co-morbidities (e.g. HIV infection, alcohol abuse, renal diseases, obesity or liver fibrosis) are 
considered the most relevant host factors [193]. African Americans were shown to have a 
resolution rate of one-third that of Caucasians [194]. This was explained in light of the 
findings of genome-wide association studies (GWAS) that demonstrated a correlation between 
specific single-nucleotide polymorphisms (SNPs) near the IL28B gene locus and the 
spontaneous resolution of infection [195]. The different alleles for these SNPs are distributed 
unequally among the different ethnicities [195, 196]. Recently, another SNP near the genes for 
HLA class II, the DQB1*03:01 was independently associated with spontaneous resolution of 
HCV infection [197]. Other genetic determinants were shown to affect HCV-infection 
outcome due to having an impact on HCV-specific immune responses; Khakoo et al., reported 
that individuals homozygous for KIR2DL3 and HLA-C1 alleles were more likely to clear 
HCV infection than individuals with other KIR2DL:HLA-C combinations [198]. KIR2DL3 
has a lower affinity for HLA-C1 than other KIR2DL alleles, so HLA-C1-mediated inhibition 
of NK cells is thought to be weaker in individuals homozygous for KIR2DL3 and HLA-C1 
(i.e. easier NK activation) [199]. Also, some HLA class I alleles (e.g. HLA-B*27) [200] and 
HLA class II alleles (e.g. HLA-DRβ1*0101) demonstrated a strong association with HCV 
clearance, whereas others (e.g. HLA-DRβ1*0701) were associated with HCV persistence 
[201-203].  
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Nevertheless, the outcome of HCV infection is determined by a ménage-à-trois 
between host genetics, the virus and HCV-specific immunity. The viral interplay with the host 
and HCV-specific immunity will be discussed in details later in this chapter.      
1.3.5. Treatment of HCV infection 
1.3.5.1. Available treatments 
IFN-α was shown to have a success rate of 6-12% in curing patients with NANB 
hepatitis in 1986, even before HCV was cloned [204]. Prolonging the treatment duration to 12 
months, addition of the antiviral ribavirin and covalently binding IFN-α to polyethylene glycol 
(PEG) boosted the success rate to ~56% against genotype 1 (which is the most resistant 
genotype to treatment) [205-207]. However, some associated side effects are severe, as 
lymphopenia, depression and anxiety that might develop into suicidal tendencies [208].  
Since 2011, the two new anti-HCV protease inhibitors; Boceprevir and Telaprevir have 
been available on the market. They were included in a triple therapy regimen (with PEG- IFN-
α and Ribavirin) to increase the cure rates to ~70%. Nevertheless, this added to the existing 
side effects and the high cost of the standard of care treatment [209, 210]. 
Responses to IFN-α based therapy fall into three main categories; sustained virological 
response (SVR), which is equivalent to success in clearing HCV, relapse and non-response 
(NR). The most significant viral factor correlating with SVR is the genotype. Genotype 1a is 
the most resistant genotype with an SVR rate of 42-46% [205, 207], versus genotypes 2 and 3 
that have the highest SVR rates. Other viral factors associated with a higher SVR rate are 
lower baseline viral load [193] and greater quasispecies diversity pre-commencement of 
treatment [211]. Ethnicity (correlated with the IL28B SNPs) and absence of accompanying co-
morbidities are considered the most relevant host factors [193, 196]. Timing of initiation of 
treatment is a crucial factor, as well, where early initiation of therapy during the acute phase 
markedly increases the SVR rate (e.g. for genotype 1a it increases to ~88%) [212, 213]. 
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1.3.5.2. Novel HCV treatments 
The ideal HCV treatment would be an all-oral, IFN-free regimen, with SVR rates 
approaching 100%, minimum side effects and minimum development of resistance. 
1.3.5.2.1. Direct-acting antiviral agents (DAAs) 
DAAs target HCV proteins in an attempt to counteract their actions. NS3/4A protease 
inhibitors act by inhibiting the NS3/4A serine protease, thus inhibiting the processing of the 
HCV-polyprotein into mature non-structural proteins. After the approval of Telaprevir and 
Boceprevir by the FDA in 2011, Simeprevir was approved in 2013 and there are still several 
anti-NS3/4A molecules that are in phase III clinical trials as Faldaprevir and Vaniprevir. 
Another class, NS5B polymerase inhibitors bind the attractive target that represents the RdRp, 
thus halting HCV-replication. They are either nucleotide analogues (e.g. Sofosbuvir) or non-
nucleoside analogues (e.g. ABT-333 and BI207127) [185]. Sofosbuvir is a very promising 
drug that was approved in 2013, with pan-genotypic action, high resistance barrier and a good 
safety profile. It showed SVR rates of ~90% for genotype 1 infected patients in clinical trials, 
when combined with IFN and Ribavirin for twelve weeks [214]. NS5A inhibitors (e.g. 
Daclatasvir and ABT267) emerged despite the fact that NS5A lacks enzymatic activity and its 
function(s) are not fully elucidated. Screening processes have shown these compounds to be 
potent antivirals causing extremely rapid HCV decline and their inhibition of HCV-replication 
was shown to be NS5A-dependant [185]. Results from a phase IIb clinical trial for a 
combination of an all-oral/IFN-free regimen are promising. Two drugs from Abbvie (Chicago, 
USA) combined with Ribavirin showed 95% SVR rate in a group of patients infected with 
HCV genotype 1. The combination of the non-nucleoside polymerase inhibitor ABT-333 and 
the protease inhibitor ABT-450 combined with Ribavirin showed SVR rates of 83-100% in 
difficult-to-treat patients and naïve patients, respectively. The addition of the NS5A inhibitor 
ABT-267 improved efficacy in difficult-to-treat patients [215]. Another study showed that 
regimens combining Daclatasvir and Sofosbuvir could achieve very high SVR rates, even in 
patients who had previous failure with Telaprevir/Boceprevir and PEG-IFNα combinations. 
Among gentotype 1 patients, 98% of 126 previously untreated patients and 41 patients who 
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did not have SVR with Telaprevir/Boceprevir and PEG-IFNα achieved SVR after 12 and 24 
weeks of treatment, respectively [216]. 
1.3.5.2.2. Host targeting agents (HTAs) 
A number of host factors were found to influence HCV replication as Cyclophylin A 
(CypA) and micro-RNA miR-122. This encouraged the search for inhibitors against those 
molecules. The CypA inhibitor, Alisporivir, showed a pan-genotypic action and a high 
resistance barrier. Nevertheless, it is currently on clinical hold due to the emergence of several 
cases of acute pancreatitis. Small molecules that would inhibit HCV uptake and entry into 
cells by targeting receptors and/or coreceptors (e.g. ITX-5061 and Erlotinib) are also in 
clinical trials [185]. Numerous side effects would be expected for this class of antivirals, 
taking into consideration that those human factors might have many other functions and 
effects on various physiological processes.  
1.3.5.2.3. Type III interferon 
IFN-lambda (IFNλ) is currently examined in clinical trials for use as a treatment for 
HCV infection [217]. IFNλ is more specific in its actions compared to IFNα, owing to the 
limited distribution of its receptor on a specific set of cells, unlike IFNα that has a ubiquitous 
receptor distribution. Thus, it is expected to have fewer side effects, whereas studies have 
shown that efficacy would not be compromised. 
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1.4. Immunity against primary HCV infection 
1.4.1. Innate sensing of HCV 
RNA viruses are recognized by TLRs and/or nucleic acid-binding proteins [218, 219]. 
In hepatocytes, pathways downstream of TLR-3 and RIG-I are the two major signalling 
pathways triggered by foreign double-stranded RNA (dsRNA), including HCV RNA (which 
has secondary dsRNA structures and a dsRNA replication intermediate) [130, 220-222] 
culminating in the secretion of type I IFNs [223, 224] (Figure 9). This induces the expression 
of hundreds of interferon-stimulated genes (ISGs) in the infected cells and sends a danger 
signal to neighbouring uninfected cells inducing ISGs expression in them, as well. This creates 
a general antiviral state in the liver that limits HCV RNA replication and cell-to-cell spread 
[225, 226]. Upregulation of ISGs is detected in liver cells early after HCV infection 
irrespective of the final outcome of the infection, suggesting that most HCV isolates are 
resistant to the antiviral effects of this line of defence [227, 228]. 
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Figure 9: Sensing HCV in hepatocytes. 
Reproduced with the permission of Macmillan Ltd: Nature Medicine [229], author copyrights 
2013. 
Legend: Innate sensing of HCV in the infected hepatocyte occurs through the combined 
actions of PKR (1), RIG-I (2) and TLR3 (3). These proteins recognize specific features of 
HCV, including the dsRNA in the IRES, poly U/UC PAMP and dsRNA that accumulates with 
HCV replication. This recognition leads to downstream signaling that results in the induction 
of antiviral genes, IFN-β and other proinflammatory cytokines. The mechanisms activating 
IFN-λ during HCV infection are not fully characterized (4). AP-1, activator protein 1; 
CLDN1, claudin 1; IKKε, IkB kinase-e; LDLR, low-density lipoprotein receptor; OCLN; 
occludin; SR-BI, scavenger receptor class B member 1; TBK-1, TANK-binding kinase 1; 
TRAF3, TNF receptor–associated factor 3; GAG, glycosaminoglycans. 
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1.4.2. Innate immune response against HCV   
Natural killer cells are more abundant in the liver than the blood of healthy individuals, 
but their frequency is even higher in the liver and lower in the blood in chronic HCV patients 
[230]. One of the determinants of HCV outcome is the threshold of NK activation. This 
activation is governed by the combination of the alleles of the KIRs expressed on NKs and the 
HLA molecules expressed on other host cells, as well as their interactions [198]. NK cells 
from HCV infected patients show a higher level of activation markers as NKp30, NKp44, 
NKp46, NKG2C and NKG2D than healthy individuals. Hyperactivation of NKs was observed 
in HCV-infected patients irrespective of the outcome of the infection [231, 232]. 
Being the bridge between innate and adaptive immunity, DCs have an impact on the 
immune response against HCV. The frequencies of mDCs and pDCs were shown to correlate 
with the outcome of infection, where normal frequencies were associated with spontaneous 
resolution of HCV infection versus lower frequencies that were associated with chronic 
infection [233]. Sustained hyper-responsiveness of DCs was associated with resolution of 
HCV infection [234]. Nevertheless, the cross-talk between NKs and DCs remains intact even 
in patients who develop persistent HCV infection [235].  
1.4.3. Adaptive immunity against HCV 
Cell-mediated immunity is of special importance in immunity against non-cytopathic 
viruses like HCV [236]. Evidence for the importance of T-cell responses, is supported by the 
association of specific alleles of MHC class I and II with clearance of HCV infection [237]. 
This importance was confirmed by depletion studies in chimpanzees [238, 239], as well as 
temporal association of appearance of HCV-specific T-cell responses and HCV clearance, 
versus the absence of these responses in infections that progress to chronicity [239].  
Studies during the acute phase of HCV infection showed that chimpanzees and humans 
capable of resolving primary HCV infection mounted an early, robust, broad/multispecific and 
polyfunctional HCV-specific immune response for both CD8 and CD4 T cells (Figure 10) 
[240-246]. Development of chronic infection was consistently associated with the failure to 
initiate or sustain such a T-cell response [96, 246, 247]. The role of anti-HCV Abs in the 
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spontaneous clearance of HCV is less defined, since neutralizing Abs appeared after clearance 
of the virus in many studies [248, 249].  
1.4.3.1. Anti-HCV cell-mediated immunity 
1.4.3.1.1. Role of CD8 T cells in the clearance of primary acute HCV  
Early onset of CD8 T response against HCV is important for clearance of the virus. 
Evidently, the only chance for the immune system to overcome HCV is during the early phase 
of infection before it has the chance to establish infection and produce enough viral proteins 
that would antagonize and/or exhaust functions of the immune system, as well as generate a 
high number of viral mutants that would enable selection for resistant variants [244]. The 
magnitude of HCV-specific T-cell responses strongly correlated with resolution of infection 
[250]. Breadth of the CD8 T-cell response and the relative dominance of the targeted epitopes 
were both shown to be determinants of the outcome of HCV infection [240, 243]. 
The initial decrease in HCV titer in infected patients and chimpanzees coincided with 
the appearance of IFNγ-secreting HCV-specific T cells in the blood and liver [57]. However, 
individual cytokines/functions did not necessarily correlate with the outcomes of HCV 
infection. Flow cytometric analysis of multiple effector functions performed simultaneously 
identified the presence of a polyfunctional population of virus-specific CD8 T cells that 
correlated with spontaneous clearance of HCV [251]. The functions included secretion of 
effector cytokines as IFNγ and TNFα, and IL-2 that helps in amplifying the immune response, 
as well as the increased surface expression of CD107a. CD107a is a surrogate marker of 
cytotoxicity since it is a measure of degranulation capacity required for the release of the 
cytotoxic/cytolytic proteins, as perforin and granzymes [251]. Vigorous and multispecific 
proliferative responses were observed for spontaneous resolvers and were maintained after 
HCV clearance [252]. Differences in T-cell responses become increasingly apparent as the 
infection progresses. In patients who become chronically infected T-cells showed decreasing 
functions, less polyfunctionality and diminished proliferative capacity [253]. HCV clearance 
was associated with responses mainly directed against non-structural proteins [244, 254].  
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Genetic restriction was shown to have an impact on HCV-specific CD8 T-cell 
responses (e.g. HLA-B*27 demonstrated a strong association with viral clearance) [200]. 
MHC class I tetramer staining showed a strong correlation between infection outcome and the 
frequency of CD8 T cells targeting a specific HCV epitope. The detection of high frequencies 
of HCV-specific tetramer-positive cells in the blood and liver of humans and chimpanzees is 
temporally and kinetically associated with the control of viraemia [130]. In spontaneously 
resolved patients up to 8% of the total CD8 T cells in the blood targeted a single 
immunodominant HCV epitope [243] and even higher frequencies could be detected in the 
livers of HCV resolving chimpanzees [255]. These tetramer positive cells displayed markers 
of T-cell activation [246, 256]. Furthermore, multi-specificity of targeted epitopes is more 
pronounced in humans and chimpanzees able to clear the infection, with up to nine different 
epitopes recognized simultaneously by CD8 T cells [240, 243]. Unlike the observation that 
specific HCV regions were more immunodominant and correlated with spontaneous clearance 
of the infection [250], there was lack of consistency in the targeted epitopes among the 
different individuals who resolved infection, even those who shared HLA alleles [96, 257]. 
A distinct phenotype of CD8 T cells was associated with spontaneous clearance of 
HCV infection. HCV-specific CD8 memory T-cell population generated following clearance 
of a primary HCV infection were shown to be CD127hi and Bcl2hi indicating they are destined 
to become long-lived memory T cells [251]. It was demonstrated that early expression of 
CD127 predicted resolution of acute infection, while loss of this marker was associated with 
viral persistence [258, 259]. 
1.4.3.1.2. Role of CD4 T cells in the clearance of primary acute HCV 
Chimpanzee studies showed that CD8 T cells alone could not clear highly mutable 
viruses as HCV, indicating that help from CD4 T cells is essential. The loss of helper CD4 T 
cell responses during acute infection correlated with HCV persistence [238, 246]. Human 
studies confirmed the same findings, where an initially functional CD8 T-cell response would 
wane resulting viral recurrence upon the loss of CD4 T-helper response [243, 246, 247]. HLA 
class II restricted CD4 T-cell responses were shown to be of direct impact on the outcome of 
acute HCV infection [247, 260] and some HLA class II alleles were associated with resolution 
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while others were associated with chronicity [201-203]. In human IDU cohorts, the 
indispensable role for helper CD4 T cells was confirmed in HIV/HCV co-infected patients, as 
the reduction of CD4 T-cell count upon HIV infection was associated with a lower level of 
protection against HCV infection [118]. 
A successful helper T-cell response is characterized by being early, of high magnitude 
and multi-specific. In patients that proceed to chronicity either one or more of these were 
lacking [130]. Early CD4 responses were temporally and kinetically correlated with control of 
viremia. Patients who cleared HCV spontaneously demonstrated CD4 T cells with a high 
magnitude of IFN-γ production [243], whereas loss of IL-2-secreting CD4 T cells was 
associated with developing chronic HCV infection [261]. Broad CD4 T-cell proliferative 
responses of high magnitude were associated with spontaneous clearance of HCV. Those 
responses appeared early in patients who resolved the infection and were maintained [243, 
247]. On the contrary, proliferating CD4 T cells were mostly absent in chronic patients, and 
even if they could be detected early in the infection, they disappeared rapidly with viral 
persistence [262, 263].  
The frequency of HCV-specific CD4 T cells targeting a specific epitope is several 
folds higher in individuals who resolved infection versus those who became chronic. CD4 
helper T cells targeting several immunodominant epitopes were associated with spontaneous 
resolution, in a human study up to 14 epitopes were targeted mapping to the core and non-
structural regions [264]. The phenotype of HCV-specific CD4 T cells is also important, since 
there is an association between the prevalence of CD4 T-cells with a Th1 cytokine-profile and 
resolving acute HCV infection [244, 265]. The Th1 responses had to be maintained to achieve 
long-term control of the virus [247].  
In conclusion, an early functional CD4 T-cell helper response directed against multiple 
immunodominant epitopes predicts control of viremia, while in cases that develop chronic 
disease CD4 helper T-cells are either absent or functionally altered or target fewer epitopes 
[247, 263, 264, 266]. Contraction of the CD4 T-cell population and its failure in sustaining a 
robust CD8+ T-cell effector response is a hallmark of HCV persistence [130]. 
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Other CD4 T cell populations, specifically regulatory T cells (Tregs) and T-helper 17 
cells (Th17), were also shown to impact the outcome of primary HCV infection. The 
percentage of CD4+ CD25+ Tregs expressing the forkhead transcription factor 3 (FoxP3) was 
shown to be elevated and more suppressive in chronic versus spontaneously resolved HCV 
patients or healthy individuals [267, 268]. Decrease in IFNγ secretion from CD4 T cells and 
the simultaneous increase in IL-10 and TGFβ production was associated with the development 
of chronic infection [263]. Our group has recently shown that imbalance between Th17 and 
Tregs could be a cause for failure of CD4 T-cell help during acute HCV. Specifically, inability 
to expand IL-21 producing Th17 cells was a key determinant of developing a chronic disease 
course [269]. 
1.4.3.2. Humoral immunity during primary HCV infection 
Although, HCV RNA reaches high serum titres by week two post infection, anti-HCV 
antibody response (seroconversion) is usually not detected before week eight [224, 270]. Early 
studies showed that antibodies targeting the hypervariable region-1 (HVR1) of the E2 
glycoprotien of HCV are neutralizing in vitro and in vivo [271, 272], but select for mutations 
in the envelope region [273]. Chimpanzee studies showed that clearance was not associated 
with the generation of antibody responses [274, 275]. The presence of antibodies targeting 
HVR1 during acute infection was even associated with the development of chronic infection 
in one study [276]. In humans, Ab-responses are delayed, have a low titre and rapidly decline 
in individuals who clear HCV spontaneously [248, 249, 277]. One study showed that nAbs 
appeared in patients after HCV has already established a chronic infection and were unable to 
clear the virus and selected for escape mutants [278]. However, another study showed that 
early induction of nAbs was associated with spontaneous resolution of HCV primary infection 
[279]. Law et al. reported the identification of monoclonal nAbs that could protect against 
heterologous viral infection [280]. Broadly nAbs confer protection against most pathogens, 
including viruses. However, the most evident exception is HIV (a chronic virus with a high 
rate of sequence variation), where broadly nAbs do not necessarily correlate with the control 
of infection or protection against superinfection [281].  
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One of the major limitations for understanding humoral immunity against HCV is the 
lack of proper tools to measure the levels of nAbs precisely. The current method measures 
neutralization by the degree of neutralization of HCV pseudo-particles (HCVpp), which are 
retroviral particles pseudotyped with HCV E1-E2 envelope proteins. The sequences of the 
included envelope proteins were derived from reference sequences, and thus do not 
necessarily represent the autologous E1/E2 sequences circulating the patient [282]. A major 
advancement was the generation of an HCVpp library of 19 genetically-distinct genotype 1 
HCVpp. This library comprises the natural variability of genotype 1 E1/E2 sequences [283]. A 
recent study using this HCVpp library demonstrated that resolution of HCV infection was 
associated with a broad nAb response generated early during the infection [284]. 
Some major limitations exist for protective humoral immunity against HCV. First, the 
envelope proteins are not highly immunogenic, causing the Ab response to be slow and weak 
during primary infection [283]. Second, Abs mostly target the HVR of the envelope protein, 
which facilitates the selection of viral sequences that are highly resistant to Ab neutralization 
[285]. This selection was shown to take place as the CMI collapsed and the infection entered 
the chronic phase [286]. Third, the epitopes targeted by nAbs are shielded by heavy 
glycosylation and complexation with host lipoproteins [287].  
The role of antibodies in the resolution of HCV infection needs further investigation, 
since the results of in vivo studies performed to date are inconclusive. 
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Figure 10: Successful versus unsuccessful immune responses during acute HCV 
infection.  
Reproduced with the permission of Macmillan Ltd: Annual Reviews of Immunology [224], 
author copyrights 2007. 
Legend: (A) Early, robust, broad and sustained CD4 and CD8 T cell responses are able to 
control and clear HCV viraemia. (B) Weak CD4 and CD8 T cell responses from the 
beginningis associated with lack of control of viremia. Initial CD4 and CD8 T cell responses 
could be able to transiently control the viraemia, but as the CD4 T cell response contracts and 
functions wane the viraemia rebounds. The role of humoral immunity remains controversial 
and needs further investigation. 
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1.4.4. Failure of immune responses against HCV 
Failure of the HCV-specific immune response could be due to primary failure of 
components of the immune system from the beginning of infection or their exhaustion over 
time. Nevertheless, even a functional immune response could be subverted by different viral 
evasion strategies adopted by HCV.  
1.4.4.1. Primary failure of the HCV-specific immune response 
Several defects have been associated with failure to control primary HCV infection. 
Those defects were either in the cells/functions of innate or adaptive immunity or both.  
NK cells’ numbers and functions, especially cytotoxic activity, were shown to be lower 
in chronic hepatitis C patients as compared to healthy donors [288-290]. In chronic HCV 
patients a reduction in number of both mDCs and pDCs was observed [291-293]. Also, 
functions of mDC and pDC were impaired in chronic HCV-infection (e.g. Ag-presentation, 
TLR-sensing and allostimulatory functions) [294-296] [296, 297].  
Primary defects in adaptive immune cells’ frequency and/or functions were reported in 
chronically infected patients. CD4 T-cell responses are very weak or absent in individuals with 
chronic HCV [73], as indicated by decreased cytokine production (especially IL-2) [261]. CD8 
T cells in chronic patients were also reported to be anergic or of an arrested developmental 
phenotype [71, 298]. Other studies showed them to be impaired in cytotoxic function and 
proliferative capacity [256, 298], thus were described as being in a ‘stunned’ state [243, 246].  
One plausible cause of failure might be the increased exhaustion of adaptive immune 
cells. Progressive functional exhaustion and subsequent deletion of HCV-specific CD4 and 
CD8 T cells is a hallmark of HCV infection developing into persistent infection [298, 299]. 
HCV-specific CD8 T cells from chronic individuals showed high expression of PD-1 [300], 
and their functions were restored by its blockade [301]. Recently, it was proposed that PD-1 
and CTLA-4 contribute synergistically to CTL exhaustion [116]. The downregulation of T-cell 
responses follow a similar pattern in patients with HCV and LCMV-infected mice, where 
virus-specific T cells show increased expression of inhibitory molecules as PD-1, CTLA-4, T-
cell immunoglobulin and mucin domain 3 (Tim-3) and CD244 [116, 299, 302, 303], and some 
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of their corresponding ligands were shown to be upregulated in the liver and plasma [269, 
304]. Those exhausted T cells lost their functions sequentially; first IL-2 production, followed 
by cytotoxicity, then IFNγ and TNFα production [305]. This could be attributed to the 
persistence of the Ag, where it was shown in the LCMV model that prolonged exposure to 
viral antigens is the main cause for reduced frequency and impaired effector functions of 
virus-specific CD8 T cells [306, 307]. The defects in HCV-specific CD8 T cells in patients 
with persistent infection were shown to correlate with HCV titer having the original sequence 
of the targeted epitope [308]. Confirming this finding, HCV-specific CD8 T cells whose 
epitope has already mutated, did not show exhaustion in chronic patients and even displayed 
markers of long-lived memory cells (e.g. CD127), since they were not subjected to such 
pressure from their corresponding antigens [251, 309].  
Suppression of HCV-specific immunity can contribute to chronicity, where the 
percentage of CD4+ CD25+ FoxP3+ Tregs producing the anti-inflammatory cytokines IL-4 and 
IL-10 were higher in chronic patients versus spontaneously resolved HCV infected patients or 
healthy individuals [265, 267, 310, 311]. Moreover, Tregs derived from chronically infected 
patients were significantly more suppressive than those from spontaneously resolved ones 
[268]. Together, this causes a shift in the ratio between T-cell sustaining cytokines (e.g. IL-2) 
and suppressive cytokines (e.g. IL-10 and TGFβ), consequently dampening the HCV-specific 
effector T-cell response [267, 312, 313]. Our group has recently shown that failure of CD4 T-
cell help during acute HCV is partially attributed to the imbalance between Th17 and Tregs, 
where IL21-producing Th17 limited the exhaustion of HCV-specific T cells, while Galactin 9-
producing Tregs enhanced this exhaustion [269]. Importantly, the lack of generalized immune 
suppression in patients with chronic HCV infection argues in favour of an Ag-specific 
suppression [314]. 
Finally, the liver as an organ represents a tolerogenic environment [315]. Thus, 
primary contact of T cells with sinusoidal endothelial cells in the liver rather than lymph nodes 
typically results in tolerance [316, 317], and this abortive activation could be the reason why 
HCV-specific T cells with the highest avidity undergo functional silencing [318]. A study 
dissecting mechanisms of failure of intrahepatic CD8 T cells demonstrated impaired 
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production of IFNγ that was limited to HCV-specific cells, despite their accumulation in the 
liver and the presence of CD4 helper T cells [319]. 
1.4.4.2. Viral evasion strategies  
The majority of HCV infections lead to chronicity, even in people with an intact 
immune system [320]. This could be attributed to the inhibition of specific steps in the 
intracellular antiviral signalling pathways by HCV proteins. NS3/4A was shown to 
specifically disrupt viral sensing pathways at early steps, by splicing mitochondrial antiviral 
signaling protein (MAVS) and TIR domain-containing adapter inducing IFN-β (TRIF) 
downstream of the two major sensors of HCV-RNA, RIG-I and TLR3, respectively (Figure 
11-A). Other HCV-proteins (e.g. the core, E2 and NS5A) disrupt various early and late steps 
along the JAK-STAT signaling pathway which is induced by type I and III IFNs (Figure 11-B)  
[321-323].  
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Figure 11: HCV proteins subvert intracellular signaling. 
Reproduced with the permission of Macmillan Ltd: Nature Medicine [229], author copyrights 
2013. 
Legend: (A) Immune evasion by HCV in the hepatocyte occurs at several points during viral 
infection. HCV NS3-NS4A protease cleaves the signaling adaptors MAVS and TRIF to 
inactivate PKR (1), RIG-I (3) and TLR3 (4) signaling pathways to prevent induction of innate 
antiviral genes and IFN-β. HCV E2 and NS5A proteins inactivate PKR-dependent activation 
of the host translation factor eIF2α to reactivate protein translation during infection (2). (B) 
Upon binding of IFN-α to receptors in neighbouring cells, HCV proteins could prevent IFN 
actions by directly or indirectly blocking Jak-STAT signaling. Tyk2, tyrosine kinase 2; Jak1, 
Janus kinase 1.  
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Inhibition of functions of innate immune cells (NKs and DCs) by HCV proteins has 
also been reported. HCV recombinant E2 protein was reported to directly inhibit NK 
cytotoxicity and IFN-γ production [324, 325] (Figure 12). The hindrance of DC functions by 
uptake of HCV proteins has been demonstrated; where core and NS3 proteins inhibited DC 
differentiation and maturation, causing inhibition of in vivo induction of cellular immune 
responses [326-328]. The NS3/4A encoded serine protease alters the transfer of glycoproteins, 
suggesting interference with MHC-I presentation of viral epitopes, which could affect T-cell 
priming [329]. However, the in vivo importance for the majority of these findings has not been 
established, since these results were obtained in vitro using overexpression of the 
corresponding proteins [224]. 
Mutational escape within targeted epitopes is the most common strategy used by RNA 
viruses to evade the adaptive immune response. Mutations of HCV genome occur early and 
become fixed in the viral quasispecies [330, 331]. CD8 T cells exerting sub-optimal immune 
pressure on their corresponding viral epitopes select for resistant variants. Specific HLA 
alleles produce selective pressure on certain epitopes [332]. The rate of mutations in MHC I-
restricted epitopes was significantly higher (thirteen-fold more) compared to other regions 
outside T-cell epitopes, indicating that these mutations were in response to a CD8 T-cell 
pressure, generating epitope sequences that are less efficiently recognized by CD8 T cells and 
poorly induce new T-cell responses [330, 333, 334]. In some cases specific mutations even in 
one epitope were associated with HCV persistence [332]. Luckily, viral fitness limits the 
variability within some HCV immunological epitopes [335]. 
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Figure 12: Mechanisms of HCV-protein interference with the immune system. 
Reproduced with the permission of Macmillan Ltd: Nature Reviews in Immunology [270], 
author copyrights 2005. 
Legend: HCV-proteins interfere with the different steps of innate immunity (A) and adaptive 
immunity (B). The details are specified in the green boxes and the text. CXCR, CXC-
chemokine receptor; FOXP3, forkhead box P3 transcription factor; NKG2A, NK group 2 – 
member A; TGFβ, transforming growth factor beta  
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1.5. Protective immunity against HCV and vaccine trials 
1.5.1. Memory immune responses against HCV 
Different chimpanzee studies have demonstrated the generation of memory T cells 
following clearance of HCV infection. Memory T-cell responses were maintained in the blood 
of chimpanzees for several years after clearance of a primary HCV infection, whereas the 
antibody titres against HCV proteins were low or even undetectable. The frequency of HCV-
specific T cells was fixed for several years after the resolution of primary infection [239]. The 
hierarchy of CD4 T-cell responses was preserved during secondary infection years later [57]. 
Nevertheless, it has been shown that frequent exposure to very low doses of HCV 
(subinfectious doses) predisposes to Tregs expansion, leading to suppression of effector Tmem 
upon subsequent infection. In vitro depletion of Tregs restored HCV-specific T-cell effector 
responses [336]. 
Evidence from rechallenge studies suggest that this memory response might be 
protective against HCV upon re-exposure, since these studies showed that chimpanzees 
spontaneously clearing a primary infection had a higher level of protection than naïve ones 
when rechallenged with homologous but not heterologous viral sequences. This was 
accompanied by a shorter duration of viremia (~42 versus ~98 days) and lower viral loads (as 
low as 100-folds) in the cases that cleared the second infection [337, 338]. However, other 
studies did not observe protection even against homologous rechallenge [339]. A broad CD8 
T-cell response with high magnitude was associated with rapid control of the second HCV 
infection upon rechallenge, even with a poor antibody response, suggesting that CMI could be 
sufficient for protection from HCV persistence [239, 240]. Control of the reinfection was 
temporally and kinetically linked to the appearance of HCV-specific CD8 T cells with 
cytolytic activity in the liver and blood. This was associated with the expansion of memory T-
helper cells [90, 238]. IFN-γ producing CD4 and CD8 T cells were detected at a higher 
frequency and as early as day fourteen into the second infection compared to eight weeks into 
the primary infection [340-343]. A recent study demonstrated that control upon HCV 
challenge following vaccination was associated with CD127+ PD1lo CD8+ T cells that 
persisted at high levels for long times and were bifunctional (IFNγ+ TNFα+) [344]. Another 
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recent study showed that clearance of HCV reinfection upon heterologous rechallenge 
depends on the activation of both intrahepatic innate and adaptive immune responses (NKs 
and CD8 markers, respectively), as well as enhanced production of IFNs type I and type II, 
and elevated ISGs [338]. The protective role of memory T cells was confirmed by using 
antibody-mediated depletion of either CD4 or CD8 T cells. CD4 T-cell depletion was 
associated with low level viremia, but memory CD8 T cells partially controlled viremia [238], 
whereas memory CD8 T cell depletion led to a significant delay in control of viremia, and this 
control coincided with the re-detection of the cells [239].  
Together, these data demonstrate a protective role for memory T cells upon repeated 
HCV challenge in chimpanzees without correlating with the development of nAbs, and show 
that it mainly reduces the level of viremia and the duration of infection (protective immunity) 
rather than conferring sterilizing immunity [224, 238, 239, 338, 341]. 
Nevertheless, these findings need to be interpreted cautiously. Despite being the closest 
primate to humans, there are several discrepancies between chimpanzees and humans in some 
gene clusters, some of which are involved in the immune response [345]. It has indeed been 
shown that chimpanzees respond differently from humans to chronic HCV infection in terms 
of pathology, disease progression and kinetics of viral clearance. In addition, the conditions 
for chimpanzee experiments are much more controlled, where the chimpanzees are maintained 
in a restricted environment and the viral sequences used for the challenging are laboratory 
reference sequences representing a single clone from one genotype [346]. In addition, the 
number of chimpanzees available for the studies is very limited. Medical Research on 
chimpanzees is no longer possible except in very limited situations [347]. 
Human studies also demonstrated the presence of HCV-specific memory was also 
demonstrated in humans. A group of women infected with HCV from a common source were 
followed for several years after the initial infection. It was shown that spontaneous resolvers 
possessed HCV-specific CD4 and CD8 Tmem that could be detected in their peripheral blood 
20 years post-clearance of the virus, whereas antibodies were barely detectable [348]. 
Phenotypic characterization of HCV-specific T cells in spontaneously resolved cases showed 
they were expressing the lymphoid homing marker CCR7 and CD45RO, both characteristics 
of memory T cells [73]. Our group and others previously demonstrated that spontaneous 
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resolution from a primary HCV infection was associated with the generation of an HCV-
specific memory population with a CD127hi Bcl2hi profile [251, 258, 259]. The increased 
expression of both markers has been correlated with the generation of long-lived memory CD8 
T cells [37]. 
There is a lack of thorough studies dissecting the determinants of a protective immune 
response upon re-exposure to HCV. Nevertheless, some studies shed light on the rates of 
reinfection in populations at risk and on the possible role of a Tmem immune response in the 
protection against persistence upon HCV reinfection. Epidemiological studies in populations 
at high risk of getting infected with HCV, especially IDUs, observed that the incidence of 
reinfection in patients who have cleared a primary HCV infection is less than those observed 
for infection in naïve patients belonging to the same cohorts under the same risk factors [118, 
119, 349]. Unfortunately, there is a great discrepancy in the results of the epidemiological 
studies, since other studies showed that the incidence rates were not significantly different or 
were even higher in spontaneous resolvers of a previous HCV infection [350-352]. One of the 
major factors causing this discrepancy is the variation in the testing intervals for HCV-RNA to 
determine the frequency of occurrence of infection or reinfection. Other factors include 
differences in the characteristics of individual subjects, as age, ethnicity and risk behaviours 
[353]. Nevertheless, all studies that measured clearance rate in both groups showed that the 
rate of clearance of reinfection was higher than that for primary infection [118, 351, 354]. This 
could be due to the fact that individuals who spontaneously clear HCV acute infection 
generate a robust Tmem population and it was already demonstrated that resolution of 
reinfection correlated with T-cell responses [355, 356]. This provided proof-of-concept that 
the human immune system is capable of conferring protective immunity against HCV. 
What we know about the signature of a protective immune response is far less defined 
than our knowledge about successful responses against primary HCV infection, especially in 
terms of the phenotype and functionality of HCV-specific populations that might be protective 
upon HCV infection in humans. Some general features of the HCV protective response were 
drawn from the few cohorts that have been established in the last few years with the potential 
of having enough patients to study the characteristics of a protective immune response [357]. 
Albeit, it remains challenging to gather enough samples longitudinally from patients with 
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differential outcomes of reinfection to thoroughly dissect the correlates of protection. The 
most elaborate human study, to date, was performed by Osburn et al. [354]. Using enzyme-
linked immunospot (ELISPOT) technique this study showed that spontaneous clearance of 
reinfection is associated with broadened T-cell responses. It also showed the generation of 
cross-reactive humoral responses in patients who spontaneously resolved the second infection 
episode. However, phenotypic and polyfunctional characterisation was not performed. 
Another limitation to this study is that 10/11 subjects examined resolved the second infection, 
thus a group of chronic patients served as the control group. To date, there are no studies 
defining the exact correlates of protection against HCV infection.  
1.5.1. HCV vaccine trials 
HCV has many attributes that makes it a candidate for eradication through prophylactic 
vaccination; it is a blood-borne infection (much easier to control than pathogens transmitted 
by aerosol or food), it has no natural non-human reservoir, it can be cleared spontaneously by 
the immune system and people who clear a primary infection have a higher clearance rate (i.e. 
more protected) upon re-exposure [358].  
An effective HCV vaccine would have a great impact on reducing the future disease 
burden worldwide, since it would break the transmission cycle in endemic developing 
countries where public health efforts have failed over decades to reduce HCV transmission 
[359]. Also, new HCV treatments have a very high cost and lower efficacy against genotypes 
other than genotype 1, thus they are not expected to have an impact on the disease burden 
worldwide [360]. 
The plethora of data suggesting that CMI is the major arm clearing primary HCV 
infection led to the assumption that it should be the target for vaccine development. 
Nevertheless, the unclear role for Abs in resolution of primary infection does not rule out a 
possible contribution of humoral immunity in protective immunity.  
There are major challenges and biological barriers facing the development of HCV 
vaccines. The first is the genetic diversity of HCV sequences and its high ability to undergo 
mutations. A successful prophylactic vaccine would need to induce an effective immune 
response capable of surmounting this high mutational capacity. Second, the ability of HCV 
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proteins to distort the different arms of the immune system necessitates the design of an 
effective vaccine that generates memory immune cells capable of mounting a prompt recall 
response upon re-exposure in a fashion that outpaces the virus and prohibits it from producing 
enough viral proteins that are able to antagonise the immune system.     
All present vaccine trials could be considered empirical, since the exact correlates that 
need to be induced and subsequently measured to verify the efficacy of protection conferred 
by candidate vaccines remain unknown. Three major approaches have been adopted for 
vaccine design against HCV. The traditional approach uses recombinant envelope proteins to 
induce nAbs. It has gained more potential recently with the discovery of broadly nAbs 
generated in chronic patients against HCV. Vaccination with recombinant E1/E2 proteins was 
shown to induce cross-reactive nAbs that might contribute to protective immunity upon 
exposure to HCV [361-363]. The second approach uses virus-like particles (VLPs) that 
express HCV structural proteins to try to induce both humoral immunity and CMI, but it 
mainly induced CMI and did not provide protection upon homologous rechallenge except in 
two out of four chimpanzees [364]. The third and most promising approach is designing an 
HCV vaccine that would induce a potent T-cell immune response. Replication-defective 
recombinant viral vectors were used to deliver HCV Ags to induce T-cell responses [e.g. 
adenovirus (Ad), vaccinia virus (VV), modified vaccinia Ankara (MVA)]. HCV proteins could 
also be delivered using DNA vaccines, where recombinant plasmids expressing various 
proteins could be injected into the host. The two candidate vaccines that showed promising 
preliminary results and are at an advanced stage of development are the vaccines developed by 
Okairos (Rome, Italy) [acquired by Glaxo-Smith-Kline Inc.] using viral vectors for priming 
and viral vectors or DNA vaccines for boosting [365].  
The first vaccine uses heterologous prime/boost regimens with chimpanzee adenovirus 
Ad3Ch3 and a rare strain of human adenovirus (Ad6) expressing the entire non-structural 
region of genotype 1b BK strain (NS3-5B). It has already been tested in a phase I clinical trial 
in humans (ClinicalTrials.gov NCT01436357). Both vectors primed broad CD4 and CD8 T 
cell responses that were capable of responding to heterologous strains of HCV genotypes 1a 
and 3a. Polyfunctional HCV-specific T cells (IL-2+ IFNγ+ TNFα+) could be sustained for at 
least a year after boosting with the heterologous vector [366]. The second vaccine uses a 
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regimen of priming with Ad6 encoding NS3-5B of genotype 1b BK strain and boosting with 
NS3-5B-encoding plasmid DNA. A study in chimpanzees that received this vaccine then 
challenged with HCV demonstrated that control upon HCV challenge following vaccination 
was associated with CD127+ PD1lo CD8+ T cells that persisted at high levels for long times 
and were bifunctional (IFNγ+ TNFα+). Nevertheless, three out of five chimpanzees were not 
protected [344]. 
An important lesson learned from HIV vaccine trials is that the presence of a memory 
immune response did not necessarily correlate with the clinical protection upon reexposure 
[107, 108]. To date, the lack of a clear definition of the signatures that would constitute a 
protective immune response upon exposure to HIV hinders the rational design of an effective 
vaccine. The same limitation faces HCV vaccine trials, since  the correlates of protective 
immunity against HCV need to be clearly defined first, so that they could be monitored to 
verify the degree of protection conferred by vaccines in humans. 
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As with many chronic viral infections, the development of an effective prophylactic 
vaccine is hindered by the lack of knowledge about the determinants of a protective memory 
immune response in humans. HCV represents a unique model to study protective immunity in 
chronic viruses upon natural exposure, since ~30% of the patients are able to clear the primary 
infection spontaneously. The objective of this thesis is to study protective immunity against 
HCV in a cohort of IDUs who cleared a primary HCV infection and are continuously at risk of 
reinfection. We performed an exhaustive longitudinal analysis at time points before, during 
and after the HCV reinfection episode to dissect the general characteristics of HCV-specific T 
cells. 
The presence of HCV-specific memory T cells has already been demonstrated in both 
chimpanzees and humans [341, 348]. Evidence from rechallenge studies in chimpanzees 
suggest that this memory response might be protective against HCV upon re-exposure, since 
these studies showed that chimpanzees spontaneously clearing a primary infection had a 
higher level of protection than naïve ones when rechallenged with homologous viral 
sequences. This was accompanied by a shorter duration of viremia and lower viral loads in the 
cases that cleared the second infection [337, 338]. However, other studies did not observe 
protection even against homologous rechallenge [339]. A protective role for memory T cells 
was confirmed by using antibody-mediated depletion of either CD4 or CD8 T cells [238, 239]. 
In humans, the majority of studies in populations at risk of HCV infection and reinfection (e.g. 
IDUs) showed that the incidence of reinfection in patients who have cleared a primary HCV 
infection is less than those observed for infection in naïve patients belonging to the same 
cohorts under the same risk factors. All the studies that measured the clearance rate in both 
groups showed that the clearance of reinfection was higher than that for primary infection, 
supporting the notion that the memory immune response is protective in most cases [118, 351, 
354]. It is necessary to understand why individuals who spontaneously resolved a primary 
HCV infection would not be able to clear a second infection episode, versus others who 
successfully clear consecutive episodes of infection. To date, there is a lack of thorough 
studies dissecting the determinants of a protective immune response upon re-exposure to HCV 
or defining the correlates of protection against chronic viruses in humans.  
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Our hypothesis is that most subjects who spontaneously resolved a primary HCV 
infection would be protected against chronicity of infection upon re-exposure, thus achieving 
protective immunity rather than sterilizing immunity (i.e. the ability to clear HCV rapidly 
rather than not developing an infection at all). Protection against reinfection would likely be 
associated with enhanced breadth, frequency, polyfunctionality and functional avidity of 
HCV-specific CD4 and CD8 memory T cells. HCV-specific memory T cells associated with 
protection would likely be distinguished by a characteristic phenotype similar to that observed 
upon spontaneous resolution of primary HCV infection. The protective capacity of memory T 
cells upon reinfection will depend on possessing a T-cell repertoire characterized by high 
diversity of its clonotypic composition and flexibility enabling the generation of de novo T cell 
responses against different viral variants. The efficacy of this memory immune response 
would be –at least partially– dependent on the degree of homology of the sequences of the 
HCV-genome in the different episodes. On the other hand, subjects who fail to clear HCV 
reinfection (despite clearing a primary infection) would suffer from defects in the generation 
of an effective memory T-cell population capable of mounting a recall response upon 
reinfection, especially against different viral variants. 
We were able to recruit nine patients who resolved a primary HCV infection, but had a 
differential outcome of the second infection, and for whom longitudinal blood samples during 
the multiple episodes of HCV-infection were available. This represented a great advantage by 
allowing us to compare the different characteristics of the immune response under the same 
conditions. This rare cohort enabled us to perform an exhaustive longitudinal phenotypic and 
functional characterization of the HCV-specific memory immune responses, and also enabled 
us to analyse the dynamics of epitope-specific CD8 T-cell repertoire upon reinfection with 
different viral variants and correlate these dynamics with their avidity. More importantly, 
examining two groups of patients with differential outcomes of reinfection enabled us to 
determine which characteristics of the recall response were specifically associated with 
protection. Despite the limited number of patients (a challenge common when working with 
such cohorts), but still this study would provide primary insight for the first time into the 
characteristics of a protective immune response against HCV in a real-life infection setting. 
This would provide a road-map for the following steps needed to fully understand protective 
immunity against HCV at the cellular, molecular and clonotypic levels. 
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We had two specific aims for the project; the first aim was to define and dissect the 
general characteristics HCV-specific T cells that confer protective immunity upon reinfection. 
The second aim was to analyse the dynamics of the TCR repertoire of HCV-specific CD8 T-
cell in protected versus unprotected patients and in relation to infection with variant viral 
sequences.  
For the first specific aim we intended to define the correlation between protective 
immunity upon HCV reinfection and several characteristics of the adaptive immune 
response. These characteristics included; 1) the total magnitude and breadth of T-cell 
responses upon stimulation with peptide pools representing the entire HCV genome, 2) the 
proliferative capacity, functionality and polyfunctionality of CD4 and CD8 T-cells upon 
stimulation with immunodominant peptide pools and minimum peptides to which the patient 
possessed specific tetramer+ CD8+ T cells, 3) the frequency and phenotype of  tetramer+ 
CD8+ T cells and 4) the effect of variation in the viral sequences of the targeted epitopes on 
the generation of an effective recall response. 
For the second specific aim we intended to define the dynamics of the clonotypic 
composition of the TCR-repertoire of HCV-specific CD8 T cells associated with 
protective immunity upon HCV reinfection. We examined the correlation between 
protective immunity upon HCV reinfection and several characteristics of the TCR repertoire. 
These characteristics included; 1) the diversity of the repertoire composition, 2) role of 
specific clonotypes in protective immunity and 3) the recruitment of new clonotypes that were 
not mobilized during the primary infection. We also examined the dynamics of the CD8 T-cell 
repertoire and its functional avidity and polyfunctionality in response to different variants of 
targeted epitopes.  
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ABSTRACT 
Background & Aims: Vaccine development against hepatitis C virus (HCV) is hindered by 
our limited understanding of immune correlates of protection during real life exposures. Our 
aim was to define such correlates during HCV reinfection.  
Methods: We monitored the phenotypic and functional dynamics of HCV-specific T cell 
memory responses in HCV-resolved injection drug users (IDUs) during natural re-exposure 
and re-infection.  
Results: Individuals who spontaneously resolved two successive infections (n=5), 
demonstrated expansion of HCV-specific polyfunctional memory CD4 and CD8 T cells. We 
detected CD127hi HCV-specific memory CD8 T cells prior to reinfection regardless of the 
ability to clear the subsequent infections. Protection against viral persistence was associated 
with the expansion of a CD127neg, PD-1lo effector memory T cells at the peak of the response. 
In addition, we observed broadening of the T cell response suggesting generation of de novo T 
cell responses. Individuals who failed to clear their subsequent infection (n=4) demonstrated 
limited expansion of HCV-specific CD4 and CD8 memory T cells and variable levels of 
expression of the exhaustion marker PD-1 on HCV-specific CD8 T cells. Finally, viral 
sequencing of dominant HCV epitope regions from patients who developed viral persistence 
upon reinfection demonstrated variations in the infecting viral sequence that were not 
recognized by the pre-existing memory T cells.  
Conclusions: Our results suggest that protection from persistence upon HCV reinfection is 
dependent on the magnitude, breadth and quality of the HCV-specific memory T cell 
response. The sequence homology and cross recognition between the infecting viral strains 
remain critical determinants of protective memory.  
Keywords: hepatitis C virus; reinfection; protective immunity 
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INTRODUCTION 
Despite the recent introduction of potent antivirals against HCV, there is an urgent 
need for an effective prophylactic vaccine. A first step is defining correlates of protective 
immunity during real life exposure among high risk populations like IDUs1. CD4 and CD8 
HCV-specific T cell responses are induced during acute HCV and mediate spontaneous 
resolution. An effective response leading to viral clearance is typically of high magnitude, 
broad, polyfunctional (i.e. producing more than one cytokine or function) and sustained2. 
Individuals who spontaneously resolve acute HCV develop long-lived memory T cells3, 4. 
Chimpanzees who have resolved one HCV infection were protected from chronic infection 
upon re-exposure but protection was less efficient upon heterologous viral re-challenge 
(reviewed in 5). Accelerated viral clearance was associated with rapid recall of memory T cell 
responses4 and CD4 T cell help was critical to maintain an efficient memory T cell response6. 
In humans, high risk IDUs who have already resolved one HCV infection were less likely to 
be re-infected than HCV-naïve individuals1, 7. Osburn et al. demonstrated that reinfections 
were characterized by reduced peak and duration of viremia as compared to primary infection 
and associated with broadened cellular immune responses that facilitated viral clearance8. 
However, the detailed phenotype and function of HCV-specific T cells during reinfection in a 
real-life exposure setting remain poorly defined. 
Here, we examined longitudinally the breadth, phenotype and effector functions of the 
HCV-specific memory T cell response and variations in viral sequence during HCV 
reinfection in a group of IDUs who have previously resolved a primary HCV infection.  
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MATERIALS AND METHODS 
HCV RNA, Genotype and HCV-Antibody Testing  
Qualitative HCV-RNA was tested using COBAS Ampliprep/COBAS Amplicor HCV Test, version 2.0 
(Roche Molecular Systems, Branchburg, NJ) (). HCV genotyping was performed as 
previously described9. Anti-HCV antibodies were assessed by the AxSym HCV Assay (Abbott 
GMBH & CO, K.G.).  
 
Peptides and HLA Class I Tetramers 
Peptides were synthesized by Sheldon Biotechnology Centre, McGill University (Montreal, 
QC, Canada). MHC class I tetramers were synthesized by the National Immune Monitoring 
Laboratory (NIML), (Montréal, QC, Canada) or the NIH Tetramer Core Facility (Emory 
University, Atlanta, GA) and are as follows: HLA-A1 restricted HCV NS3 peptide amino 
acids (aa) 1436–1444 (ATDALMTGY) [A1/NS3-1436], HLA-A2 restricted HCV NS3 
peptide aa 1073–1081 (CINGVCWTV) [A2/NS3-1073], HLA-B27 restricted HCV peptide 
NS5B peptide aa 2841-2849 (ARMILMTHF) [B27/NS5B-2841].. 
 
Flow cytometry based assays 
All assays were performed on frozen PBMCs using a standard BD LSR II instrument with 
FACSDiva software version 6.1.3 (BD Biosciences). Data files were analyzed using FlowJo 
software version 9.5 for Mac (Tree Star, Inc., Ashland, OR). Tetramer staining coupled with 
phenotypic analysis, intracellular cytokine staining (ICS) and CD107a degranulation assay 
were performed as previously described10 in response to HCV peptide pools (1 µg/ml) or HCV 
minimum peptide (10 µg/ml). Polyfunctionality was assessed by exporting flow cytometry 
standard (FCS) data as Boolean gates using FlowJo and SPICE softwares11. 
Carboxyfluorescein succinimidyl ester (CFSE) 6 days proliferation assays were performed as 
previously described10 with or without HCV minimum peptide or peptide pool.  
 
HCV Epitope Sequencing  
HCV RNA was extracted from EDTA plasma using AxyPrep Body Fluid Viral DNA/RNA 
Miniprep Kit (Axygen, Union City, CA), reverse transcribed, PCR amplified, cloned and 
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sequenced as previously described10 at the Molecular Biology and Functional Genomics 
service of the Institut de Recherches Cliniques de Montréal (Montreal, QC). 
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RESULTS 
Identification of HCV reinfection cases 
This study was conducted among participants of the Montreal Acute Hep C IDU 
Cohort Study (HEPCO)12 and approved by the institutional ethics committee (Protocol 
SL05.014). Primary HCV infection was identified in cohort participants who were initially 
negative for both HCV RNA and anti-HCV antibodies for at least 6 months of follow-up, then 
had a positive HCV RNA and/or antibody test as previously described10, 13. Participants who 
have resolved their primary HCV infection or participants who tested HCV RNA negative and 
HCV antibody positive at recruitment were enrolled in the reinfection study and followed 
every 3 months. HCV reinfection was defined by an HCV-RNA positive test following two 
negative tests, at least 60 days apart. The day of the first positive RNA test was defined as day 
zero post detection of reinfection (p.ri.). This study includes nine cases of reinfection 
identified between 2009 and 2012 for whom clinical data documenting their primary infection 
and longitudinal blood samples during the reinfection episode were available. Samples before 
the reinfection episode were available for 6 patients. Samples from time points during or right 
after clearance of the primary infection were available for 4 patients. Five patients 
spontaneously resolved their second infection while four patients became chronically infected, 
referred to hereafter as the SR/SR group and the SR/CI group, respectively. Patients’ 
demographics, clinical characteristics and infection history are listed in Supplementary Table 
S1.  
 
Spontaneous resolution of HCV reinfection is associated with an increase in the 
magnitude and breadth of the HCV-specific T cells 
We examined the magnitude and breadth of the HCV-specific T cells using an IFNγ 
enzyme-linked immunospot (ELISPOT) assay against overlapping peptide pools representing 
the HCV genotype 1a H77 polyprotein. We chose this reference sequence for the preliminary 
screening since all second infections were of genotype 1 and subtype 1a is the most common 
subtype in our cohort. The genotype of the primary infecting HCV viral strain could not be 
determined in many subjects because of rapid viral clearance, low viral loads or unavailability 
of samples. Wherever samples were available, we monitored the ELISPOT response before 
and during the second infection in the SR/SR (Figure 1A) and SR/CI (Figure 1B) patients. The 
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magnitude of the HCV-specific T cell response during reinfection was higher in the SR/SR 
group as compared to the SR/CI group. The average frequency at the earliest time point tested 
following reinfection (Mean: 8 weeks) was 7440 spot forming cells (SFC)/million PBMCs in 
the SR/SR group versus 1760 SFC/million PBMCs in the SR/CI group. The response to pools 
representing the structural and non-structural regions of HCV was higher for the SR/SR group 
(Mean: 1470 and 5970 SFC/million PBMCs, respectively) as compared to the SR/CI group 
(Mean: 160 and 1600 SFC/million PBMCs) (Figure 1C). The breadth of the immune response, 
measured by the number of peptide pools targeted by the immune response, was also higher in 
the SR/SR group at the earliest time point during reinfection. An average of 10 (out of 11) 
peptide pools were targeted in the SR/SR group, versus 7 pools for the SR/CI group (Figures 
1A, 1B and data not shown).  
Expansion of the HCV-specific memory T cells was associated with viral clearance 
upon reinfection in the SR/SR group. One exception was patient SR/SR-3, who successfully 
cleared his reinfection within 4 weeks despite no change in the magnitude and breadth of the 
response against the HCV genotype 1a peptides (Supplementary Figure S1A). Since the 
infecting subtype could not be determined, we tested his response to a panel of peptides 
corresponding to genotype 1b J4 reference sequence and observed an increase in the overall 
frequency and breadth of HCV-specific T cell responses upon reinfection (Supplementary 
Figure S1B). We also retested patients where the reinfection subtype was undetermined using 
genotype 1b peptides (Supplementary Figure S1 C, D and E) and demonstrated that the 
response was slightly higher against the 1a peptide panel as compared to 1b at the same time 
points suggesting that they were probably infected with a genotype 1a virus. 
 
Spontaneous resolution of HCV reinfection is associated with enhanced proliferation of 
HCV-specific CD4 and CD8 T cells 
Next, we examined the proliferative capacity of HCV-specific CD4 and CD8 T cells in 
a CFSE dilution assay against peptide pools corresponding to the immunodominant regions of 
HCV (NS3 and NS5B) and/or the peptide pools showing the highest response in ELISPOT. 
Representative FACS data are presented in Supplementary Figure S2. Proliferation data for 
CD4 and CD8 T cells from two patients of each group are presented as stimulation index (SI) 
in Figure 2. Patient SR/SR-1 for whom samples prior to reinfection were available 
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demonstrated high proliferation of CD4 T cells against the peptide pools tested (NS3-1 and 
NS5B-1) at baseline (Figure 2A). This proliferative capacity increased 3 folds at 6 weeks p.ri. 
Similarly, patient SR/SR-4 demonstrated some CD4 T cell proliferation at week 6 p.ri. against 
several pools that increased 3-5 fold by 32 weeks p.ri. (Figure 2A). In contrast, we observed 
very limited increase in CD4 T cell proliferation for patient SR/CI-1 and the existing 
proliferative response became undetectable by week 57 p.ri and patient SR/CI-3 demonstrated 
very limited proliferation (Figure 2B).  
For CD8 T cell proliferation, patient SR/SR-1 demonstrated high proliferative response 
prior to reinfection that increased to an SI of 560 in response to NS3 pool 1 at 6 weeks p.ri. 
(Figure 2C). In patient SR/SR-4 very high levels of proliferation were observed at 6 weeks 
against all pools tested and although they partially declined at week 14, they recovered and 
were sustained at week 51 p.ri. (Figure 2C). In contrast, no CD8 proliferative responses were 
detected in the two SR/CI patients against the peptide pools tested (Figure 2D). In summary, 
spontaneous resolution of second HCV infection was associated with an increase in HCV-
specific CD4 and CD8 T cell proliferative responses. 
 
Spontaneous resolution of HCV reinfection is associated with enhanced cytokine 
production by HCV-specific T cells 
Polyfunctional CD8 T cells producing several effector cytokines and molecules are 
associated with spontaneous resolution of primary acute HCV10. We thus examined the 
polyfunctionality of HCV-specific T cells longitudinally during reinfection in two SR/SR and 
two SR/CI patients against peptide pools corresponding to the immunodominant regions of 
HCV and/or pools showing the highest response in ELISPOT. We assessed the production of 
the antiviral cytokines IFNγ, tumor necrosis factor alpha (TNFα) and the T cell growth factor 
IL-2 for CD4 and CD8 T cells. For CD8 T cells we also monitored the expression of the 
degranulation marker CD107a. Representative FACS plots are presented in Supplementary 
Figure S3.  
The production of the individual cytokines by CD4 T cells was higher in the two 
SR/SR patients (Figures 3A and 3B) when compared to the SR/CI patients (Figures 3C and 
3D). IFNγ was the major cytokine produced by CD3+CD4+ T cells from the SR/SR patients 
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reaching up to 3.33% followed by TNFα reaching up to 2.13% (Figures 3A and 3B). In 
contrast, production of individual cytokines was weak in the two patients from the SR/CI 
group reaching only 0.69% of CD3+CD4+ T cells (Figures 3C and 3D). When 
polyfunctionality was examined, we observed that 6-33% of the total cytokine producing cells 
in patient SR/SR-1 produced more than one function at different stages of reinfection as 
compared to 3-21% in patient SR/CI-2. Cytokines producing cells were strictly 
monofunctional, producing primarily IFNγ in patient SR/SR-4. In patient SR/CI-4, although 
50% of cytokine producing cells produced two cytokines at 23 weeks p.ri, the low frequency 
of cytokine producing cells may have biased the results. These results suggest an association 
between the level of individual cytokine production (IFNγ or TNFα) by HCV-specific CD4 T 
cells rather than polyfunctionality with the protection from chronicity upon reinfection. 
HCV-specific CD8 T cells from the SR/SR patients also expressed higher levels of the 
individual cytokines and CD107a as compared to SR/CI patients (Figure 4). IFNγ was the 
major cytokine produced by CD3+CD8+ T cells from the SR/SR patients reaching up to 5.22% 
followed by TNFα and the degranulation marker CD107a (Figures 4A and 4B). Individual 
cytokine production or CD107a expression was weak in the SR/CI group with a maximal 
production of 0.49% of CD3+CD8+ T cells (Figures 4C and 4D). Polyfunctionality was also 
higher in the SR/SR group, where we observed that ~6% of the total functional cells in the two 
SR/SR patients produced three functions at different stages of reinfection as compared to none 
in the two SR/CI patients. Furthermore, 15-52% of total cytokine/CD107a expressing cells 
expressed two functions in the SR/SR patients as compared to none in the SR/CI group 
(except the latest time point in patient SR/CI-4 where the overall frequency of functional cells 
was 0.2%) (Figure 4). In summary, the frequency of individual cytokine producing CD8 T 
cells was higher in the SR/SR group and within these functional cells the frequency of 
polyfunctional cells was higher. These results suggest an association between the level of 
individual cytokine production and polyfunctionality of HCV-specific CD8 T cells and 
protection from viral persistence upon reinfection. 
 
Spontaneous resolution of HCV reinfection is associated with higher polyfunctionality of 
HCV-specific CD8 T cells targeting minimal epitopes 
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 Next, we evaluated polyfunctionality of HCV-specific CD8 T cells in response to 
predicted minimal epitopes restricted by HLA-A2 and showing the highest response (NS5B-
2594 and NS3-1073) in two patients from the SR/SR and two patients from the SR/CI group. 
The production of individual cytokines and/or expression of CD107a was higher in the SR/SR 
group when the cells were stimulated with the minimum cognate peptide reaching 3.58% 
(mean 0.54%) of the total CD3+CD8+ T cells (Figures 5A and 5B). In contrast, individual 
cytokine production and/or CD107a expression in the SR/CI group never exceeded 0.22% 
(mean 0.06%) (Figures 5C and 5D). The frequency of CD3+CD8+ T cells expressing two or 
three functions was 14% and 7%, respectively of total CD3+CD8+ functional T cells in the 
SR/SR patients (Figures 5A and 5B) and almost none in the SR/CI patients (Figures 5C and 
5D). Similar to previous results using peptide pools, these data suggest an association between 
the level of individual cytokine production and polyfunctionality of HCV-specific CD8+ T 
cells targeting dominant epitopes with the protection from persistent viremia upon reinfection 
with HCV. 
 
Spontaneous Resolution of HCV reinfection is associated with expansion of CD127lo 
HCV tetramer+ CD8 T cells 
Next, we performed longitudinal phenotypic analysis of HCV-specific CD8 T cells to 
assess their frequency, differentiation and exhaustion status using the predicted MHC class I 
tetramers detailed in Supplementary Table S1. We monitored markers of T cell maturation and 
memory (CD27 and CD127) and T-cell activation/exhaustion (PD1, 2B4 and Tim3) on 
tetramer+ CD8 T cells. Representative FACS results for patient SR/SR-1, using the A2/NS3-
1073 tetramer are shown in Figure 6A and Supplementary Figure S4A, and for A2/NS5B-
2594 tetramer in Supplementary Figure S5. Representative data for patient SR/CI-1, using the 
A1/NS3-1436 tetramer, are shown in Figure 6B and Supplementary Figure S4B. Tetramer 
frequency data during reinfection in all subjects are represented in Figure 6C. We observed an 
average expansion of 42 folds at the peak of response (<6 weeks p.ri.) in patients of the SR/SR 
group (Figure 6C). The only exception was patient SR/SR-3, where the reinfecting HCV 
genotype was likely 1b rather than the 1a sequence used in the tetramer (Supplementary 
Figure S1A). Very limited expansion was observed in the tetramer+ population upon 
reinfection in all patients of the SR/CI group (Figure 6C).  
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The most distinctive phenotypic change was expression of CD127. In one SR/SR and 
two SR/CI patients where samples were available during the first infection, we observed that 
approximately half of the HCV tetramer+ CD8 T cells were CD127hi. As patients cleared their 
primary HCV infection, the majority of tetramer+ CD8 T cells became CD127hi as previously 
described10 and consistent with a memory T cell phenotype14. A similar phenotype was 
observed for the tested time points prior to reinfection. At the earliest time point tested during 
reinfection we observed peak expansion of tetramer+ cells in SR/SR patients and the majority 
of these expanded cells were CD127lo, consistent with an effector phenotype (Figures 6A and 
6D). In the SR/CI patients, tetramer+ cells did not expand or undergo significant changes in 
the CD127 expression (Figures 6B and 6D). There was no significant variation in the 
expression of the other markers examined (CD27, Tim3 or 2B4) at the different time points 
tested for the two groups of patients (Supplementary Figure S4). Finally, We observed higher 
expression of the activation marker PD1 on HCV tetramer+ CD8+ T cells in most patients 
(3/4) of the SR/CI group in comparison to SR/SR patients (Figures 6B and 6E). In summary, 
spontaneous resolution of a second HCV infection was associated with expansion of pre-
existing memory T cells into CD127lo effectors and lower levels of PD1. 
In patient SR/SR-1 who was positive to two tetramers A2/NS3-1073 and A2/NS5B-
2594, we observed different levels of expansion of CD8 T cells specific to the two tetramers. 
The frequency of the A2/NS5B-2594 tetramer+ T cells was at a much lower level than that for 
NS3-1073 prior to reinfection (0.082% and 0.458%, respectively) (Figure 5A and 
Supplementary Figure S5), yet the A2/NS5B-2594 tetramer+ population expanded 120 folds 
upon reinfection (Supplementary Figure S5) compared to 7 folds only for the A2/NS3-1073 
tetramer+ population (Figure 5A) (9.84% and 3.37%, respectively). This suggests a shift in the 
dominance of the epitopes targeted in this patient during reinfection.  
 
Heterogeneity in targeted epitopes and reduced recognition during reinfection in the 
SR/CI group 
Despite the limited expansion of HCV-tetramer+ CD8 T cells in patients of the SR/CI 
group upon reinfection, they proliferated in response to their cognate epitope in an in vitro 
CFSE proliferation assay (data not shown) suggesting that they are not inherently defective in 
proliferation. To determine whether this lack of expansion in the SR/CI patients is due to 
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reinfection with variant viral sequences that are not recognized by the pre-existing memory T 
cells, and to determine whether the change existed since the beginning or arose during 
reinfection, we sequenced the NS3-1436 and NS3-1073 epitopes targeted by the four patients 
at the earliest and the latest time points available during reinfection (Figure 7A). We detected 
a mismatch between the amino acid sequence of the reference peptide used in the tetramer and 
the autologous HLA-A1 restricted NS3-1436 epitope in patients SR/CI-1 and SR/CI-3 at the 
early and late time points. This 1444 Y → F substitution was previously shown to be recognized 
less efficiently by specific T cells15. An amino acid substitution 1077V → A was observed in 
the NS3-1073 for patients SR/CI-2 and SR/CI-4 at the early time point. This variant was also 
previously suggested to be less efficient in inducing CD8 T cell expansion and IFNγ 
production16, 17. This variant remained fixed in patient SR/CI-4 at the late time point but 
underwent three additional changes in patient SR/CI-2: 1077V → A; 1081V → I and 1078 W→ L 
substitution.  
To determine how well the pre-existing memory T cells recognized the reference 
versus the autologous sequences, we tested their functional avidity by measuring dose-
dependent production of IFNγ in response to stimulation by the different epitope variants 
during the reinfection episode in SR/SR and SR/CI patients. We observed higher functional 
avidity of HCV-specific T cells from SR/SR patients in response to the NS3-1073 reference 
epitope sequence when compared to SR/CI patients (Figure 7B). Patient SR/SR-4 had higher 
functional avidity than patient SR/SR-1 in response to the reference sequence and the response 
was >10-folds than patient SR/CI-2. Patient SR/CI-4 poorly recognized all variants. 
Interestingly, Patient SR/SR-4 also responded to the intermediate variant sequence of the NS3-
1073 epitope indicating better cross-recognition of this variant. The reference sequence of the 
NS3-1436 was also better recognized than the autologous variant by patients SR/CI-1 and 
SR/CI-4. Altogether, these results suggest that variations in the targeted epitope could be a 
possible mechanism underlying the functional differences or lack of recognition in HCV-
specific CD8 T cells observed between the two groups of patients. 
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DISCUSSION 
We have performed an exhaustive phenotypic and functional characterization of the 
virus-specific T cell response during HCV reinfection. Although all nine patients in this study 
had successfully eliminated an earlier HCV infection, only five of them were able to 
spontaneously resolve their subsequent infection. Spontaneous resolution of reinfection was 
associated with an increase in both the magnitude and breadth of the total HCV-specific T cell 
response suggesting generation of de novo T cells responses. In addition, we observed 
expansion of HCV-specific memory T cells and the transient appearance of CD127low 
population indicative of an effector T cell phenotype. Patients who failed to clear their 
subsequent infection showed very limited expansion of HCV-specific T cells. Variations in the 
autologous sequence of the targeted epitopes were detected in all patients of this group and not 
recognized by the pre-existing memory T cells.  
Protection from viral persistence upon HCV reinfection was associated with an 
increase in the magnitude and breadth of the HCV-specific T-cell response as observed by 
ELISPOT assays and tetramers consistent with the observations of Osburn et al. 8. For the 
SR/SR group the increase in the magnitude and the de novo responses mostly targeted the non-
structural proteins underscoring the immune dominance of this region18, 19. Furthermore, in 
patient SR/SR-1, we observed a shift in dominance between the two epitopes targeted. Further 
research with additional patients is required to elucidate whether shifting dominance may 
occur upon reinfection with variant viral strains or may reflect differential expansion capacity 
of memory T cells. 
Proliferation of CD4 and CD8 T cells is predictive of the outcome of primary HCV 
infection20, 21. We demonstrate that protective immunity upon reinfection was associated with 
higher proliferative capacity for both CD4 and CD8 T cells when stimulated with peptide 
pools representing immunodominant regions. Nevertheless, proliferation assays using cognate 
epitopes demonstrated that HCV tetramer+ memory CD8 T cells in the SR/CI unprotected 
group proliferated to similar levels as those of the SR/SR protected group (data not shown). 
This suggests they are not inherently defective, and despite being present at low frequency, 
they could expand if stimulated with the right peptide or antigen. 
Spontaneous resolution of primary acute HCV and response to vaccination were 
associated with generation of polyfunctional HCV-specific CD127+ CD8 T cells10, 22. Here, 
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we demonstrate that polyfunctionality is also an important determinant of viral clearance upon 
reinfection. Furthermore, we extend this polyfunctionality to CD8 T cells targeting entire 
regions of HCV, as well as, minimal epitopes. Data from the HIV model suggest that such 
polyfunctional T cells are cells of the highest functional avidity23. It is also tempting to 
speculate that repeated reinfections with the same viral variant would selectively expand and 
enrich such cells. On the other hand, rechallenge with a slightly different antigenic variant 
may favor expansion of T cells carrying a flexible T cell receptor that can recognize these new 
variants. Flexibility in the T cell repertoire correlated with control of viral escape mutants 
during HCV and HIV infections24-26 and would require further investigation in the reinfection 
setting. 
Our results suggest that pre-existing variations in the viral sequence of the epitopes 
targeted by the memory immune response could be a possible reason for persistence upon 
reinfection. We demonstrated higher functional avidity in response to the reference sequence 
of the epitope in the SR/SR group. In addition, three SR/CI patients had higher response to the 
reference sequence than the autologous sequence. No mutations were observed during the 
course of the reinfection, except for the NS3-1073 epitope in patient SR/CI-2 where the 
epitope underwent three changes during the reinfection episode, suggesting that it may have 
been under immune selection pressure. The fact that this intermediate variant was recognized 
by patient SR/SR-4 suggests that this variant can be recognized by some individuals. 
However, those changes in the targeted epitopes do not explain the general decrease in the 
frequency of the immune response observed in ELISPOT analysis. Thus, the association 
between the magnitude of the T cells and the degree of homology in the entire HCV genome 
between the infecting viruses in both episodes of infection remains to be assessed.  
The capacity to detect HCV reinfection is dependent on the testing interval, so we 
cannot rule out that we have missed shorter low level infections that may have contributed to 
exhaustion of HCV-specific T cells or expansion of HCV-specific regulatory T cells (Tregs) 
that may suppresses T cell responses against subsequent primary acute infection27. Since the 
patients studied here have all cleared a previous primary acute HCV infection with systemic 
viremia and that the memory T cells responded efficiently to in vitro stimulation with their 
cognate peptides, it is unlikely that inhibition by Tregs was a major player. These issues need 
to be addressed by closer follow-up intervals and improved patient questionnaires that can 
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identify high risk exposures, with tools to detect low level viremia or potential subclinical 
infections. Similarly, the contribution of other CD4 T cell subsets like Th17 cells in the 
maintenance of memory CD8 T cells, as well as the cross regulation between Tregs and Th17 
will require additional investigations13. 
Osbourn et al. demonstrated that spontaneous resolution upon HCV reinfection 
correlates with generation of neutralizing antibodies. We attempted to examine the 
neutralizing capacity of longitudinal plasma samples against a panel of cell-cultured HCV 
(HCVcc) representing the most common HCV genotypes in Canada (Genotypes 1a, 1b and 
3a). However, no distinct difference could be detected between the SR/SR and SR/CI group 
which may be due to the low number of patients in each group (data not shown).  
In conclusion, we demonstrate that protection against HCV persistence upon re-
exposure is possible. Although we could not assess whether there was sterilizing immunity or 
long-term protection in our cohort, our results and results from other groups suggest that 
protection from viral persistence is higher upon subsequent exposure than primary infection. 
We also demonstrate that changes in the breadth of the immune response and immune 
dominance are possible, suggesting generation of de novo T cell responses and offering hope 
for vaccine development. Immunization and boosting with different HCV genotypes may 
afford a broader and more effective protection.  
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         Figure 1 
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Figure 1: Higher magnitude and breadth of the HCV-specific T cell response in the 
SR/SR as compared to SR/CI patients. PBMCs from the indicated time points were tested in 
an IFNγ ELISPOT assay against overlapping peptide pools representing the HCV (H77) 
polyprotein. The frequencies of IFNγ spot forming cells (SFC) per million PBMCs from four 
SR/SR patients (A) and four SR/CI patients (B) are shown. The dashed lines delineate the 
different infection episodes. (C) Frequency of cells targeting the structural versus the non-
structural proteins at the earliest time point (mean 8 weeks) during reinfection in the SR/SR 
(open symbols) and the SR/CI (solid symbols) patients. 
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         Figure 2 
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Figure 2: Higher proliferative capacity of HCV-specific CD4 and CD8 T cells from 
SR/SR patients as compared to SR/CI patients. Proliferation of HCV-specific T cells in a 6-
day CFSE proliferation assay against overlapping peptide pools spanning the HCV proteins 
indicated. Representative proliferation data for CD4 T cells from two SR/SR (A) and two 
SR/CI (B) patients. Representative proliferation data for CD8 T cells from two SR/SR (C) and 
two SR/CI (D) patients. Proliferating cells were identified as percent viable CFSElo, CD4+ or 
CD8+, CD3+ T cells and presented as stimulation index (SI). SI is calculated by dividing the 
percentage of proliferating cells in the stimulated sample by the percentage of proliferating 
cells in the non-stimulated control under the same conditions. 
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         Figure 3 
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Figure 3: Higher production of cytokines by HCV-specific CD4 T cells from SR/SR 
patients as compared to SR/CI patients during reinfection. PBMCs were stimulated with 
overlapping peptide pools representing HCV (NS3 and NS5B) and pools showing the highest 
response in the IFNγ ELISPOT then ICS was performed to measure the production of IFNγ, 
IL-2 and TNFα. Representative results from two SR/SR patients (A, B) and two SR/CI 
patients (C and D), gated on CD4+ CD3+ viable T lymphocytes. Peptide pools are indicated 
between brackets and represent the following regions: NS3-1 (NS3 aa: 1016-1341), NS5B-1 
(NS5B; aa: 2416-2720) and NS5B-2 (NS5B; aa: 2710-3014). For polyfunctionality, orange 
represents triple functional cells, green represents double functional and yellow represents 
monofunctional cells of any combination.  
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         Figure 4 
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Figure 4: Higher polyfunctionality of HCV-specific CD8 T cells from SR/SR patients in 
comparison to SR/CI patients during reinfection. PBMCs were stimulated overnight with 
overlapping peptide pools representing HCV (NS3 and NS5B) and HCV pools showing the 
highest response in the IFNγ ELISPOT. ICS was performed to measure the production of 
IFNγ, IL-2 and TNFα and expression of CD107a. Representative results from two SR/SR 
patients (A, B) and two SR/CI patients (C and D), gated on CD8+ CD3+ viable T 
lymphocytes. Peptide pools are indicated between brackets and represent the following 
regions: NS3-1 (NS3 aa: 1016-1341), NS5A-2 (NS5A; aa: 2192-2426) and NS5B-1 (NS5B; 
aa: 2416-2720). For polyfunctionality, orange represents triple functional cells, green 
represents double functional and yellow represents monofunctional cells of any combination.  
 
  96 
 
 
         Figure 5 
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Figure 5: Higher polyfunctionality of HCV-specific CD8 T cells targeting minimal 
epitopes in SR/SR patients in comparison to SR/CI patients during reinfection.  PBMCs 
from the indicated time points were stimulated overnight with the minimum cognate peptide 
and ICS/CD107a staining was performed. Representative results from two SR/SR patients (A 
B) and two SR/CI patients (C and D), gated on viable CD3+CD8+ T lymphocytes. Peptides 
used are: 1073 = A2 restricted NS3-1073 and 2594 = A2 restricted NS5B-2594. 
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Figure 6: Expansion of HCV-specific tetramer+ CD8 T cells upon reinfection and 
generation of a CD127lo effector T cell population in SR/SR patients. HCV tetramer 
staining and phenotyping were performed directly ex vivo on PBMCs from the indicated time 
points. Representative dot plots for longitudinal tetramer staining (upper panels) and 
phenotyping (lower panels) for (A) patient SR/SR-1 with A2/NS3-1073 tetramer and (B) 
patient SR/CI-1 with A1/NS3-1436 tetramer. Top panels are gated on viable CD3+ T 
lymphocytes. Lower panels are gated on viable CD3+CD8+ T lymphocytes. Tetramer 
frequency is represented as percent Tetramer+ CD8+ CD3+ T cells. In lower panels, black 
dots represent the tetramer+ HCV-specific CD8+ T cells overlaid on grey contour plots of 
CD8+ CD3+ T cells. Numbers in each quadrant represent percent expression on tetramer+ 
CD8+ CD3+ T cells. The dashed lines delineate the different infection episodes. (C-E) 
Tetramer expansion and phenotyping data from all SR/SR and SR/CI patients; (C) Frequency 
of HCV tetramer+ CD8+ CD3+ T cells, (D) Frequency of CD127+ tetramer+ CD8+CD3+ T 
cells, (E) Frequency of PD1+ tetramer+ CD8+CD3+ T cells. 
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Figure 7: Sequence variation in targeted epitope and reduced recognition by CD8 T cells 
in SR/CI patients. (A) Sequences of the epitopes targeted by tetramer+ CD8 T cells in SR/CI 
patients at early and late time points during reinfection. (B) Responses of total PBMCs 
collected during reinfection in a dose-response IFN-γ ELISPOT assay to the reference 
sequences versus variant autologous sequences for two SR/SR patients in response to the NS3-
1073 epitope (left panels), two SR/CI patients in response to the NS3-1073 epitope (middle 
panels) and two SR/CI patients in response to the NS3-1436 epitope (right panels). 
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Supplementary Table S1: Patients’ characteristics and demographics 
 
Patient 
code 
Status at start of 
follow-up 
Age at 
reinfection 
(years) 
 
Gender 
 
Duration  
of 
injection  
(years) 
 
No of 
Injections 
during past 
montha 
 
Serum ALT 
during early 
reinfectionb 
(U/L) 
HCV Genotype 
(First infection/ 
Second infection) 
HLA 
Class I 
Reactive 
Tetramers 
     
  
   
SR/SR-1 HCV Resolver 53 M 13.4 
 
> 30 
 
 
 
3090 
 
ND/1 A2, B58 A2/NS3-1073 
A2/NS5B-2594 
          
SR/SR-2 HCV Resolver 43 M 15.4 
 
< 30 
 
25 ND/1 
A24/A26, 
B27/B49 
B27/NS5B-2841 
          
SR/SR-3 HCV Naïve 42 M 14.4 
 
> 30 
 
23 1a/1 
A23/A32 
B27/B44 
B27/NS5B-2841 
          
SR/SR-4 Early reinfection 36 F 12.3 
 
< 30 
 
15 ND/1 
A2/A24 
B7/B39 
A2/NS3-1073 
          
SR/SR-5 Early reinfection 44 M 31.5 
 
> 30 
 
183 ND/1a 
A2/A23 
B18/B49 
None 
          
          
SR/CI-1 HCV Naive 28 M 6.1 
 
> 30 
 
88 ND/1a 
A1 /A3      
B44/B49 
A1/NS3-1436 
          
SR/CI-2 Acute primary HCV 29 M 1.1 
 
< 30 
 
17 1a/1a 
A2,    
B39/B44 
A2/NS3-1073 
          
SR/CI-3 HCV Resolver 30 F 4.1 
 
< 30 
 
42 ND/1a 
A1/A29 
B35/B44 A1/NS3-1436 
          
SR/CI-4 Early reinfection 33 M 3 
 
> 30 
 
20 ND/1b 
A2,      
B44/B51 
A2/NS3-1073 
          
 
ND = Not determined; SR: Spontaneous Resolution; CI: Chronic Infection 
a A strong and independent predictor of HCV incidence in this cohort (Bruneau J et al, Addiction. 2012 Jul;107(7):1318-27) 
b at < 4 wks 
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Supplementary Figure S1: Lack of expansion of HCV-specific T cells in patient SR/SR-3 
upon reinfection, is due to being infected by a different HCV subtype. Results from 
longitudinal ELISPOT assays for patient SR/SR-3 where PBMCs were stimulated with 
overlapping peptide pools representing the entire HCV genome for (A) genotype 1a and (B) 
genotype 1b. The dashed lines delineate the different infection episodes. Responses to 
genotype 1b peptide pools during the reinfection episode for patients with genotype 1 and an 
unknown subtype SR/SR-1 (C), SR/SR-4 (D) and SR/CI-4 (E). BDL = Below detection level. 
The genotype of the infecting virus during primary infection was 1a for patient SR/SR-3, but 
unknown for the other three patients. The reinfecting virus was genotype 1 for the three SR/SR 
patients, but the subtype was not defined. For patient SR/CI-4 the reinfecting virus was 
genotype 1b.   
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    Supplementary Figure S2 
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Supplementary Figure S2: Higher proliferative capacity for HCV-specific CD4 and CD8 
T cells in SR/SR patients in comparison to SR/CI patients. Proliferation of HCV-specific 
CD4 and CD8 T cells was assessed in a 6-day CFSE proliferation assay against a panel of 
overlapping peptide pools representing the immunodominant regions of HCV (NS3 and 
NS5B) and HCV regions showing the highest response in the IFNγ ELISPOT assay. 
Representative dot plots showing the proliferation indicated by the percentage of CFSElo cells 
from patient SR/SR-4 (A) non-stimulated versus (B) stimulated with peptide pool NS3-1 (NS3 
aa: 1016-1341) and patient SR/CI-3 (C) non-stimulated versus (D) stimulated with peptide 
pool P7/NS2 (P7/NS2 aa: 743-1026). The cells were gated on viable CD3+ then CD4+ or 
CD8+ T lymphocytes. The percentage of proliferating cells is shown on the left of the 
histograms (upper panels) and on the dot plots (lower panels). 
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Supplementary Figure S3 
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Supplementary Figure S3: Higher production of cytokines/CD107a expression by HCV-
specific CD8 T cells in patients from SR/SR group in comparison to patients from SR/CI 
group.  (A) Gating strategy. Representative dot plots from (B) patient SR/SR-4 and (C) 
patient SR/CI-2 showing the production of cytokines (IFNγ, IL-2 and TNFα) and the 
expression of CD107a in response to stimulation with peptide pools representing NS5B-1 and 
NS3-1, respectively, gated on viable CD8+ CD3+ T lymphocytes.  
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    Supplementary Figure S4 
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Supplementary Figure S4: No significant changes in CD27 or the exhaustion markers 
Tim3 or CD244 (2B4) in either of the 2 groups of patients. Representative dot plots for 
phenotyping of (A) patient SR/SR-1 with A2/NS3-1073 tetramer and (B) patient SR/CI-1 with 
A1/NS3-1436 tetramer, showing the expression of CD27, Tim3 and 2B4 on tetramer+ cells. 
The black dots represent the tetramer+ HCV-specific CD8+ T cells overlaid on the grey 
contour plots representing total CD3+ CD8+ T cells in the same patient. Percentages of 
expression on tetramer+ cells are shown in each quadrant. 
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    Supplementary Figure S5 
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Supplementary Figure S5: Shift in immunological dominance of the targeted epitope 
between the primary infection and the reinfection episode in patient SR/SR-1. Dot plots 
for longitudinal tetramer staining (upper panel) and phenotyping (lower panel) from patient 
SR/SR-1 with A2/NS5B-2594 tetramer gated on viable CD3+ T lymphocytes. The A2/NS5B-
2594 tetramer+ population expanded higher frequencies than the A2/NS3-1073 tetramer+ cells 
that were present at a higher frequency post the primary infection (Figure 5A and 5C). 
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DETATILED MATERIALS AND METHODS 
IFNγ  ELISPOT assay 
HCV-specific T cell responses were measured using an IFNγ ELISPOT assay as previously 
described1 and an input of 2 × 105 PBMCs /well against 10 pools of overlapping peptides 
spanning the entire HCV polyprotein. Peptides were corresponding to the HCV genotype 1a 
(H77) and genotype 1b (J4) sequences (BEI Resources, Manassas, VA). Specific Spot forming 
cells (SFC) were calculated as “mean number of spots in test wells − mean number of spots in 
negative control wells” and normalized to SFC/106 PBMCs. A response was scored positive if 
greater than 50 SFC/106 PBMCs. 
 
Flow cytometry Antibodies 
Directly conjugated antibodies against the following molecules were used: CD3-Alexa Fluor® 
700 or –FITC (clone UCHT1), CD4-Pacific BlueTM or –PE or –FITC (clone RPA-T4), CD8-
Alexa Fluor® 700 or –Pacific BlueTM (clone RPA-T8), CD8-APC-H7 (clone SK1), CD27-
APC-H7 (clone M-T271), CD279/PD-1-APC (clone MIH4), CD244/2B4-FITC (clone 2-69), 
IFNγ-APC (clone B27), IL-2-PE (MQ1-17H12), TNFα-Alexa Fluor® 700 (clone MAb11) and 
CD107a/LAMP-1-PE-CyTM 5 (clone H4A3) all from BD Biosciences, San Diego, CA; CD3-
ECD (clone UCHT1) and CD8-ECD (clone SFCI21Thy2D3) from Beckman Coulter, 
Marseille, France; CD127/IL-7Ra-eFluor®450 (clone eBioRDR5) from eBioscience, San 
Diego, CA; Tim3-PerCP (clone 344823) from R&D Systems Inc., San Diego, CA). Live cells 
were identified using Aqua Live/Dead fixable dead cell Stain Kit (Life Technologies, 
Burlington, ON). Fluorescence minus one (FMO) control stains were used to determine 
background levels of staining. Multiparameter flow cytometry was performed using a standard 
BD LSR II instrument equipped with blue (488 nm), red (633 nm), and violet (405 nm) lasers 
(BD Biosciences,) using FACSDiva software version 6.1.3 (BD Biosciences). Data files were 
analyzed using FlowJo software version 9.4.11 for Mac (Tree Star, Inc., Ashland, OR).  
 
Phenotypic and functional analysis of HCV-specific T cells 
All assays were performed on archived frozen PBMCs. Tetramer staining for CD8-specific T 
cells was performed as previously described2 using the listed panel of tetramers. Intracellular 
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cytokine staining (ICS) and CD107a degranulation assay were performed as previously 
described2 in response to HCV peptide pool (1 µg/ml) or HCV minimum peptide (10 µg/ml) 
or SEB (200 ng/ml) as a positive control. Polyfunctionality was assessed by exporting flow 
cytometry standard (FCS) data as Boolean gates using FlowJo (version 9.5) and SPICE 
software3. Carboxyfluorescein succinimidyl ester (CFSE) proliferation assays were performed 
as previously described2 in a 6 day proliferation assay with or without HCV minimum-peptide 
or peptide pool (final concentration 1 µg/ml). Recombinant human IL-2 (20 IU/ml) (NIH 
AIDS Research and Reference Reagent Program, ATCC, Manassas, VA) was added 3 days 
post stimulation. 
 
Functional avidity assays 
Functional avidity of epitope specific CD8 T cells was measured as the dose-dependent 
production of IFNγ in response to stimulation by the reference and variant epitope sequences 
in an IFN-γ ELISPOT assay, as previously described 4. 
 
Statistical Analysis 
Statistical analysis for ELISPOT results was performed with GraphPad Prism 5 using one-
tailed Mann-Whitney test at a confidence interval of 90%.  
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ABSTRACT 
We have previously demonstrated that protection upon HCV reinfection correlates 
with increased breadth of the immune response and shifting epitope dominance (observed in 
one patient), suggesting the generation of de novo T-cell responses. Protection was also 
associated with HCV-specific T cells possessing higher polyfunctionality and functional 
avidity in response to reference epitopes and higher flexibility in response to epitope variants 
than T cells in the non-protected group. Here, we performed longitudinal analysis of the HCV-
specific T cell repertoire during HCV reinfection in the same two groups of patients; protected 
patients, who spontaneously resolved two consecutive infections (SR/SR group, n=3) and non-
protected patients, who resolved primary infection but became persistently infected upon 
reinfection (SR/CI group, n=2). Our results demonstrate that effector CD8 T-cell clonotypes 
associated with protection upon reinfection were recruited from the pre-existing memory 
population, but with a change in dominance and hierarchy of the clonotypes. The TCR 
repertoire was narrow in SR/SR patients pre-reinfection, with increased focusing upon 
reinfection. These results suggest that effector HCV-specific CD8 T-cell clonotypes associated 
with protection upon reinfection are recruited from the memory population, with focusing of 
the repertoire on specific clonotypes that exhibit superior functional avidity and 
polyfunctionality. 
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INTRODUCTION 
Definition of the correlates of protective immunity is crucial for designing prophylactic 
vaccines against chronic viruses such as HIV and HCV. We have previously demonstrated that 
protection from chronicity upon reinfection with HCV correlated with expansion of HCV-
specific polyfunctional effector T cells and increased breadth of T-cell responses, suggesting 
the generation of de novo T cell responses. In contrast, viral persistence was associated with 
limited expansion of virus-specific T cells and infection with variant viral strains, which were 
not recognized by the pre-existing virus-specific memory T cells 1. 
In this previous study we showed higher levels of functionality and polyfunctionality in 
protected (SR/SR) patients when compared to non-protected (SR/CI) patients in response to 
cognate minimal epitope 1. Autologous HCV-epitopes sequenced during reinfection were 
different from the reference epitopes in all SR/CI patients.  Dose-responses demonstrated 2 to 
10-folds higher avidity of HCV-specific T cells in SR/SR patients to the reference sequence 
when compared to SR/CI patients, and one SR/SR patient had a good response to one of the 
epitope variants, suggesting higher flexibility of the TCR-repertoire. SR/CI patients had very 
low/no avidity for the autologous epitope sequence of the reinfecting virus 1. 
The adaptive immune system generates a large number of T-cell clonotypes, each 
expressing a unique T-cell receptor (TCR). The TCR is formed of a heterodimer of the α and 
β chains. The variable region of both chains is generated by somatic gene recombination 
encoded by the variable (V), junction (J) and diversity (D) gene segments. Hypervariable 
complementarity-determining regions (CDRs) are encoded within the V gene segments. CDR3 
of the β-chain is formed by combinatorial and junctional variation, and has a major role in 
determining the specificity of the TCR2. The interplay between the TCR-repertoire and chronic 
viruses has been previously studied for different viral infections. For HIV, specific clonotypes 
dominated the response against an HIV-epitope in patients who controlled viral replication. 
These specific clonotypes showed higher avidity and polyfunctionality, and both 
characteristics were interrelated 3, 4. Certain clonotypes were observed in several controllers, 
thus termed “public” 5, 6, whereas other studies did not observe preferential use of particular 
clonotypes 7, 8. Mutations occurred in targeted epitopes to avoid recognition by these highly 
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effective clonotypes, driving expansion of alternative clonotypes with dual reactivity against 
both the original and mutated epitopes 9. For HCV, rechallenging chimpanzees with HCV 
following clearance of a primary infection demonstrated that resolution temporally coincided 
with the expansion of the dominant clonotype that was associated with the clearance of the 
primary infection 10. Higher diversity within the CDR3 region of TCR correlated with viral 
clearance and better control of the evolution of escape mutations within the targeted epitope, 
with temporary narrowing of the repertoire at the peak of the recall response 11.  
Here, we examined dynamics of the TCR repertoire relative to changes in HCV sequences 
during reinfection. Our objectives were to distinguish the role of pre-existing memory versus 
de novo T-cell responses in protection and to determine the importance of flexibility and 
diversity in the T-cell repertoire in controlling infection with variant HCV strains. Our results 
suggest that HCV-specific tetramer+ CD8+ T-cell clonotypes mobilized during the reinfection 
episode were exclusively recruited from the pre-existing memory population and that 
protective immunity in SR/SR patients is associated with a narrower TCR-repertoire that 
becomes more focused upon reinfection. 
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MATERILAS AND METHODS  
Study population and identification of HCV reinfection cases 
This study was conducted among participants of the Montreal Acute Hep C IDU 
Cohort Study (HEPCO)12 and approved by the institutional ethics committee (Protocol 
SL05.014). Primary HCV infection was identified in cohort participants who were initially 
negative for both HCV RNA and anti-HCV antibodies for at least 6 months of follow-up, then 
had a positive HCV RNA and/or antibody test as previously described13, 14. Participants who 
have resolved their primary HCV infection or participants who tested HCV RNA negative and 
HCV antibody positive at recruitment were enrolled in the reinfection study and followed 
every 3 months. HCV reinfection was defined by an HCV-RNA positive test following two 
negative tests, at least 60 days apart. The day of the first positive RNA test was defined as day 
zero post detection of reinfection (p.ri.). Nine cases of reinfection identified between 2009 and 
2012. This study includes five patients for whom samples before the reinfection episode were 
available. Samples from time points during or right after clearance of the primary infection 
were available for three patients. These five patients belonged to two groups; three patients 
spontaneously resolved their second infection while two patients became chronically infected, 
referred to hereafter as the SR/SR group and the SR/CI group, respectively. Patients’ 
demographics, clinical characteristics and infection history are listed in Table 1.  
 
HLA Class I Tetramers 
MHC class I tetramers were synthesized by the National Immune Monitoring Laboratory 
(NIML), (Montréal, QC, Canada) or the NIH Tetramer Core Facility (Emory University, 
Atlanta, GA) and are as follows: HLA-A1 restricted HCV NS3 peptide amino acids (aa) 
1436–1444 (ATDALMTGY) [A1/NS3-1436], HLA-A2 restricted HCV NS3 peptide aa 1073–
1081 (CINGVCWTV) [A2/NS3-1073], HLA-B27 restricted HCV peptide NS5B peptide aa 
2841-2849 (ARMILMTHF) [B27/NS5B-2841].  
 
Flow cytometry Antibodies 
Directly conjugated antibodies against the following molecules were used: CD3–FITC (clone 
UCHT1), CD8–Pacific BlueTM (clone RPA-T8) and CD45RO–Alexa Fluor® 700 (clone 
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UCHL1) from BD Biosciences, San Diego, CA; CD127/IL-7Ra–Alexa Fluor® 647 (clone 
HIL-7R-M21) from eBioscience, San Diego, CA. Live cells were identified using Aqua 
Live/Dead fixable dead cell Stain Kit (Life Technologies, Burlington, ON). Multiparameter 
flow cytometry and sorting was performed using a BD Aria II u instrument equipped with blue 
(488 nm), red (633 nm), and violet (405 nm) lasers (BD Biosciences,) using FACSDiva 
software version 6.1.3 (BD Biosciences). Data files were analyzed using FlowJo software 
version 9.4.11 for Mac (Tree Star, Inc., Ashland, OR).  
 
Purification and sorting of tetramer+ CD8+ T cells 
Frozen PBMCs were thawed and the CD8+ T cells were purified using the negative selection 
MACS CD8+ T cell Isolation Kit (Miltenyi Biotec Inc, Auburn, CA). Tetramer staining for 
CD8-specific T cells was performed as previously described13 using the listed panel of 
tetramers. Surface staining for CD3, CD8, CD45RO and CD127 was performed as previously 
described13 using the listed panel of antibodies. 
 
Sequencing the Vβ-chain of the TCR 
Genomic DNA was extracted from the sorted cells and the variable β-chain (Vβ) of TCR was 
sequenced using the high-throughput sequencing technology provided by Adaptive 
Biotechnology (Seattle, USA). The obtained data were analyzed using ImmunoSEQTM 
software. Clonotypes with a percentage of less than 0.01% of the total repertoire were 
excluded from the analysis.  
  
  126 
RESULTS  
Clonotypes expanding at the peak of reinfection are recruited from the pre-existing 
memory population rather than being de novo responses 
We performed longitudinal analysis of the HCV-epitope-specific T-cell repertoire 
during HCV reinfection in five patients with different outcomes of the reinfection episode; 
three patients who resolved two successive HCV infections (SR/SR group), and two patients 
who became persistently infected upon reinfection (SR/CI group) (Table 1). Epitope-specific 
CD8 T cells identified by MHC class I tetramer (as detailed in Table 1) were sorted at various 
time points; pre-reinfection, at the peak of reinfection and late/post the reinfection episode. 
The gating strategy used for sorting is explained in Supplementary Figure 1. The TCRBV 
gene and TCRBJ gene usage, as well as the CDR3 chain amino acid sequence for all Vβ 
chains for the different T-cell clonotypes were analysed (Supplementary Tables S1 to S5). 
This analysis led to several observations about the TCR-repertoire of epitope-specific CD8 T 
cell populations.  
We and others have reported that reinfection was associated with a significant increase 
in the breadth of T-cell responses suggesting the generation of de novo T-cell responses 1, 15. 
This raised the possibility that within the epitope-specific CD8 T-cell population, the effector 
cells appearing at the peak of the immune response during reinfection in the SR/SR group 
could be due to the recruitment of new clonotypes from the naïve T-cell pool. We 
distinguished the effector versus memory HCV-specific T cells according to the expression of 
the IL7-receptor α chain (CD127), and analyzed the repertoire of HCV-specific T-cell 
populations at the peak of immune response against reinfection to determine whether effector 
T cells were recruited from the memory pool or generated de novo. 
Our longitudinal analysis of the Vβ-chain of TCR did show a conserved pattern of Vβ 
usage in all of the tested patients, where the dominant and sub-dominant clonotypes forming 
the population at the peak of immune response during reinfection were recruited from the 
memory population generated following the clearance of the primary infection, with lack of 
appearance of new clonotypes (Figure 1 and Supplementary Tables S1 to S5). Nevertheless, 
the frequency of the different clonotypes changed upon reinfection causing a change in the 
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hierarchy of the utilized clonotypes. These results suggest that the effector CD8 T cells were 
effector memory cells (TEM) recruited from the central memory pool rather than being 
recruited from the naïve repertoire. 
 
Protective immunity in SR/SR patients is associated with a narrower TCR-repertoire 
that becomes more focused upon reinfection 
The interplay between the TCR-repertoire of epitope-specific CD8 T cells and chronic 
viruses has been studied in the context of the LCMV model, as well as HIV and HCV 
infections. The results from these studies were controversial concerning the diversity of the 
repertoire and its correlation with control of infection and reinfection, where some studies 
showed control was associated with a more diverse TCR-repertoire11, while other studies 
demonstrated it was associated with a more focused repertoire16, 17. 
Our analysis revealed that the clonotype-composition of the repertoire in the tested 
SR/SR patients was less diverse than that observed for SR/CI patients at pre-reinfection, where 
75-83% of the repertoire was attributed to 14-23 TCR-clonotypes, and it became more focused 
at the peak of the immune response during reinfection for patients SR/SR-1 and SR/SR-2 
(92% and 96% of the repertoire was attributed to 15 and 2 TCR-clonotypes, respectively) 
(Figure 2A, 2B and 2C). In those two patients, the repertoire retained a more focused status 
post reinfection when compared to the pre-reinfection time point, with 77% and 93% of the 
repertoire attributed to 16 and 4 clonotypes, respectively (Figure 2A and 2B). Patient SR/SR-3 
showed no focusing of the repertoire upon reinfection (Figure 2C), and this comes in 
accordance with our previous results, where there was no expansion of the tetramer+ 
population in this patient upon reinfection, and ELISPOT data suggested the patient was 
reinfected with a different HCV subtype 1. In contrast, the repertoire in the tested SR/CI 
patients was more diverse; where the dominant clonotypes (present at ≥1%) represented 37% 
and 55% of the repertoire and were attributed to 18 and 23 TCR-clonotypes, respectively. At 
the peak of the immune response during reinfection the repertoire was still more diverse than 
in the SR/SR patients (the dominant category represented 28-64% of the repertoire) (Figure 
3A and 3B). The remaining ~40-60% of the repertoire was represented by 130-300 clonotypes, 
whereas in the SR/SR patient the number of minor clonotypes never exceeded 116 unique 
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clonotypes (except at the time point post infection for patient SR/SR-1, where the sample was 
a leukaphoresis sample, and it had ~10-40 fold the number of sequences available for other 
time points in the same patient and other patients (indicated by an asterisk in the top row of 
Figure 2A)). Late during reinfection, we did not observe increased focusing of the repertoire in 
SR/CI patients, as compared to the pre-reinfection time point.  
A narrower repertoire that becomes more focused upon reinfection in the protected 
group was further supported by the observation that the top three clonotypes and the top two 
clonotypes in patients SR/SR-1 and SR/SR-2 represented 28% and 59% of the repertoire pre-
reinfection, respectively (Figure 2A and 2B, the dissected pie-charts in the lower rows). Upon 
reinfection they became more dominant, representing 51% and 96% of the repertoire, 
respectively. Post reinfection they were more dominat when compared to the pre-reinfection 
time point, forming 39% and 90% of the repertoire, respectively. On the other hand, the top 
three clonotypes in the tested SR/CI patients never represented more than 27% of the 
repertoire, and were sometimes as low as 9% (Figure 3A and 3B, the dissected pie-charts in 
the lower rows).  
Similarly, the Jβ usage was less diverse for SR/SR patients in comparison to SR/CI 
patients; where the top three TCRBJ alleles utilized at the different time points had an average 
of 81% in the former group versus 55% in the latter (Figure 4). The top Jβ-gene allele in the 
SR/SR group was TCRBJ 2.7, and it accounted for 43-97% of the total usage within the TCRβ 
chains in all clonotypes, versus 23-28% for the top Jβ-gene allele in SR/CI patients.  
Distinct clonotypes mobilized against the same epitope in different patients 
A study in HIV patients with a similar HLA allele background showed that infection 
controllers targeted an immunodominant epitope with T-cell clonotypes distinct from those 
observed in progressors. These clonotypes were characterized by superior control of viral-
replication in vitro and enhanced cross-reactivity to different variants of the epitope 8. Some of 
these clonotypes were recurrently observed in several patients of the controllers’ group (6/19) 
5. Whether protective immunity upon HCV reinfection in a human cohort would be associated 
with specific clonotypes dominating the TCR-repertoire that are distinct from clonotypes 
observed in the non-protected group is still an area that needs extensive studying. 
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Our analysis demonstrate that the dominant and subdominant Vβ-CDR3-Jβ detected in 
the tested patients showed no overlap, where no clonotypes were found to be common 
between patients targeting the same epitope, whether they belonged to different groups 
(SR/SR-1 and SR/CI-2 recognizing the HLA-A2 restricted NS3-1073 epitope) (Supplementary 
Tables S1 and S4) or even when they belonged to the same group (SR/SR-2 and SR/SR-3 
recognizing the HLA-B27 restricted NS5B-2841 epitope) (Supplementary Tables S2 and S3). 
Sequencing the Vβ-chain from more patients is needed, to verify whether some clonotypes are 
recurrent in the repertoire of different patients from the same group and thus represent “public 
clonotypes” associated with the outcome. Also, it would allow us to identify whether distinct 
clonotypes are found in the SR/SR repertoire versus the SR/CI repertoire. 
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DISCUSSION 
Defining the correlates of protective immunity at the clonotypic level is essential for 
the fine-tuning of the design of prophylactic vaccines against chronic viruses with highly 
variable sequences such as HIV and HCV. This study represents an initial insight into the 
dynamics of the virus-specific CD8 T-cell repertoire during HCV reinfection episodes in a 
real-life setting. Our results suggest that the effector HCV-specific CD8 T-cell clonotypes 
associated with protection upon reinfection were recruited from the memory population, rather 
than being de novo responses. The repertoire was narrower in the protected patients in 
comparison to un-protected patients, and it became more focused upon reinfection. As we 
previously demonstrated, these HCV-specific CD8 T-cells were associated with higher 
functional avidity and polyfunctional potential than those from un-protected patients 1.  
Our longitudinal analysis of the Vβ-chain of the TCR showed a conserved pattern of 
Vβ usage, where the dominant and sub-dominant clonotypes forming the effector population 
at the peak of immune response during reinfection were recruited from the pre-existing 
memory population generated following the clearance of the primary infection, without the 
appearance of new clonotypes. It has been demonstrated before in the LCMV model that the 
TCR repertoire of the primary epitope-specific CD8 T-cell response was conserved in the 
memory pool and the secondary effector recall response, where there was identity between the 
clonotypes that formed 60-100% of the primary effector, memory and recall responses 18, 19. 
Rapid resolution of HCV infection upon rechallenging chimpanzees also coincided with the 
expansion of T-cell clonotypes that dominated the memory CD8 T-cell pool. These specific 
TCR clonotypes were tracked through the different HCV challenges 10, 11. 
With regards to the diversity of the repertoire, data from the LCMV mouse model and 
the HCV chimpanzee model suggested that repeated reinfections would selectively expand 
and enrich cells of higher functional avidity already recruited during the primary infection 
provided that the targeted epitope remain unchanged11, 18. Indeed, our longitudinal analysis of 
the TCR-repertoire during HCV reinfection demonstrates that the repertoire composition in 
the tested SR/SR (protected) patients was narrower and less diverse than the repertoire in the 
SR/CI (unprotected) patients at the time point pre-reinfection and it became more focused at 
the peak of the immune response during reinfection, and retained a highly focused 
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composition post reinfection. In contrast, the repertoire in the tested SR/CI patients was more 
diverse, even at the peak of immune response during reinfection. It has been demonstrated 
before in the LCMV mouse model that the repertoire of an epitope-specific CD8 T-cell 
population was highly focused, where 70% of the response against LCMV was due to three 
clonotypes 18. In the cytochrome-c antigen system there was narrowing of the T-cell repertoire 
upon second exposure relative to the primary repertoire, suggesting selection of the clonotypes 
with highest affinity 20. Analysis of the TCR repertoire of epitope-specific CD8 T cells in HIV 
patients also demonstrated narrower and more focused TCR-repertoires of high-avidity 
populations in patients who were able to control HIV-1 infection compared to progressors 21. 
On the other hand, a previous study of an HCV-epitope (NS3-1406) suggested that higher 
diversity of the repertoire would be more advantageous, otherwise the virus would undergo 
mutation of the epitope to exploit gaps present in the repertoire 22. A chimpanzee rechallenge 
study suggested a similar conclusion, since the majority of HCV-epitopes that escaped 
immune recognition upon reinfection were targeted by a CD8 T-cell repertoire with reduced 
CDR3 amino acid diversity. This suggested that it is more advantageous to generate and 
maintain a diverse TCR repertoire against individual epitopes, since limited TCR diversity 
would facilitate CTL escape mutations in HCV infected chimpanzees 11. Unfortunately, there 
are no previous studies analyzing the TCR-repertoire for HCV-specific T-cells in humans, and 
results from chimpanzee studies should be taken cautiously, since it was shown that some 
TCRBV genes in the chimpanzee have been lost in humans. This could be a probable cause of 
discrepancy of findings between chimpanzee and human studies for responses against the 
same HCV-epitopes 23. Another important factor that might cause discrepancy is that the 
chimpanzees in these studies were rechallenged with a specific and homologous viral 
sequence and therefore exposed to a less diverse viral infection, which is completely different 
from natural human infections where the viral sequences circulating within an individual 
patient and infecting other humans are a mosaic of highly diverse “quasispecies” 24.  
Particular clonotypes were found to be preferentially selected in several HIV-infected 
individuals who controlled viral-replication. These public clonotypes exhibiting higher avidity 
imposed selective pressure causing early mutation in the epitope that enables the virus to 
escape their recognition 5, 9. However, recent data demonstrated that even variant epitopes 
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could be recognized by highly efficient T-cell clonotypes expressing particular TCRs that are 
more flexible and thus recognize multiple epitope variants and possess higher functional 
avidity 5, 25. Our longitudinal analysis of the dominant and subdominant Vβ-CDR3-Jβ 
clonotypes in the tested patients showed no overlap, where no clonotypes were found to be 
common between patients with the same HLA background and targeting the same epitope, 
even when they belonged to the same group (patients SR/SR-2 and SR/SR-3). It is very early 
to draw a definitive conclusion about whether or not specific clonotypes could correlate with 
protection, taking into consideration the limited number of patients included in this study. In 
HIV studies, up to 19 patients needed to be recruited to show that some public clonotypes 
were present in 6 patients 5.  
We previously demonstrated that protected patients (the SR/SR group) showed higher 
avidity of HCV-specific T cells to the reference sequence of the targeted epitopes. 
Unprotected (SR/CI) patients had moderate/low avidity for the reference epitope sequence, but 
no avidity for the autologous epitope sequence of the reinfecting virus 1 which could be 
attributed to “original antigenic sin” 26. One SR/SR patient had a moderate response to one of 
the variant epitopes, suggesting higher flexibility of the TCR-repertoire. Flexibility in the T 
cell repertoire correlated with better control of viral escape mutants in both the HCV and HIV 
field 5, 8, 9, 11 and it would be interesting to validate such results in a reinfection model. We also 
observed in our previous study that polyfunctionality upon stimulation with minimum peptides 
correlated with avidity, where patients with highest avidity had the highest functionality and 
polyfunctionality, and vice versa 1. This has already been shown within the context of HIV 
infection, where superior functional avidity of epitope-specific CD8 T cells was interlinked 
with their high polyfunctional capacity 3.  
These results for the TCR-repertoire from peripheral blood mononuclear cells 
(PBMCs) are expected to reflect what is happening in the liver, since chimpanzees studies 
showed that the peripheral epitope-specific CD8 T-cell repertoire reflected the intra-hepatic 
response, where identical clonotypes were present in both the liver and the peripheral 
circulation, differing only in having a higher magnitude in the liver 10. 
In conclusion, our results show that epitope-specific CD8 T-cell clonotypes expanding 
at the peak of reinfection episodes are recruited from the memory pool, rather than being de 
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novo clonotypes mobilized from the naïve pool. The repertoire is narrower in the protected 
patients in comparison to unprotected patients, and it becomes more focused upon reinfection, 
suggesting that distinct TCRs would provide superior control of HCV-infection due to having 
higher functional avidity and polyfunctionality. These results argue in favour of designing 
vaccines that focus on immunodominant epitopes that induce distinct public clonotypes 
possessing superior functional avidity and polyfunctionality. One major constraint of vaccine 
development for HIV and HCV is the highly heterologous nature of these viruses. It is 
possible that a vaccination regimen rechallenging humans with different antigenic variants of 
the epitope may favour “stretching” of the repertoire by mobilizing T-cell clonotypes bearing 
flexible TCRs that can recognize different variants of the epitope. Analysis of the T-cell 
repertoire for more patients and for populations targeting other HCV-epitopes would be 
needed to confirm these results and to verify the presence of public clonotypes conferring 
protection against HCV persistence. Generating cell-lines from individual clonotypes would 
enable testing their individual avidity, functionality and antiviral efficacy. 
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Table 1: Patients’ demographics and sequencing results for the epitopes during reinfection 
 
Patient 
code 
Status at start 
of follow-up 
Age at 
reinfection 
(years) 
 
Gender 
 
HCV 
Genotype 
(First 
infection/ 
reinfection) 
HLA 
Class I 
Tetramers 
 
Autologous epitope sequence during reinfection 
compared to reference sequence* 
 
 
Early 
 
Late 
       
  
SR/SR-1 HCV Resolver 53 M ND/1 A2, B58 
A2/NS3-1073 
A2/NS5B-2594 
  
         
SR/SR-2 HCV Resolver 43 M ND/1 A24/A26, 
B27/B49 
B27/NS5B-2841   
         
SR/SR-3 HCV Naïve 42 M 1a/1 
A23/A32 
B27/B44 
B27/NS5B-2841 
  
         
         
         
         
SR/CI-2 Acute primary  
HCV 
29 M 1a/1a A2,    
B39/B44 
A2/NS3-1073 
 
CINGVCWTV 
----A---- (10/10) 
 
CINGVCWTV 
------L—I (8/8) 
SR/CI-3 HCV Resolver 30 F ND/1a A1/A29 
B35/B44 
A1/NS3-1436 
 
ATDALMTGY 
--------F (4/4) ** 
 
ATDALMTGY 
--------F (11/11) 
 
         
 
ND = Not determined; SR: Spontaneous Resolution; CI: Chronic Infection 
* Dashes indicate identity with the reference sequence of the peptide used in the tetramer 
** No. of positive clones/Total no. of clones 
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Figure 1 
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Figure 1: HCV-specific tetramer+ CD8 T-cell clonotypes mobilized during the 
reinfection episode were exclusively recruited from the pre-existing memory 
population. The top ten dominant clonotypes (frequency ≥1%) isolated directly ex vivo 
from (A) three SR/SR patients and (B) two SR/CI patients followed-up longitudinally 
during primary HCV infection (patient SR/SR-3) and reinfection episode at pre-
reinfection, peak expansion and post reinfection (all five patients). The numbers between 
brackets beside the patient’s number indicates the epitope for which the T-cell population 
is specific. 
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                 Figure 2 
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Figure 2: Narrowly focused epitope-specific CD8 T cell repertoire in SR/SR patients. Distribution 
of the different categories of clonotypes forming the epitope-specific CD8 T cell repertoire for three 
SR/SR patients at pre-reinfection, peak and post reinfection episode (A) patient SR/SR-1 (B) SR/SR-2 
and (C) SR/SR-3. For patient SR/SR-3 there was follow-up during primary HCV infection, as well. 
The pie charts in the upper rows show the percentage of each category with respect to the total 
repertoire (dominant, sub-dominant, low-abundance and lowest abundance clonotypes in blue, red, 
green and violet, respectively). The percentages are represented by black numbers inside the pie. The 
numbers between brackets around the pie charts represent the number of unique clonotypes forming 
each category (indicated in the corresponding color). The sliced pie charts in blue at the lower rows 
represent the dissection of the individual clonotypes forming the dominant category, with the frequency 
of the most dominant 3 clonotypes written in white inside the corresponding slice. 
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                 Figure 3 
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Figure 3: More diverse epitope-specific CD8 T cell repertoire in SR/CI patients. Pie charts 
showing the distribution of the different categories of clonotypes forming the epitope-specific CD8 T 
cell repertoire for two SR/CI patients pre-, at the peak and late during the reinfection episode (A) 
patient SR/CI-2 and (B) SR/CI-3. The pie charts in the upper rows show the percentage of each 
category (dominant, sub-dominant, low-abundant and lowest abundant clonotypes in blue, red, green 
and violet, respectively) with respect to the total clonotypes. The percentages are represented by black 
numbers inside the pie. The numbers between brackets around the pie charts represent the number of 
unique clonotypes forming each category (indicated in the corresponding color). The sliced pie charts 
in blue at the lower rows represent the dissection of the individual clonotypes forming the dominant 
category, with the frequency of the most dominant 3 clonotypes written in white inside the 
corresponding slice. 
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                 Figure 4 
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Figure 4: Less diverse TRBV-J usage for epitope-specific CD8 T cell repertoire in SR/SR patients 
as compared to SR/CI patients. Shown are the percentages of specific J-chain usage for unique 
clonotypes for (A) three SR/SR patients and (B) two SR/CI patients pre-, at the peak and post/late the 
reinfection episode. 
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Supplementary Table 1: Clonotype usage in epitope-specific CD8 T cells for patient SR/SR-1 
during an HCV reinfection episode. TRBV and TRBJ usage, CDR3 amino acid sequence, clonotype 
frequency for the dominant clonotypes (clonotypes present at frequency ≥1%) and the count of 
TCRβ sequences corresponding to the percentages. The epitope-specific CD8 T cells were isolated 
directly ex vivo from patient SR/SR-1 at time points (A) pre-reinfection, (B) peak reinfection CD127- 
cells, (C) peak reinfection CD127+ cells and (D) post reinfection, and were analyzed for the TCR-
repertoire of epitope-specific CD8 T cells. 
 
(A)  Patient SR/SR-1 at pre-reinfection (Wk -55) 
          
TRBV CDR3 TRBJ Freq. (%) Count 
06-01 CASSDPLAGGNEQYF 02-07 11.68 7771 
20 CSAWTGSATEAFF 01-01 8.55 5686 
06-01 CASSEVVTAFSYEQYF 02-07 7 4656 
07-09 CASISSNQPQHF 01-05 4.56 3036 
04-02 CASSQLLAGGSYEQYF 02-07 4 2662 
24 CATSDAPGTGIPYEQYF 02-07 3.78 2517 
07-08 CASSLASLGLALSSYEQYF 02-07 3.71 2469 
27-01 CASSLGTQTYEQYF 02-07 3.16 2099 
03 CASSQDLGLLRDTGELFF 02-02 2.99 1986 
27-01 CASSPGTSDPANYGYTF 01-02 2.69 1788 
12 CASSLSGTGELFF 02-02 2.66 1769 
20 CSAPGPGVSVEKLFF 01-04 2.5 1660 
28-01 CASSSGQGNIQYF 02-04 2.05 1366 
03 CASSQEPSGSWGEQYF 02-07 2.04 1360 
04-01 CASSQAAGVGYPTEAFF 01-01 2.03 1350 
10-03 CAISRDSIQFGNTIYF 01-03 1.99 1322 
04-03 CASSQEQGAPGELFF 02-02 1.77 1174 
14-01 CASSRGPDTEAFF 01-01 1.59 1055 
12 CASSFGDQQYF 02-07 1.4 933 
24 CATSDQSREQYF 02-07 1.34 890 
06 CASSYLFGDANTGELFF 02-02 1.31 872 
07-03 CASSLTCDRTHSVYGYTF 01-02 1.16 769 
30-01 CAWRLGSGEKLFF 01-04 1.12 743 
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(B)  Patient SR/SR-1 at peak reinfection - CD127- Tet+ Cells (Wk 3) 
          
TRBV CDR3 TRBJ Freq. (%) Count 
20 CSAWTGSATEAFF 01-01 33.37 67293 
27-01 CASSLGTQTYEQYF 02-07 10.12 20402 
24 CATSDAPGTGIPYEQYF 02-07 8.19 16511 
27-01 CASSPGTSDPANYGYTF 01-02 7.54 15209 
06-01 CASSDPLAGGNEQYF 02-07 5.8 11692 
07-09 CASISSNQPQHF 01-05 5.16 10411 
28-01 CASSSGQGNIQYF 02-04 3.57 7208 
04-02 CASSQLLAGGSYEQYF 02-07 3.57 7197 
14-01 CASSRGPDTEAFF 01-01 3.16 6376 
unresolved CASSLSGTGELFF 02-02 2.45 4947 
28-01 CASSSGQGNIQYF 02-04 2.37 4785 
03 CASSQDLGLLRDTGELFF 02-02 2.02 4069 
20 CSAQTGRDTEAFF 01-01 1.94 3909 
05-06 CASSQGGDRGDPGDGYTF 01-02 1.23 2488 
07-08 CASSLASLGLALSSYEQYF 02-07 1.09 2193 
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(C)  Patient SR/SR-1 at peak reinfection - CD127+ Tet+ Cells (Wk 3) 
        
TRBV CDR3 TRBJ Freq. (%) Count 
20 CSAWTGSATEAFF 01-01 25.68 57007 
06-01 CASSDPLAGGNEQYF 02-07 14.86 32989 
04 CATSDAPGTGIPYEQYF 02-07 9.26 20554 
27-01 CASSPGTSDPANYGYTF 01-02 7.86 17448 
04-02 CASSQLLAGGSYEQYF 02-07 4.54 10070 
27-01 CASSLGTQTYEQYF 02-07 3.28 7280 
12 CASSLSGTGELFF 02-02 3.27 7249 
06-01 CASSEVVTAFSYEQYF 02-07 2.63 5831 
03 CASSQDLGLLRDTGELFF 02-02 2.53 5614 
07-09 CASISSNQPQHF 01-05 2.2 4875 
03 CASSQEPSGSWGEQYF 02-07 1.86 4133 
07-08 CASSLASLGLALSSYEQYF 02-07 1.26 2787 
14-01 CASSRGPDTEAFF 01-01 1.14 2540 
28-01 CASSSGQGNIQYF 02-04 1.07 2366 
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(D)  Patient SR/SR-1 at post reinfection (Wk 24) 
        
TRBV CDR3 TRBJ Freq. (%) Count 
20 CSAWTGSATEAFF 01-01 15.62 78987 
06-01 CASSDPLAGGNEQYF 02-07 13.45 68019 
24 CATSDAPGTGIPYEQYF 02-07 10.14 51281 
27-01 CASSPGTSDPANYGYTF 01-02 7.25 36680 
27-01 CASSLGTQTYEQYF 02-07 5.25 26560 
04-02 CASSQLLAGGSYEQYF 02-07 4.98 25169 
07-09 CASISSNQPQHF 01-05 3.56 17975 
12 CASSLSGTGELFF 02-02 2.94 14843 
06-01 CASSEVVTAFSYEQYF 02-07 2.28 11524 
07-08 CASSLASLGLALSSYEQYF 02-07 2.19 11083 
28-01 CASSSGQGNIQYF 02-04 1.89 9543 
03 CASSQDLGLLRDTGELFF 02-02 1.74 8775 
14-01 CASSRGPDTEAFF 01-01 1.69 8569 
04-01 CASSQAAGVGYPTEAFF 01-01 1.62 8186 
03 CASSQEPSGSWGEQYF 02-07 1.51 7629 
05-06 CASSQGGDRGDPGDGYTF 01-02 1.15 5800 
 
 
  
  150 
Supplementary Table 2: Clonotype usage in epitope-specific CD8 T cells for patient SR/SR-2 
during an HCV reinfection episode. TRBV and TRBJ usage, CDR3 amino acid sequence, clonotype 
frequency for the dominant clonotypes (clonotypes present at frequency ≥1%) and the count of 
TCRβ sequences corresponding to the percentages. The epitope-specific CD8 T cells were isolated 
directly ex vivo from patient SR/SR-2 at time points (A) pre-reinfection, (B) peak reinfection and (C) 
post reinfection, and were analyzed for the TCR-repertoire of epitope-specific CD8 T cells. 
 
(A)  Patient SR/SR-2 at pre-reinfection (Wk -46) 
     
TRBV CDR3 TRBJ Freq. (%) Count 
11-02 CASSFDSGAYEQYF 02-07 35.97 13631 
19-01 CASSTKQGWYEQYF 02-07 23.46 8889 
10-02 CASSDAYNEKLFF 01-04 2.9 1098 
19-01 CASSTKQGWYEQYF 02-07 2.81 1065 
04-01 CASSPLVQGGLQPQHF 01-05 1.9 720 
02-01 CASSEGTTNTGELFF 02-02 1.52 575 
07-03 CASSWDSGAEAFF 01-01 1.45 549 
05-06 CASSLKAVVTGELFF 02-02 1.44 544 
04-01 CASSFDGGNQPQHF 01-05 1.3 493 
06 CASSIDKLNTEAFF 01-01 1.22 464 
04-01 CASSFDFQGSYEQYF 02-07 1.16 439 
04-01 CASSQVHLGQSTLNTEAFF 01-01 1.12 425 
06 CASALRGANVLTF 02-06 1.07 404 
27-01 CASSPYGGSNTGELFF 02-02 1.05 397 
     
     
(B)  Patient SR/SR-2 at peak reinfection (Wk 4) 
          
TRBV CDR3 TRBJ Freq. (%) Count 
19-01 CASSTKQGWYEQYF 02-07 81.88 68836 
11-02 CASSFDSGAYEQYF 02-07 13.7 11514 
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(C)  Patient SR/SR-2 at post reinfection (Wk 12) 
          
TRBV CDR3 TRBJ Freq. (%) Count 
19-01 CASSTKQGWYEQYF 02-07 66.44 40660 
11-02 CASSFDSGAYEQYF 02-07 24.29 14863 
04-01 CASSFDGGNQPQHF 01-05 1.07 656 
10-02 CASSDAYNEKLFF 01-04 1.02 625 
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Supplementary Table 3: Clonotype usage in epitope-specific CD8 T cells for patient SR/SR-3 
during an HCV reinfection episode. TRBV and TRBJ usage, CDR3 amino acid sequence, clonotype 
frequency for the dominant clonotypes (clonotypes present at frequency ≥1%) and the count of 
TCRβ sequences corresponding to the percentages. The epitope-specific CD8 T cells were isolated 
directly ex vivo from patient SR/SR-3 at time points at (A) primary infection CD127- cells, (B) primary 
infection CD127+ cells (C) pre-reinfection, (D) peak reinfection and (E) post reinfection, and were 
analyzed for the TCR-repertoire of epitope-specific CD8 T cells. 
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(A)  Patient SR/SR-3 at primary infection - CD127- Tet+ Cells  
(Wk -53) 
          
TRBV CDR3 TRBJ Freq. (%) Count 
13-01 CASRLGASSYNEQFF 02-01 9.83 17131 
06 CASSYGQAYQPQHF 01-05 9.56 16650 
06 CASSYSNLPVFSPNQPQHF 01-05 6.58 11465 
19-01 CASSIVGHMNTEAFF 01-01 6.06 10549 
27-01 CASSLYGGSNTGELFF 02-02 5.62 9791 
02-01 CASSEGSHSNQPQHF 01-05 5.15 8966 
20 CSASITGTEQYF 02-07 4.51 7852 
19-01 CASSIVGHLNTEAFF 01-01 3.87 6737 
04-03 CASSRARGSTEVREQFF 02-01 3.8 6619 
12-05 CASGYAGANVLTF 02-06 3.47 6042 
05-01 CASSFDRGGYEQYF 02-07 2.56 4451 
04-01 CASSFDGQGYEQYF 02-07 2.2 3833 
18-01 CASSPATGTEAFF 01-01 2.18 3799 
05-06 CASSLNLGAGNNEQFF 02-01 2.1 3657 
29-01 CSVGGTGTYGYTF 01-02 2 3486 
28-01 CASSLKGQVGEQYF 02-07 1.77 3079 
09-01 CASSVSPDNTDTQYF 02-03 1.48 2571 
28-01 CASSLEGSAGELFF 02-02 1.42 2469 
10-03 CAISESGQALITYEQYF 02-07 1.42 2468 
05-01 CASSPGTTNTGELFF 02-02 1.33 2323 
11-02 CASSLASNEQFF 02-01 1.33 2312 
04-01 CASSHDTGGYEQYF 02-07 1.26 2202 
11-02 CASSFLGGLDEQFF 02-01 1.21 2113 
04-03 CASSFDRGGYEQYF 02-07 1.21 2110 
05-01 CASSLDASSASYEQYF 02-07 1.13 1974 
06-05 CASSSGLALVFEQFF 02-01 1.1 1910 
04-01 CASSFSSGGYEQYF 02-07 1.04 1813 
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(B)  Patient SR/SR-3 at primary infection - CD127+ Tet+ Cells  
(Wk -53) 
          
TRBV CDR3 TRBJ Freq. (%) Count 
06 CASSYGQAYQPQHF 01-05 13.78 16767 
06 CASSYSNLPVFSPNQPQHF 01-05 9.21 11203 
20 CSASITGTEQYF 02-07 7.78 9466 
19-01 CASSIVGHLNTEAFF 01-01 5.46 6638 
02-01 CASSEGSHSNQPQHF 01-05 5.08 6184 
13-01 CASRLGASSYNEQFF 02-01 3.3 4013 
04-01 CASTAGSNTGELFF 02-02 2.7 3288 
29-01 CSVGGTGTYGYTF 01-02 2.64 3210 
05-06 CASSLNLGAGNNEQFF 02-01 2.49 3030 
11-02 CASSFLGGLDEQFF 02-01 2.4 2922 
28-01 CASSLEGSAGELFF 02-02 2.2 2678 
05-01 CASSFDRGGYEQYF 02-07 2.08 2531 
11-02 CASSLAVSSEQFF 02-01 2.07 2524 
19-01 CASSIVGHMNTEAFF 01-01 2.07 2516 
05-06 CASSLGLPGLAGAYEQYF 02-07 2.03 2475 
04-01 CASSFDTGGYEQYF 02-07 1.93 2345 
06 CASSWTAIEQYF 02-07 1.77 2159 
18-01 CASSPATGTEAFF 01-01 1.77 2148 
05-01 CASSPGTTNTGELFF 02-02 1.7 2074 
06-05 CASSSGLALVFEQFF 02-01 1.61 1953 
11-02 CASSLASNEQFF 02-01 1.55 1890 
27-01 CASSLYGGSNTGELFF 02-02 1.47 1792 
12-05 CASGYAGANVLTF 02-06 1.35 1644 
10-03 CAISESGQALITYEQYF 02-07 1.25 1519 
04-03 CASSRARGSTEVREQFF 02-01 1.17 1427 
04-03 CASSFDRGGYEQYF 02-07 1.08 1316 
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(C)  Patient SR/SR-3 at pre-reinfection (Wk -34) 
          
TRBV CDR3 TRBJ Freq. (%) Count 
05-01 CASSLDASSASYEQYF 02-07 25.51 23533 
05-01 CASREDGGGYEQYF 02-07 7.03 6486 
06 CASSYGQAYQPQHF 01-05 6.96 6418 
06 CASSYSNLPVFSPNQPQHF 01-05 6.07 5597 
20 CSASITGTEQYF 02-07 5.55 5122 
19-01 CASSIVGHLNTEAFF 01-01 4.23 3898 
02-01 CASSEGSHSNQPQHF 01-05 3.56 3279 
19-01 CASSIVGHMNTEAFF 01-01 3.25 3002 
13-01 CASRLGASSYNEQFF 02-01 2.86 2637 
05-06 CASSLNLGAGNNEQFF 02-01 2.69 2478 
28-01 CASSLEGSAGELFF 02-02 2.61 2411 
27-01 CASSLYGGSNTGELFF 02-02 1.62 1496 
29-01 CSVGGTGTYGYTF 01-02 1.51 1391 
27-01 CASSLYRVGYNEQFF 02-01 1.48 1366 
11-02 CASSFLGGLDEQFF 02-01 1.44 1328 
05-01 CASSPGTTNTGELFF 02-02 1.36 1251 
05-01 CASSFDRGGYEQYF 02-07 1.32 1218 
05-06 CASSLGLPGLAGAYEQYF 02-07 1.21 1113 
10-02 CASCDNTGYEQYF 02-07 1.06 974 
11-02 CASSLAVSSEQFF 02-01 1.03 953 
04-01 CASSFDGQGYEQYF 02-07 1.03 952 
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(D)  Patient SR/SR-3 at peak reinfection (Wk 4) 
          
TRBV CDR3 TRBJ Freq. (%) Count 
05-01 CASSLDASSASYEQYF 02-07 9.43 7774 
06 CASSYSNLPVFSPNQPQHF 01-05 8.81 7265 
20 CSASITGTEQYF 02-07 8.08 6662 
27-01 CASSLYGGSNTGELFF 02-02 7.46 6150 
04-01 CASSFDGQGYEQYF 02-07 5.63 4644 
28-01 CASSLKGQVGEQYF 02-07 4.77 3931 
13-01 CASRLGASSYNEQFF 02-01 3.7 3049 
05-01 CASSFDRGGYEQYF 02-07 3.56 2933 
19-01 CASSIVGHLNTEAFF 01-01 3.49 2878 
05-01 CASREDGGGYEQYF 02-07 3.44 2840 
28-01 CASSLEGSAGELFF 02-02 3.16 2606 
02-01 CASSEGSHSNQPQHF 01-05 2.88 2373 
04-03 CASSRARGSTEVREQFF 02-01 2.31 1905 
27-01 CASSLYRVGYNEQFF 02-01 2.07 1711 
29-01 CSVGGTGTYGYTF 01-02 1.86 1533 
11-02 CASSLAVSSEQFF 02-01 1.83 1513 
11-02 CASSLASNEQFF 02-01 1.81 1494 
04-03 CASSQSSMQDPYGYTF 01-02 1.55 1278 
06 CASSYGQAYQPQHF 01-05 1.5 1235 
04-03 CASSFDRGGYEQYF 02-07 1.39 1144 
06 CASSWTAIEQYF 02-07 1.19 982 
19-01 CASSIVGHMNTEAFF 01-01 1.1 909 
02-01 CASNFDKGGYEQYF 02-07 1.07 885 
09-01 CASSVSPDNTDTQYF 02-03 1.06 871 
29-01 CSVAHTGTEQYF 02-07 1.03 847 
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(E)  Patient SR/SR-3 at post reinfection (Wk 12) 
          
TRBV CDR3 TRBJ Freq. (%) Count 
27-01 CASSLYGGSNTGELFF 02-02 9.75 7078 
20 CSASITGTEQYF 02-07 9.04 6562 
04-01 CASSFDGQGYEQYF 02-07 8.87 6438 
V06 CASSYSNLPVFSPNQPQHF 01-05 7.31 5309 
28-01 CASSLKGQVGEQYF 02-07 6.71 4870 
05-01 CASSLDASSASYEQYF 02-07 6.56 4762 
13-01 CASRLGASSYNEQFF 02-01 4.86 3525 
05-01 CASSFDRGGYEQYF 02-07 3.85 2792 
05-01 CASREDGGGYEQYF 02-07 3.51 2546 
28-01 CASSLEGSAGELFF 02-02 2.87 2085 
19-01 CASSIVGHLNTEAFF 01-01 2.5 1813 
04-03 CASSQSSMQDPYGYTF 01-02 2.41 1750 
27-01 CASSLYRVGYNEQFF 02-01 2.29 1663 
11-02 CASSLASNEQFF 02-01 2.22 1614 
09-01 CASSVSPDNTDTQYF 02-03 2.01 1461 
06 CASSYGQAYQPQHF 01-05 1.89 1374 
11-02 CASSLAVSSEQFF 02-01 1.72 1252 
29-01 CSVGGTGTYGYTF 01-02 1.47 1068 
19-01 CASSIVGHMNTEAFF 01-01 1.26 917 
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Supplementary Table 4: Clonotype usage in epitope-specific CD8 T cells for patient SR/CI-2 
during an HCV reinfection episode. TRBV and TRBJ usage, CDR3 amino acid sequence, clonotype 
frequency for the dominant clonotypes (clonotypes present at frequency ≥1%) and the count of 
TCRβ sequences corresponding to the percentages. The epitope-specific CD8 T cells were isolated 
directly ex vivo from patient SR/CI-2 at time points (A) pre-reinfection, (B) peak reinfection and (C) 
late during reinfection, and were analyzed for the TCR-repertoire of epitope-specific CD8 T cells. 
 
(A) Patient SR/CI-2 at pre-reinfection (Wk -20) 
          
TRBV CDR3 TRBJ Freq. (%) Count 
06 CASTSQSELFF 01-04 6.91 21786 
03 CASSRFLGSGGAAEQFF 02-01 4.22 13302 
07-09 CASLEEDTGELFF 02-02 4.13 13023 
05-06 CASGTGANEKLFF 01-04 2.85 8983 
06-05 CASIRLAGEHNEQFF 02-01 2.77 8742 
04-03 CASSQDPLAGGGGEQFF 02-01 1.71 5397 
02-01 CASSDGQTEKLFF 01-04 1.62 5105 
24 CANRDRGRDEQFF 02-01 1.54 4860 
07-06 CASSLEVAGGNEQFF 02-01 1.38 4360 
06-05 CASVGGNYGYTF 01-02 1.36 4282 
06-06 CASSYSAGTLDYGYTF 01-02 1.32 4149 
04-02 CASSQQGEKLFF 01-04 1.24 3912 
02-01 CASSQGQTNEKLFF 01-04 1.14 3605 
05-06 CASSTGGGTEAFF 01-01 1.11 3505 
06-01 CASSELGTGDYEQYF 02-07 1.06 3341 
05-04 CASSLPQGRYMNTEAFF 01-01 1.04 3286 
02-01 CASRDVVGRLSSYNEQFF 02-01 1.02 3201 
06-06 CASTRDTEAFF 01-01 1 3168 
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(B)  Patient SR/CI-2 at peak reinfection (Wk 10) 
          
TRBV CDR3 TRBJ Freq. (%) Count 
06 CASTSQSELFF 01-04 6.47 30139 
03 CASSRFLGSGGAAEQFF 02-01 5.44 25332 
06-05 CASIRLAGEHNEQFF 02-01 2.86 13300 
07-09 CASLEEDTGELFF 02-02 2.68 12479 
04-03 CASSQDPLAGGGGEQFF 02-01 1.91 8907 
04-02 CASSPEQGPLEAFF 01-01 1.42 6618 
24 CANRDRGRDEQFF 02-01 1.31 6083 
06 CASSPWAVGAMNTEAFF 01-01 1.31 6082 
06-01 CASSELGTGDYEQYF 02-07 1.3 6074 
05-06 CASGTGANEKLFF 01-04 1.28 5974 
02-01 CASSDGQTEKLFF 01-04 1.25 5833 
02-01 CASRDVVGRLSSYNEQFF 02-01 1.11 5152 
     
     
     
(C)  Patient SR/CI-2 at late reinfection (Wk 66) 
          
TRBV CDR3 TRBJ Freq. (%) Count 
04-01 CASSQGLPNEKLFF 01-04 3.18 8151 
02-01 CASSQGQTNEKLFF 01-04 2.68 6872 
05-04 CASSLEQGAVDGNTIYF 01-03 2.63 6745 
06-05 CASIRLAGEHNEQFF 02-01 2.18 5584 
04-03 CASSQDPLAGGGGEQFF 02-01 2.15 5520 
07-06 CASSLEVAGGNEQFF 02-01 1.99 5100 
03 CASSRFLGSGGAAEQFF 02-01 1.7 4353 
02-01 CASSQGQTNEKLFF 01-04 1.62 4155 
05-06 CASSLRSDTEAFF 01-01 1.38 3530 
21-01 CASSKQTGTGETKNIQYF 02-04 1.37 3514 
19-01 CASSTPPGVNSNQPQHF 01-05 1.29 3313 
02-01 CASRDVVGRLSSYNEQFF 02-01 1.22 3123 
19-01 CASGWPGGLNSNQPQHF 01-05 1.09 2798 
06-06 CASSSAPEGLSYEQYF 02-07 1 2567 
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Table 5: Clonotype usage in epitope-specific CD8 T cells for patient SR/CI-3 during an HCV 
reinfection episode. TRBV and TRBJ usage, CDR3 amino acid sequence, clonotype frequency for the 
dominant clonotypes (clonotypes present at frequency ≥1%) and the count of TCRβ sequences 
corresponding to the percentages. The epitope-specific CD8 T cells were isolated directly ex vivo from 
patient SR/CI-3 at time points (A) pre-reinfection, (B) peak reinfection and (C) late during reinfection, 
and were analyzed for the TCR-repertoire of epitope-specific CD8 T cells. 
     
(A)  Patient SR/CI-3 at pre-reinfection (Wk -37) 
          
TRBV CDR3 TRBJ Freq. (%) Count 
10-03 CAISESTAGSQPQHF 01-05 10.65 4989 
07-09 CAGNNRDSSTDTQYF 02-03 5.34 2501 
10-03 CAITDGASGANEQFF 02-01 4.83 2263 
11-02 CASSLILAGGSYNEQFF 02-01 3.53 1656 
10-03 CAISESPQSYEQYF 02-07 2.3 1077 
20 CSARPIDSSNQPQHF 01-05 2.25 1056 
02-01 CASSEGEINNQPQHF 01-05 2.23 1047 
05-01 CASRGDTFYEQYF 02-07 2.17 1019 
07-03 CASSLVGSGDTQYF 02-03 2.17 1016 
12 CASSIAGPPYNEQFF 02-01 1.83 856 
24 CATSDASLSSYNEQFF 02-01 1.77 831 
28-01 CASRTPGHLYEQYF 02-07 1.75 818 
02-01 CASSEIGQLETQYF 02-05 1.66 780 
05-01 CASSWWETSHEQFF 02-01 1.51 706 
09-01 CASSPASSSFYEQYF 02-07 1.46 685 
19-01 CASSIRDIGNQPQHF 01-05 1.37 644 
27-01 CASSLRTAGYNEQFF 02-01 1.35 635 
02-01 CASSGTRQISGTEAFF 01-01 1.35 633 
21-01 CASSTGLAAQETQYF 02-05 1.32 620 
16-01 CASSQSDLTAKQPQHF 01-05 1.29 603 
05-01 CASSPWTSGGAYNEQFF 02-01 1.2 561 
06 CASRSLLGTRVETEAFF 01-01 1.14 535 
05-01 CASSLWGADGYTF 01-02 1 468 
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(B)  Patient SR/CI-3 at Peak reinfection (Wk 5) 
          
TRBV CDR3 TRBJ Freq. (%) Count 
02-01 CASSGTRQISGTEAFF 01-01 11.76 4708 
10-03 CAISESTAGSQPQHF 01-05 10.46 4187 
27-01 CASIEQGGDFTDTQYF 02-03 4.84 1938 
06-01 CASSETGQTYEQYF 02-07 4.42 1771 
07-09 CAGNNRDSSTDTQYF 02-03 3.85 1541 
19-01 CASSIRDIGNQPQHF 01-05 3.42 1369 
10-03 CAITDGASGANEQFF 02-01 2.95 1182 
07-03 CASSLVGSGDTQYF 02-03 2.71 1086 
04-01 CASSQEGSDNQPQHF 01-05 2.44 975 
11-02 CASSLILAGGSYNEQFF 02-01 2.33 933 
09-01 CASSGGLINTGELFF 02-02 2.29 915 
12 CASSIAGPPYNEQFF 02-01 1.92 770 
20 CSAREIASSNQPQHF 01-05 1.76 703 
06 CASRSLLGTRVETEAFF 01-01 1.59 635 
09-01 CASSPASSSFYEQYF 02-07 1.58 631 
06 CASSPTGPFYGYTF 01-02 1.37 547 
16-01 CASSQSDLTAKQPQHF 01-05 1.19 478 
10-03 CAISESAVGYNEQFF 02-01 1.19 477 
24 CATSDASLSSYNEQFF 02-01 1.14 458 
05-01 CASSPWTSGGAYNEQFF 02-01 1.11 445 
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(C)  Patient SR/CI-3 at late reinfection (Wk 41) 
          
TRBV CDR3 TRBJ Freq. (%) Count 
20 CSARPIDSSNQPQHF 01-05 6 1737 
10-03 CAISESTAGSQPQHF 01-05 5.73 1658 
02-01 CASSGTRQISGTEAFF 01-01 4.69 1356 
11-02 CASSLILAGGSYNEQFF 02-01 3.91 1130 
02-01 CASSEIGQLETQYF 02-05 3.85 1114 
07-03 CASSLVGSGDTQYF 02-03 3.36 972 
09-01 CASSSAVIVPGELFF 02-02 3.19 923 
27-01 CASIEQGGDFTDTQYF 02-03 2.53 732 
09-01 CASSGGLINTGELFF 02-02 2.34 677 
19-01 CASSIRDIGNQPQHF 01-05 2.31 668 
07-09 CAGNNRDSSTDTQYF 02-03 2.27 656 
12 CASSIAGPPYNEQFF 02-01 2.03 588 
10-03 CAITDGASGANEQFF 02-01 1.87 541 
10-03 CAISESPQSYEQYF 02-07 1.76 508 
02-01 CASSDPLGQGFSYEQYF 02-07 1.56 452 
20 CSAREIASSNQPQHF 01-05 1.52 439 
05-01 CASSLWGADGYTF 01-02 1.49 430 
05-01 CASRGDTFYEQYF 02-07 1.43 415 
09-01 CASSPASSSFYEQYF 02-07 1.35 390 
10-03 CAISESAVGYNEQFF 02-01 1.14 330 
06-01 CASSDTGTHIYEQYF 02-07 1.11 322 
07-03 CASSSAPGQLETQYF 02-05 1.07 309 
04-01 CASSQEGSDNQPQHF 01-05 1.03 299 
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Supplementary Figure 1 
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Supplementary Figure 1: The gating strategy used for the sorting of different epitope-specific 
tetramer+ CD8+ T-cell populations, as well as naïve CD8+ T cells to be used as a control. 
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Supplementary Figure 2 
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Supplementary Figure 2: Verification of the purity of sorted T-cell populations. Dot plots showing 
the post-sorting purity of the sorted (A) epitope-specific tetramer+ CD8+ T-cell population and (B) 
naïve CD8+ T cells. 
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CHAPTER 5: 
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The objective of this study was to define the general characteristics of the adaptive 
immune responses associated with protection upon reinfection with HCV. HCV represents a 
unique model that enables studying the correlates of immune protection against chronic 
viruses, since ~30% of infected patients are able to resolve primary HCV infection 
spontaneously. It has been shown before that humans and chimpanzees who cleared primary 
HCV infection or who received trial-vaccines generated long-lived memory T-cells. 
Nevertheless, their protective potential upon re-exposure to HCV was not consistent in all the 
studies conducted, where some subjects who successfully cleared a primary HCV-infection 
developed chronic infection when re-exposed to HCV, especially upon reinfection with 
heterologous viral sequences [338, 339, 350, 351]. More important, immunological 
characteristics and signatures associated with protection upon reinfection remain largely 
undefined. These correlates of protective immunity represent the most crucial factors to be 
considered and modeled in vaccine design. Even in chimpanzees and humans clearing the 
reinfecting virus, this occurred after a brief infection period, indicating the absence of 
sterilizing immunity that was observed for other viruses where the immune response 
neutralizes the pathogen before establishing an infection. Thus, it is suggested that for 
complex chronic viruses such as HCV and HIV it is rather protective immunity that could be 
achieved through vaccination to prevent the establishment of persistent infection upon 
exposure. 
We recruited a group of IDUs who resolved a primary HCV infection and were still at 
risk of being reinfected with HCV due to sharing needles with HCV-positive individuals. 
Several subjects among them got reinfected and longitudinal blood samples during the 
reinfection episode were available for nine patients who had a differential outcome of the 
second infection. This represented a great advantage by allowing us to compare the different 
characteristics of the immune response in patients who resolved the second infection (SR/SR 
group, n= 5) versus a group of patients who became persistently infected upon reinfection 
under the same conditions (SR/CI group, n= 4) (Manuscript 1 – Supplementary Table S1). 
This rare cohort of patients and the available longitudinal samples allowed us to address 
several issues pertaining to protective immunity against chronic viruses in a human setting. 
Specifically, it enabled us to perform an exhaustive longitudinal phenotypic and functional 
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characterization of the HCV-specific memory immune responses for both CD4 and CD8 T 
cells, as well as for epitope specific CD8 T cells during the reinfection episode. This unique 
group of patients also enabled us to longitudinally analyse the repertoire of epitope-specific 
CD8 T cells and define its dynamics upon reinfection with different viral variants and the 
correlation with the avidity and polyfunctionality of these populations, and how these factors 
are associated with protection. This also allowed us to verify the role of pre-existing memory 
versus de novo T cell responses.  
Our results demonstrate that protection from viral-persistence upon reinfection with 
HCV was associated with higher magnitude and breadth of the cell-mediated immune 
response, higher functionality/polyfunctionality and proliferative capacity of HCV-specific 
CD4 and CD8 T cells, and expansion of polyfunctional epitope-specific CD8 TEM cells. We 
also show that for epitope-specific CD8 T cells, a more focused TCR-repertoire composed of 
distinct clonotypes with higher functional avidity was associated with protection. 
5.1. Correlation between total magnitude and breadth of T-cell 
responses and protective immunity upon HCV reinfection 
Previous studies from our laboratory, as well as other groups have demonstrated an 
association between the magnitude and breadth of the immune response and spontaneous 
resolution of primary HCV infection [243, 250]. It was even shown that there was an 
association between the overall magnitude of response to certain immunodominant non-
structural regions of the HCV genome and spontaneous resolution [250]. Another study in an 
IDU cohort also demonstrated that CD4 T-cell responses predominantly targeting non-
structural proteins were associated with resolved HCV infection [254]. 
We monitored the overall magnitude and breadth of the HCV-specific T-cell responses 
in incident cases of reinfection before and during the second infection using an 
IFNγ−ELISPOT assay. Our results showed that the overall magnitude and breadth were higher 
in the SR/SR group as compared to the SR/CI group (Manuscript 1 - Figure 1). The average 
total frequency of IFNγ−producing HCV-specific T-cells at the earliest time point tested 
following reinfection was 5-folds higher in the SR/SR group as compared to the SR/CI group. 
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The responses to pools representing the structural and non-structural region of HCV were 
higher for the SR/SR group than the SR/CI group (11-folds and 4-folds, respectively).  
The breadth of the immune response, measured by the number of peptide pools 
targeted by the immune response, was also higher in the SR/SR group at the earliest time point 
during reinfection. An average of 10 out of 11 peptide pools were targeted in the SR/SR group 
(representing 9 out of the 10 HCV regions) versus 7 pools for the SR/CI group (Manuscript 1 
– Figure 1). In patients for whom samples prior to reinfection were available, a higher increase 
in the magnitude and breadth of the immune response to HCV-peptides was observed in the 
SR/SR patients, when compared to their levels prior to reinfection. The de novo responses 
were almost all within the non-structural region (data not shown).  
In summary, protection from viral persistence upon HCV reinfection was associated 
with a higher magnitude and breadth of the total HCV-specific T-cell response as measured by 
ELISPOT assay. In the SR/SR group, viral clearance upon reinfection was associated with 
expansion of the HCV-specific memory T cells, in particular cells targeting the non-structural 
proteins, where the increase in the magnitude and the de novo responses were more evident in 
response to peptide pools of the non-structural region underscoring the immune dominance of 
this region as previously reported during acute HCV infection [96, 250]. 
These results suggest that broadening of the HCV-immune response (with the potential 
generation of de novo responses) is associated with protection from chronicity upon 
reinfection. This is consistent with the observations of Osburn et al., where they observed the 
generation of de novo T-cell responses in patients resolving an HCV reinfection episode, as 
suggested by the increase in the number of new T-cell responses in comparison to a group of 
chronically-infected patients [354].  
5.2. Correlation between T-cell proliferative capacity and 
protective immunity 
It has been previously shown that the proliferative capacity of CD4 and CD8 T cells is 
predictive of the outcome of primary HCV infection [243, 246]. Examining the proliferative 
capacity of HCV-specific CD4 and CD8 T cells against a panel of peptide pools corresponding 
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to the immunodominant regions of HCV demonstrated higher proliferative capacity in SR/SR 
patients for both CD4 and CD8 T cells (Manuscript 1 - Figure 2). The proliferative capacity of 
CD4 T cell increased 3-5 folds from the baseline levels at 6-32 weeks post reinfection (p.ri) in 
SR/SR patients. In contrast, we observed very limited increase in CD4 T cell proliferation for 
SR/CI patients and proliferation gradually became undetectable, even if they had a detectable 
IFNγ-response to the same peptide pool as measured by ELISPOT. The difference in the 
proliferative response between the two groups was even more striking for CD8 T-cell 
proliferation. SR/SR patients demonstrated high proliferative responses prior to reinfection 
that increased at the peak of reinfection to reach very high levels (up to 560-fold of the non-
stimulated negative control) and were sustained after viral clearance. In contrast, no CD8 
proliferative responses were detected in the SR/CI patients against the peptide pools tested.  
In summary, our results demonstrate that protective immunity upon reinfection was 
associated with higher proliferative capacity for both CD4 and CD8 T cells when stimulated 
with peptide pools representing immunodominant non-structural regions. This is in accordance 
with a chimpanzee vaccine study demonstrating that increase in peripheral and intra-hepatic T-
cell proliferative responses coincided with the decline in the HCV-RNA titers [364]. Another 
chimpanzee rechallenge study confirmed the same finding, where vigorous proliferation of 
CD4 T cells correlated with clearance of the reinfecting virus. It is noteworthy that this 
vigorous proliferation of CD4 T cells was accompanied by increased frequency, as well as 
phenotypic and functional changes of tetramer+ CD8+ T cells [341]. 
This comes in the same line of evidence for the importance of the role of CD4 T cells 
with helper functions in supporting an effective CD8 T cell recall response upon HCV 
reinfection. CD4-depletion studies in chimpanzees demonstrated their indispensable role for 
supporting CD8 T-cell functionality [238]. In human IDU cohorts, this indispensable role for 
helper CD4 T cells was confirmed, as the reduction of CD4 T-cell count upon HIV infection 
led to loss of protection against HCV reinfection [118]. The underlying cause(s) of CD4 T-cell 
failure is an important factor for loss of protective immunity that necessitates further 
investigation. 
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5.3. Functionality of HCV-specific T-cells is associated with 
protective immunity 
Our group and others have demonstrated that CD8 T cells simultaneously producing 
several effector cytokines and effector molecules (i.e. polyfunctional CD8 T cells) are 
associated with spontaneous resolution of primary HCV infection [251, 367]. This has also 
been demonstrated for other viruses, as HIV, where control of viral replication was associated 
with the generation of virus-specific polyfunctional T-cells [88].  
Whether polyfunctional CD4 and CD8 T cells were also critical for spontaneous 
clearance upon reinfection was an important factor that had not been previously studied for 
chronic viruses in a human setting. We tested the production of the antiviral cytokines IFNγ 
and TNFα, T-cell growth factor IL-2 and the expression of the degranulation marker CD107a, 
in response to stimulation with peptide pools corresponding to the immunodominant regions 
of HCV. We measured the frequency of cells producing individual or multiple cytokines and 
analyzed the frequency of CD4 or CD8 T cells producing different combinations of the tested 
cytokines  at time points before, during and after the reinfection episode (Manuscript 1 – 
Figures 3 and 4).  
For CD4 T cells, the production of the individual cytokines tested was higher in the 
SR/SR patients with IFNγ as the major cytokine produced by CD3+CD4+ T cells followed by 
TNFα (Manuscript 1 – Figure 3). In contrast, individual cytokine production was weak in the 
SR/CI patients. The frequency of polyfunctional cells was low for CD4 T cells in all patients. 
Nevertheless, when calculated as a percentage of the total cytokine producing cells, we 
observed that 3-6% of CD4 T cells produced more than one function at baseline in SR/SR 
patients, reaching 33% at the peak of the reinfection episode. In contrast, cytokine-producing 
CD4 T cells were strictly monofunctional in SR/CI patients during the reinfection episode, and 
bifunctional populations appeared to be biased by the low frequency of cytokine producing 
cells.   
For HCV-specific CD8 T cells, SR/SR patients also demonstrated higher levels of 
production of the individual cytokines/functions tested as compared to SR/CI patients 
(Manuscript 1 – Figure 4). IFNγ was the major cytokine produced by CD3+CD8+ T cells from 
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the SR/SR group followed by TNFα and the degranulation marker CD107a. Polyfunctionality 
was also higher in the SR/SR group, where the frequency of bifunctional and triple functional 
cells was 7 and 16 fold higher in the SR/SR group as compared to the SR/CI group. When 
results were examined as a percentage of total cytokine producing cells, ~6% of the total 
cytokine producing cells produced three functions simultaneously at the different stages of 
reinfection and 15-52% were bifunctional in the SR/SR patients, as compared to none in the 
SR/CI group (Manuscript 1 – Figure 4, pie charts).  
Analyzing the polyfunctionality of CD8+ cells in response to their cognate minimal 
epitope showed a higher level of production of the individual cytokines in patients from the 
SR/SR group when compared to patients from the SR/CI group (Manuscript 1 - Figure 5). The 
production of individual cytokines/expression of CD107a was 9-folds higher and the total 
frequency of functional cells was 14-folds higher in SR/SR patients. The percentages of 
bifunctional and triple-functional cells within the total CD3+CD8+ functional T cells in the 
SR/SR patients was 14% and 7%, respectively. In contrast, cytokine-producing cells were 
strictly monofunctional in SR/CI patients. These data suggest an association between the level 
of individual cytokine production and polyfunctionality of HCV-specific CD8+ T cells 
targeting dominant epitopes with the protection from persistent viremia upon reinfection with 
HCV. 
In summary, the frequency of individual cytokine producing CD8 and CD4 T cells was 
higher in the SR/SR group and within these functional cells the frequency of polyfunctional 
cells was higher. These results suggest an association between the level of individual cytokine 
production and polyfunctionality of HCV-specific CD8 T cells and protection from viral 
persistence upon reinfection. 
Data from chimpanzee and vaccination studies have also confirmed these findings 
[258, 344]. Where it has been recently shown that protection upon rechallenging chimpanzees 
that were previously vaccinated was associated with the generation of a population of 
bifunctional CD8 T cells (IFNγ+TNFα+) [344]. Here, we confirm in a human cohort that 
polyfunctionality is an important determinant of viral clearance upon reinfection. Furthermore, 
we extend this polyfunctionality analysis to both CD4 and CD8 T cells targeting entire regions 
of HCV, as well as minimal epitopes.  
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The induction of such polyfunctional CD4 and CD8 T cells against HCV 
immunodominant regions would be very important for successful vaccination. Nevertheless, 
several points remain to be elucidated; specifically, which combination(s) of 
cytokines/functions would be the ones consistently correlated with protection? What are the 
molecular mechanisms underlying the generation of such polyfunctional cells? And what is 
the contribution of innate immunity to the fine-tuning of these responses? In parallel, it would 
also be important to define the mechanisms of failure to develop such polyfunctional potential 
by HCV-specific T cells in SR/CI patients despite their ability to resolve their primary HCV 
infection.  
5.4. Frequency and Phenotype of epitope-specific CD8 T-cells 
associated with protective immunity 
The frequency and phenotype of epitope-specific CD8 T cells are among the important 
factors that were demonstrated to correlate directly with clearance of viral infection and the 
generation of a long-lived memory population [251]. These virus-specific memory populations 
are suggested to confer protection upon reinfection [341]. 
We used MHC class I tetramers and a nine color antibody panel to detect markers of T-
cell maturation and memory (CD27 and CD127), T-cell activation/exhaustion (PD1, 2B4 
[CD244] and Tim3) on viable CD3+ CD8+ Tetramer+ cells (Manuscript 1 – Figure 6 and 
Supplementary Figures S4 and S5). This longitudinal phenotypic analysis of HCV-specific 
CD8 T cells showed an average expansion of 42 folds in the frequency of tetramer+ CD8+ T 
cells at the peak of response upon reinfection in SR/SR patients, in contrast to a very limited 
expansion in all SR/CI patients.  
The most distinctive phenotypic changes were in the expression of CD127. For 
patients where samples were available during the first infection, we observed that 
approximately half of the HCV tetramer+ CD8 T cells were CD127+ and as the patients 
cleared their primary infection the majority of tetramer+ CD8 T cells became CD127hi. At the 
first time point following incidence of reinfection we observed that the majority of expanded 
cells were CD127lo, consistent with an effector phenotype. In the SR/CI group, there was no 
significant change in the expression of CD127 in these individuals. This CD127+ CD8+ 
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tetramer+ T population accounted for the polyfunctional population that was observed in 
response to the cognate minimal peptide. Another important feature observed was the 
consistently higher expression of the activation marker PD1 on HCV tetramer+ CD8+ T cells 
in most patients (3/4) of the SR/CI group in comparison to SR/SR patients. Nevertheless, 
proliferation assays using minimum peptides demonstrated that HCV tetramer+ memory CD8 
T cells in the SR/CI unprotected group proliferated at a similar level to those of the protected 
group (data not shown). This suggests they are not inherently defective, and despite being 
present at low frequency, they could expand if rechallenged with their cognate peptide with its 
original amino acid sequence. 
Taken together, these results suggest that protective immunity is associated with the 
generation of long-lived memory CD127hi CD8 T-cell population that gives rise to an effector 
memory population upon reinfection. Nevertheless, a similar CD127hi CD8 T-cell population 
was generated following resolution of the primary infection in the SR/CI group, but did not 
generate an effector recall response during the reinfection episode. Whether variation in the 
amino acid sequence of targeted epitopes could be the sole reason that accounts for this failure 
would need further investigation to rule out the possibility of other causes within the signalling 
pathways and transcriptome of virus-specific memory T-cells. 
Our results are concordant with similar observations in chimpanzees that were 
protected against HCV persistence upon rechallenge after vaccination with an HCV vaccine 
expressing the NS3-5. The vaccine-induced T-cells appeared early and were maintained at 
high frequencies for a long time after HCV challenge. These T-cells displayed high levels of 
CD127 and were bifunctional (IFNγ+TNFα+). PD1 expression was lower than the mock-
vaccinated group and seemed to be associated with control viremia [344]. This was also 
previously described by Shin et al. [258] and is consistent with a memory T cell phenotype 
[37]. 
The association between the frequency, phenotype and polyfunctionality of certain 
epitope-specific CD8 T cells and the resolution of primary HCV infection was previously 
demonstrated [251], and as we show here protective immunity upon reinfection argues for the 
induction of such immunodominant epitope-specific responses through vaccination. Vaccine 
design would have to take into consideration the induction of memory immune responses 
 
 
179 
against immunodominant epitopes associated with the most prevalent HLA alleles in humans 
to assert the highest probability of protection on the population level. Vaccination strategies 
should also take into account the different variants of the epitopes to be included in the 
vaccine to insure an adequate recall response to the different common HCV strains humans are 
exposed to.  
5.5. Effect of viral-epitope variation on protection upon HCV 
reinfection 
HCV is one of the viruses with the highest mutation rates. It replicates rapidly with a 
half-life of ~3 hours producing an average of 1012 viruses/day/patient. With a low fidelity 
RdRp that lacks a proof-reading function, it has a high mutation rate of 1/1000 bases per year. 
Continuous mutation during infection is partially driven by the immune pressure exerted by 
the specific T-cells and antibodies (reviewed in [368]). Importantly, higher mutation rate was 
observed in the epitope-regions targeted by virus-specific T-cells versus other regions outside 
the epitope-regions, where the rate of mutation in the former was 13-folds higher than that in 
the latter [369]. 
We aimed at determining whether the lack of expansion of HCV-tetramer+ CD8 T 
cells in patients of the SR/CI group upon reinfection is due to infection with variant viral 
sequences that are not recognized by the pre-existing memory immune response. For this, we 
sequenced the region of targeted HCV-epitopes from all four SR/CI patients at early and late 
time points during reinfection (Manuscript 1 – Figure 7A). We consistently detected a 
mismatch between the amino acid sequence of the reference peptide used in the tetramer and 
the autologous epitopes in all patients. The 1444 Y→F substitution observed in the NS3-1436 
epitope was previously reported [251, 309, 370], and shown to result-in reduced cytokine 
production, but did not compromise recognition by the T-cell receptor (TCR) [96, 309]. On 
the other hand, the 1077V→A substitution observed in the NS3-1073 epitope was suggested to 
affect the recognition by TCR and to be less efficient in the induction of IFNγ production 
[334, 335, 370]. Surprisingly, this variant underwent three changes in patient SR/CI-2 during 
the reinfection episode despite the lack of expansion in the tetramer+ population and the lack 
of specific functionality in response to the minimum peptide (i.e. in the absence of immune 
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pressure). Specifically, the 1077V→A reverted to the reference sequence and two amino acid 
substitutions occurred (1081V→I suggested to affect the HLA-A2 binding of the epitope and 
1078 W→L). 
Our results suggest that variations in the amino acid viral sequence of the epitopes 
targeted by the memory immune response could be a possible mechanism underling the 
functional differences or lack of recognition in HCV-specific CD8 T cells observed between 
the two groups of patients. It could also be a possible reason for the phenotypic differences 
observed between the SR/SR group and SR/CI group. However, those changes in the targeted 
epitopes do not explain the general decrease in the frequency of the HCV-specific immune 
response observed in ELISPOT analysis for the SR/CI group. Thus, the association between 
the total magnitude of the memory immune response and the degree of homology in the entire 
HCV sequences between the infecting viruses in both episodes of infection remains to be 
assessed.  
These results highlight the major impact of HCV variability on the protective capacity 
of the immune system upon reinfection, and argue in favour of the hypothesis that protection 
has a rather narrow spectrum that is effective mainly against closely-related viral sequences. 
This would translate to the necessity to design vaccination regimens that include various forms 
of immunodominant epitopes to circumvent the high variability of viral sequences, which is a 
hallmark of HCV. 
5.6. Avidity of HCV-specific T cells and protective immunity 
Functional avidity is a measure of the sensitivity of specific TCR to the p-MHC 
complex, where T-cell clonotypes with higher affinity/avidity would recognize p-MHC at 
lower concentrations and respond more rapidly with higher functionality. Studies analyzing 
the TCR-repertoire of epitope-specific CD8 T cells in HIV patients revealed that patients who 
were able to control HIV-1 infection (controllers) had CD8 T-cells with higher avidity and 
functionality compared to patients where the infection progressed to AIDS (progressors) [88, 
371]. Further investigation showed that functional avidity was a major determinant of the 
polyfunctionality and HIV-suppressive capacity [89].  
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We measured the dose-dependent production of IFNγ in response to stimulation by the 
different epitope sequences in an ELISPOT assay. Results of these dose-response experiments 
showed higher avidity of HCV-specific T cells in SR/SR patients to the reference sequence 
when compared to SR/CI patients (Manuscript 1 – Figure 7B). The results of functional 
avidity were similar to the results of functionality and polyfunctionality; where patient SR/SR-
4 who had higher functional avidity than patient SR/SR-1, showed a higher frequency of 
functional cells for the epitope-specific CD8 T cells. A similar pattern was observed for SR/CI 
patients, where patient SR/CI-2 who had a relatively higher functionality when compared to 
SR/CI-2 upon stimulation with the minimum peptide, showed a higher avidity in response to 
the reference-sequence of the epitope. Both SR/CI patients had higher avidity for the reference 
epitope sequence than the autologous epitope sequence of the reinfecting virus. We also 
observed that patient SR/SR-4 had a good response to one of the mutated epitopes, despite not 
being infected with this amino acid sequence of the epitope in either episodes of infection. 
Together with the polyfunctionality data observed upon stimulation with minimum 
peptides we could observe the obvious correlation, where the patient with the highest avidity 
(SR/SR-4) had the highest functionality and polyfunctionality upon stimulation by the 
reference sequence of the cognate peptide. This has already been shown within the context of 
HIV infection, where superior functional avidity of epitope-specific CD8 T cells was 
interlinked with their high polyfunctional capacity [88]. It has also been demonstrated in the 
cytochrome-c protein mouse-model that there was a link between kinetics of the CD4 T-cell 
repertoire and the affinity of pMHC-TCR interactions [372]. Thus it was necessary to analyze 
the repertoire of TCRs for epitope-specific CD8 T cells to verify whether it was a decisive 
factor in the outcome of HCV reinfection and the establishment of protective immunity, 
especially against different viral variants. 
The fact that all four SR/CI patients had higher avidity for the reference epitope 
sequence than the autologous epitope sequence of the reinfecting virus could be attributed to 
“original antigenic sin” (Manuscript 1 – Figure 7B). This hypothesis postulates that once a 
naïve T cell targeting a specific epitope expands and develops into memory, it becomes 
incapable of recognizing new variants of the same epitope, which facilitates viral persistence 
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upon generation of escape mutations in targeted epitopes or upon reinfection with an 
unrecognizable viral variant [373]. 
Patient SR/SR-4 had a moderate response to one of the mutated epitopes, indicating the 
possibility of higher flexibility of the TCR-repertoire. A study in HIV patients with similar 
HLA allele backgrounds showed that infection controllers possessed TCR clonotypes 
characterized by enhanced cross-reactivity to different variants of the epitope [374]. HIV 
controllers possessed alternative clonotypes that were mobilized and dominated the response 
to recognize the mutant form of the epitope. Those newly mobilized clonotypes were shown to 
recognize both forms of the epitope with similar affinity thus provided high flexibility within 
the epitope-specific CD8 T-cell repertoire [375, 376]. Indeed, flexibility in the T cell 
repertoire correlated with better control of viral escape mutants in both the HCV and HIV field 
[94, 374-376] and it would be interesting to validate such results in a reinfection model. 
5.7. Memory versus de novo CD8 T-clonotypes in protective 
immune responses 
It has been reported before that reinfection was associated with a significant increase in 
the breadth of T-cell responses suggesting the generation of de novo T-cell responses [354], a 
finding that we observed with our ELISpot results, as well. This raised the possibility that 
within the epitope-specific CD8 T-cell population, the effector cells appearing at the peak of 
immune response during reinfection could be due to the recruitment of new clonotypes from 
the naïve T-cell pool. Our phenotyping panel was designed to examine the memory and 
exhaustion status of the epitope-specific CD8 T-cell population, but we still needed to confirm 
whether the CD127lo Teff cells appearing at the peak of response to the reinfection episode 
were recruited from the naïve repertoire or if they were TEM recruited from the TCM pool. 
Clonotypic analysis of TCR could help us verify whether the source of the effector T cells 
(CD127lo) is expansion of pre-existing memory or generation of de novo T cell responses 
[377]. Taking into consideration data from the HIV and HCV models it was tempting to 
speculate that repeated reinfections would selectively expand and enrich such cells of higher 
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functional avidity already recruited during the primary infection provided that the targeted 
epitope remain unchanged [94, 374-376]. 
We performed longitudinal analysis of the HCV-epitope-specific T-cell repertoire 
during HCV reinfection in five patients with different outcomes of the reinfection episode; 
three patients who resolved two successive HCV infections (SR/SR group), and two patients 
who became persistently infected upon reinfection (SR/CI group) (Manuscript 2 - Table 1). 
Epitope-specific CD8 T cells identified by MHC class I tetramer (as detailed in the table) were 
sorted at various time points; pre-, at the peak and late/post the reinfection episode. The gating 
strategy used for sorting is explained in Supplementary Figure 1 of Manuscript 2. The TCRBV 
gene and TCRBJ gene usage, as well as the CDR3 chain amino acid sequence for all Vβ 
chains for the different T-cell clonotypes were analysed (Manuscript 2 - Supplementary Tables 
S1 and S2).  
Our longitudinal analysis of the Vβ-chain of TCR did show a conserved pattern of Vβ 
usage in all of the tested patients, where the dominant and sub-dominant clonotypes forming 
the population at the peak of immune response during reinfection were recruited from the 
memory population generated following the clearance of the primary infection, with lack of 
appearance of new clonotypes (Figure 1 and Supplementary Tables S1 and S2). Nevertheless, 
the frequency of the different clonotypes changed upon reinfection causing a change in the 
hierarchy of the utilized clonotypes. These results suggest that the effector CD8 T cells were 
TEM recruited from the TCM pool rather than being recruited from the naïve repertoire. 
It has been demonstrated before in the LCMV model that the TCR repertoire of the 
primary epitope-specific CD8 T-cell response was conserved in the memory pool and the 
secondary effector recall response, where there was identity between the clonotypes that 
formed 60-100% of the primary effector, memory and recall responses [378, 379]. Rapid 
resolution of HCV infection upon rechallenging chimpanzees also coincided with the 
expansion of T-cell clonotypes that dominated the memory CD8 T-cell pool. These specific 
TCR clonotypes were tracked through the two consecutive HCV challenges [90, 94]. 
The increase in the breadth of the T-cell responses in SR/SR patients and the narrow 
TCR-repertoire (that becomes more focused upon reinfection) are seemingly contradictory. 
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Nevertheless, a possible explanation is that the immune system generates a broader response 
(i.e. targeting more epitopes) to insure more effective attack on the different viral regions, but 
without compromising the focusing of the TCR-repertoire of epitope-specific T cells on the 
fittest clonotypes that would possess higher functional avidity and better cross-reactivity.  
5.8. Diversity of the repertoire of HCV-specific CD8 T cells and 
protective immunity 
Studies on the interplay between the TCR-repertoire of epitope-specific CD8 T cells 
and chronic viruses (LCMV model, as well as HIV and HCV infections) had controversial 
results concerning the diversity of the repertoire and its correlation with control of infection 
and reinfection, where some studies showed that control was associated with a more diverse 
TCR-repertoire, while other studies demonstrated it was associated with a more focused 
repertoire [94, 371, 378]. 
Our analysis revealed that the repertoire-composition in the tested SR/SR patients was 
less diverse than that observed for SR/CI patients at all the time points tested (pre-, peak and 
post reinfection); where 75-83% of the repertoire was attributed to 14-23 TCR-clonotypes, and 
it became more focused at the peak of the immune response during reinfection for patients 
SR/SR-1 and SR/SR-2 (92% and 96% of the repertoire was attributed to 15 and 2 TCR-
clonotypes, respectively) (Manuscript 2 - Figure 2A, 2B and 2C). In those two patients, the 
repertoire retained a more focused status post reinfection when compared to the pre-
reinfection time point, with 77% and 93% of the repertoire attributed to 16 and 4 clonotypes, 
respectively (Manuscript 2 - Figure 2A and 2B). Patient SR/SR-3 showed no focusing of the 
repertoire upon reinfection (Manuscript 2 - Figure 2C), and this comes in accordance with our 
previous results, where there was no expansion of the tetramer+ population in this patient 
upon reinfection, and ELISPOT data suggested the patient was reinfected with a different 
HCV subtype [380]. In contrast, the repertoire in the tested SR/CI patients was more diverse; 
where the dominant clonotypes (present at >1%) represented 37% and 55% of the repertoire 
and were attributed to 18 and 23 TCR-clonotypes, respectively. At the peak of the immune 
response during reinfection the repertoire was still more diverse than in the SR/SR patients 
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(the dominant category represented 28-64% of the repertoire) (Manuscript 2 - Figure 3A and 
3B). The remaining ~40-60% of the repertoire was represented by >130-300 clonotypes, 
whereas in the SR/SR patient the number of minor clonotypes never exceeded 116 unique 
clonotypes (except at the time point post infection for patient SR/SR-1, where the sample was 
a leukaphoresis sample, and it had ~10-40 fold the number of sequences available for other 
time points in the same patient and other patients (Manuscript 2 - Figure 2A)). Post 
reinfection, we did not observe increased focusing of the repertoire in SR/CI patients, as 
compared to the pre-reinfection time point.  
A narrower repertoire that becomes more focused upon reinfection in the protected 
(SR/SR) group was further supported by the observation that the top three clonotypes and the 
top two clonotypes in patients SR/SR-1 and SR/SR-2 represented 28% and 59% of the 
repertoire pre-reinfection, respectively (Manuscript 2 - Figure 2A and 2B, the dissected pie-
charts in the lower lines). Upon reinfection they became more dominant, representing 51% 
and 96% of the repertoire, respectively. Post reinfection they were more dominat when 
compared to the pre-reinfection time point, forming 39% and 90% of the repertoire, 
respectively. On the other hand, the top three clones in the tested SR/CI patients never 
represented more than 27% of the repertoire, and were sometimes as low as 9% (Manuscript 2 
- Figure 3A and 3B, the dissected pie-charts in the lower lines). 
It has been demonstrated before in the LCMV mouse model that the repertoire of an 
epitope-specific CD8 T-cell population was highly focused, where 70% of the response 
against LCMV was due to three clonotypes [378]. In the cytochrome-c antigen system there 
was narrowing of the repertoire upon second exposure relative to the primary repertoire, 
suggesting selection of the clonotypes with highest affinity [372]. Analysis of the TCR 
repertoire of epitope-specific CD8 T cells in HIV patients also demonstrated narrower and 
more focused TCR-repertoires of high-avidity populations in patients who were able to control 
HIV-1 infection compared to progressors [371]. On the other hand, a previous study of an 
HCV-epitope (NS3-1406) suggested that higher diversity of the repertoire would be more 
advantageous, otherwise the virus would undergo mutation of the epitope to exploit gaps 
present in the repertoire [93]. A chimpanzee rechallenge study suggested a similar conclusion, 
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since the majority of HCV-epitopes that escaped immune recognition upon reinfection were 
targeted by a CD8 T-cell repertoire with reduced CDR3 amino acid diversity. This suggested 
that it is more advantageous to generate and maintain a diverse TCR repertoire against 
individual epitopes. In contrast, limited TCR diversity facilitated CTL escape mutations in 
HCV infected chimpanzees [94]. Interestingly, an earlier study showed that despite some 
TCRBV sequences being identical in chimapnzees and humans, other TCRBV genes in the 
chimpanzee have been lost in humans. This could be a probable cause of discrepancy of 
findings between chimpanzee and human studies for the different HCV-epitopes [381]. 
Another important factor that might cause discrepancy in the results from chimpanzee studies 
is that the animals were rechallenged with the same viral sequence and therefore exposed to 
less diversity on the virus side, which is completely different from natural human infections 
where individuals are usually infected with a mixture of quasispecies.  
5.9. Role of specific CD8 T-clonotypes in protective immunity 
A study of epitope-specific CD8 T-cell repertoire in HIV patients suggested the 
preferential recruitment of particular clonotypes endowed with superior functionality [87]. 
Another study in HIV patients with a similar HLA-allele background showed that infection 
controllers targeted an immunodominant epitope with TCR clonotypes distinct from those 
observed in progressors. These clonotypes were characterized by superior control of viral-
replication in vitro and enhanced cross-reactivity to different variants of the epitope [374]. 
Whether protective immunity upon HCV reinfection in a human cohort would be associated 
with specific clonotypes dominating the TCR-repertoire that are distinct from the clonotypes 
observed in the non-protected group is still an area that needs extensive studying. Also, 
particular clonotypes were preferentially selected in several HIV-infected individuals who 
controlled viral-replication. These public clonotypes exhibiting superior avidity imposed 
selective pressure causing early mutation in the epitope that enables the virus to escape their 
recognition [375, 376]. However, the variant epitopes were recognized by specific T-cell 
clonotypes that were moblilized by the immune system. These newly mobilized clonotypes 
were more flexible (i.e. recognize multiple epitope variants) and still possessed high functional 
avidity [375, 382].  
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The longitudinal sequencing of the Vβ-chain of the TCR showed that the dominant and 
subdominant Vβ-CDR3-Jβ  detected in the tested patients showed no overlap, where no 
clonotypes were found to be common between patients targeting the same epitope, whether 
they belonged to different groups (SR/SR-1 and SR/CI-2 recognizing the HLA-A2 restricted 
NS3-1073 epitope) or even when they belonged to the same group (SR/SR-2 and SR/SR-3 
recognizing the HLA-B27 restricted NS5B-2841 epitope) (Supplementary Tables S1 and S2). 
Sequencing the Vβ-chain from more patients and T cells targeting other HCV-epitopes is 
needed, to verify whether some clonotypes are recurrent in the repertoire of different patients 
from the same group and thus represent “public clonotypes” associated with the outcome. 
Also, it would confirm whether distinct clonotypes are found in the SR/SR repertoire versus 
the SR/CI repertoire. 
It is noteworthy that all of these results for the TCR-repertoire from peripheral blood 
mononuclear cells (PBMCs) is expected to reflect what is happening in the liver, since 
rechallenge studies in chimpanzees showed that the peripheral epitope-specific CD8 T-cell 
repertoire reflected the intra-hepatic response, where identical clonotypes were present in both 
the liver and the peripheral circulation which differed only in the magnitude (where it was 10-
folds higher in the liver) [90]. 
Collectively, the results from the studies presented in this thesis led us to propose a 
hypothetical model for the correlates of protection against chronicity upon HCV reinfection 
(Figure 13). 
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Figure 13: Hypothetical model for protective and non-protective immunity upon HCV 
reinfection. 
Reproduced with the permission of Frontiers scholarly communications: Frontiers in 
Immunology [10], author copyrights 2014. 
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Legend: Individuals who spontaneously clear primary HCV infection develop long-lived 
virus-specific memory CD4 and CD8 T cells. Such memory T cell populations are maintained 
by the action of homeostatic cytokines like IL-7, IL-15, and IL-21. Upon HCV reinfection, 
some individuals will be protected against viral persistence while others will be unprotected. 
(A) Spontaneous resolution of primary and secondary HCV infections (SR/SR). The 
protected individuals will be able to spontaneously clear the second infection with a shorter 
period of viremia, as well as reduced peak viremia. Viral clearance will be accompanied by an 
accelerated memory T cell recall response detectable in both liver and blood characterized by 
the increased breadth magnitude and functionality/polyfunctionality, together with the 
expansion of HCV-specific CD8 T cells. The exact characteristics of a protective response are 
yet to be defined in terms of breadth and quality. (B) Spontaneous resolution of primary 
HCV infection followed by chronic infection upon reinfection (SR/CI).  In unprotected 
individuals, reinfection will be associated with a weak or late recall response and incomplete T 
cell-mediated control of viremia. The underlying causes of failure to resolve the reinfection 
despite the ability to spontaneously resolve a prior infection maybe low levels of homeostatic 
cytokines affecting the maintenance of memory T populations, reduced breadth, or quality of 
the recall response upon reinfection and increased frequency of Tregs leading to dampening of 
the immune response, viral persistence, and rapid exhaustion of HCV-specific T cells. 
 Neutralizing antibodies, host genetics, and homology between the infecting viral sequences at 
different episodes might also be determinants of protection upon reinfection. 
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5.10. Shifting epitope dominance upon HCV reinfection 
For patient SR/SR-1 who was responsive to two tetramers A2/NS3-1073 and 
A2/NS5B-2594, we observed different levels of expansion of CD8+ T cells specific to the two 
tetramers. The frequency of NS5B-2594 tetramer+ population increased by 120 folds upon 
reinfection compared to 7 folds only for the NS3-1073 tetramer+ population (Manuscript 1 – 
Figure 6A and Supplementary Figure S5). This occurred despite the fact that the frequency of 
the tetramer+ cells for the NS5B-2594 was at a much lower level than that for NS3-1073 at the 
time point before reinfection. This suggests that a shift in the dominance of the targeted 
epitopes occurred upon reinfection. 
This comes in contrast with previous results from rechallenge studies in chimpanzees 
that showed hierarchy preservation of the frequency of epitope-specific CD4 T cells targeting 
different epitopes [57]. On the other hand, monitoring the kinetics of three immunodominant 
epitopes during primary, memory and recall responses in the LCMV model demonstrated 
changes in the epitope-specific T-cell hierarchies [379].   
Nevertheless, we need to examine more patients with multiple tetramer+ populations 
recognizing different epitopes to verify this assumption, especially patients for whom 
longitudinal samples from the first episode of infection are available. Also, further 
investigation is needed to verify whether the change in the hierarchy of these two epitopes is 
due to differences in the kinetics of epitope processing/presentation or whether it could be 
attributed to the differential expression kinetics of the two protein regions they are included in 
(NS3 region versus the NS5B), or both factors. 
5.11. Correlation between specific HLA-alleles and protective 
immunity 
Patient SR/SR-3 successfully cleared his reinfection despite the decline in magnitude 
and breadth of the immune response against the genotype 1a reference peptide panel upon 
reinfection (Manuscript 1 - Supplementary Figure S1). Being reinfected with HCV of an 
unknown subtype, we tested his response to a panel of peptides corresponding to genotype 1b 
reference sequence, and we observed an increase in the overall frequency and breadth of 
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HCV-specific T cell responses upon reinfection. This represents an interesting case for further 
study to clarify the mechanisms that enabled this patient to achieve protection against a second 
infection by HCV even of a different subtype. It is noteworthy that this patient has an HLA 
allele B*27, which has been previously associated with higher ability to spontaneously clear 
HCV and control HIV infection [200, 383, 384]. These results suggest that patients bearing 
this HLA allele might also have superior protection from HCV-persistence upon reexposure. 
Also, some HLA class II alleles demonstrated a strong association with primary HCV 
clearance, whereas others were associated with HCV persistence [201-203]. It would be 
interesting to study these correlations in a reinfection setting. 
5.12. Conclusions, limitations and future studies 
5.12.1. General conclusions 
The rational design of prophylactic vaccines against chronic viral infections 
necessitates the clear definition and dissection of the correlates of protective immunity, so that 
they could be monitored during new vaccine trials to verify the degree of protection conferred 
by these new vaccines. However, several challenges impede the definition of the 
characteristics of protective immunity for chronic viruses, because in the majority of cases the 
virus is never eliminated from the body of the host after the primary infection and for viruses 
where some patients clear the virus spontaneously (e.g. HCV), it has been very challenging to 
study immune responses in a human reinfection setting. Marginalized populations (as IDUs) 
represent the major population at risk, with many challenges related to recruitment of patients 
belonging to these groups. And within these cohorts, it is still more challenging to be able to 
recruit patients who cleared a primary infection and are at risk of getting reinfected. We were 
able to recruit patients who resolved a primary HCV infection, but had a differential outcome 
of the second infection, and for whom longitudinal blood samples during the multiple episodes 
of HCV-infection were available. This rare cohort enabled us to perform an exhaustive 
longitudinal phenotypic and functional characterization of the HCV-specific memory immune 
responses upon reinfection.  
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A general conclusion from our study is that no sterilizing immunity was observed upon 
reinfection with HCV in patients who previously resolved a primary infection. This comes in 
accordance with several rechallenge studies conducted in chimpanzee and epidemiological 
studies in IDU-cohorts who cleared a primary HCV infection and were still at risk due to 
continuous exposure to HCV [118, 119, 349]. Our results and results from other groups 
suggest that protection from viral persistence is higher upon subsequent exposure than 
resolution of primary infection, offering hope for vaccine development [118, 351, 354]. 
Spontaneous resolution of reinfection was associated with an increase in both the magnitude 
and breadth of total HCV-specific T-cell responses in 4/5 protected patients. In addition, we 
observed expansion of HCV-specific memory T cells and the transient appearance of CD127lo 
population indicative of an effector T cell phenotype in 3/4 protected patients who recognized 
specific tetramer. On the other hand, all patients who failed to clear their second infection 
episode (4/4) showed very limited expansion of HCV-specific T cells, although they did 
exhibit HCV-specific T cells with a memory phenotype prior to reinfection. Variations in the 
amino acid sequences of the epitopes targeted by the HCV-specific CD8 memory T cells were 
detected in all patients of the non-protected group suggesting a role of variation in viral 
sequence in the failure of recall response. HCV-specific CD4 and CD8 T cells showed higher 
functionality/polyfunctionalty and proliferative capacity in the protected group. Analysis of 
the TCR-repertoire of epitope-specific CD8 T cells demonstrated that a more focused 
repertoire of distinct clonotypes was associated with protection. These T-cell populations 
showed higher functional avidity and polyfunctionality compared to their counterparts in non-
protected patients. 
The fact that protection was associated with expansion and broadening in the responses 
for both CD4 and CD8 T cells upon reinfection, in contrast to non-protected patients who had 
defective responses for both populations, argues in favour of the assumption that failure to 
generate a polyfunctional and broad CD8 recall response upon reinfection is –at least 
partially– a result of CD4 failure. Nevertheless, it is imperative to study other possible causes 
associated with defects within the signaling and transcriptome networks for the failure of 
memory CD8 T cells, as well as the inherent causes of failure of memory CD4 T cells to 
provide the necessary help. 
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Overall, our results suggest that memory T-cell populations formed following the 
spontaneous resolution of a primary HCV infection are not all created equal; but rather 
represent a broad spectrum of cells with different capacities ranging from high-quality 
memory (capable of resolving future episodes of infection, sometimes of a different 
genotype/subtype) to low-quality memory (that fails to mount a strong recall response even 
against closely similar variants). This is supported by similar findings in chimpanzee 
rechallenge studies [338-340]. What remains crucial to be elucidated, are the factors that 
contribute to the formation of such high-quality protective memory, and how to tailor vaccines 
that would induce such a response. 
Our results also demonstrated that avidity, diversity and specific clonotypic-
composition of the virus-specific T-cell repertoire are important determinants of protective 
immunity. Our data, together with data from the HIV model suggest that T-cell populations 
with highest polyfunctionality are the same with highest avidity. It is also tempting to 
speculate that repeated infections would selectively expand and enrich such cells of higher 
functional avidity provided that the targeted epitope remain unchanged. Indeed, protection 
upon reinfection was associated with a more focused TCR repertoire, in contrast to previous 
findings in chimpanzee studies that associated protection upon HCV reinfection with a more 
diverse repertoire. Nevertheless, these studies also showed that protection was associated with 
the expansion of the same TCR-clonotypes that were tracked during the primary HCV 
challenge [90, 94]. Flexibility in the T-cell repertoire correlated with better control of viral 
escape mutants in both HCV and HIV infections [94, 374-376], and HIV controllers mobilized 
alternative cross-reactive clonotypes capable of recognizing the mutant form of the epitope to 
dominate the response. Thus, exposure to different forms of the epitope could help higher 
clonal turnover, and those newly mobilized clonotypes were shown to recognize both forms of 
the epitope with similar affinity thus provided high flexibility within the epitope-specific CD8 
T-cell repertoire [375, 376]. These findings can be applicable to many other chronic viral 
infections, especially those with high variability like HCV. And it is important to verify these 
findings in the reinfection setting, and extend those findings to other immunodominant HCV-
epitopes. 
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5.12.2. Limitations 
Despite being the first study to dissect the general characteristics of protective 
immunity against HCV in a natural reinfection human setting, we are aware of some 
limitations that represent a challenge for studies with such cohorts in general. These include 
the limited number of patients and lack of specific time points for some patients (especially 
during the primary infection episode), the inability to specify the exact start-date of the 
infection/reinfection episode and the possibility of missing brief infection episodes. We tried 
to overcome these cohort-related limitations by narrowing the testing intervals for HCV-RNA 
in our patients, but this does not completely rule out the occurrence of brief episodes of HCV 
that are missed due to rapid clearance and/or low levels of viremia. Nevertheless, the testing 
intervals chosen represent the ideal compromise between the probability of not missing on any 
of the infection episodes and the cost/space, as well as other logistic limitations related to 
sample acquisition and preservation. These issues are recognized by researchers in the field 
and were previously addressed for such rare cohorts in general [357]. Besides, some technical 
caveats exist, where the number of epitopes that could be tested for a patient of a certain HLA-
background is limited by the number of tetramers available for such an allele. We have tested 
the MHC class I tetramers available for the corresponding HLA alleles in each patient. 
5.12.3. Probable causes of failure of protective immunity   
These two studies provide an important insight for the first time into the general 
characteristics associated with protective immunity against HCV in a natural infection setting 
in humans. Nevertheless, more patients need to be examined to confirm the preliminary 
conclusions we drew from these studies and several important issues remain to be resolved to 
have a more complete picture about the causes of failure of the memory immune response in 
providing protection upon reinfection in the SR/CI group. Understanding these factors would 
be pivotal for successful vaccine design.  
5.12.3.1. Defects in signaling pathways and transcription of HCV-specific T cells 
Transcriptional control of memory CD8 T cell differentiation has been shown to 
include different transcription factors biasing the formation of effector T-cell populations 
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towards specific subsets (reviewed in [385]). Examining the transcriptome profile of HCV 
tetramer+ CD8 T cells at different time points during the reinfection episode would enable 
defining the molecular defects associated with failure in establishing protective immuity.   
 5.12.3.2. Suppression by Tregs  
The role of other CD4 T-cell subsets in the establishment/failure of protective 
immunity needs to be defined. Tregs could be beneficial or detrimental during HCV infection, 
by either limiting immunopathology in the liver and preventing the apoptosis of highly 
activated CD8 T cells [363] or suppressing protective T-cell responses [386]. Acute resolving 
HCV is characterized by a strong Th1/Th17 response with specific expansion of IL-21 
producing CD4 T cells that correlated with the frequency of HCV-specific CD8 T cells [269]. 
5.12.3.3. Absence of neutralizing Antibodies 
The role of humoral immunity in spontaneous resolution of primary HCV infection and 
during reinfection episodes remains controversial [248, 249, 279, 338, 341, 354]. Its role 
during reinfection is even less defined. Examining the neutralizing capacity of longitudinal 
plasma samples using custom HCVpp with the variant E1/E2 sequences would enable the 
definition of the contribution of humoral responses to protective immunity. 
5.12.3.4. Lack of particular T-cell clonotypes  
It has been shown before within the context of HIV infection that certain epitope-
specific clonotypes possess a higher avidity and flexibility in response to different variants of 
the epitope [89, 376]. Analyzing the TCR-repertoire from additional patients to verify whether 
specific clonotypes correlate with protection in response to the different variants of the 
epitope. This will also determine whether there is recurrent usage of specific TCR-clonotypes 
(public clonotypes) in protected patients. 
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5.13. Significance of the study 
The importance of this study is that it provides a first insight into the general 
characteristics of the adaptive immune response associated with resolution of reinfection by a 
chronic virus in a human cohort. This signature of a protective immune response necessitates a 
deeper insight into the transcriptome and signalling correlates that ensure the generation of 
efficient memory populations capable of mounting a recall response that clears the reinfecting 
virus. In parallel, it is important to define the underlying causes of failure to mount such a 
response in patients who failed to clear HCV during the reinfection episode despite 
spontaneously resolving the primary infection. On another level, a more complete insight into 
the clonotypic requirements of epitope-specific CD8 T cells associated with protective 
immunity against different viral variants could be achieved by analyzing the TCR-repertoire in 
more patients and for various immunodominant epitopes. This would enable the identification 
of specific public clonotypes with optimum avidity and flexibility that confers such protection. 
Despite the limited number of patients included in this study (which is a common 
limitation for such cohorts), we were able to draw some conclusions about the general 
signatures of the protective immune responses against HCV during reinfection episodes. Our 
results suggest that it would be very important for next-generation vaccine design to focus on 
epitopes that have the ability to generate responses inducing specific public clonotypes against 
immunodominant epitopes that possess superior functional avidity and polyfunctionality. 
Combining several immunodominant epitopes that would induce the generation high-avidity 
public clonotypes and that escape at a high fitness price would maximize the chances of a 
vaccine to eliminate the virus rapidly. This would inhibit the virus from establishing a 
foothold in the patient and acquiring the ability to manipulate the patient’s immune response. 
This combination has to take into consideration the coverage of the most common HLA alleles 
in human populations to ensure a minimum response in patients with different genetic 
backgrounds. It is also essential to elucidate the kinetics associated with responses to different 
epitopes; both the kinetics of processing/presentation and the differential expression kinetics 
of the immunodominant protein regions that contains them. This could be a critical point for 
the choice of epitopes/proteins to be included in a vaccine and the precise design of 
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vaccination regimens that would ensure broad responses without having a specific response 
hamper the following responses or overshadowing the preceding responses to other 
epitopes/regions. 
One major constraint of vaccine development for HIV and HCV is the heterologous 
nature of the sequences of these viruses where they circulate as quasispecies even within the 
same individual. This might be overcome by designing prime/boost vaccination regimens that 
would “stretch” the flexibility of the repertoire of epitope-specific T cells to the optimum, thus 
preparing the immune system for the expected challenge against the different possible variants 
of the same epitope. It is possible that rechallenge with a slightly different antigenic variant 
might favour expansion of T cells carrying a flexible T cell receptor that caould recognize 
these new variants. Thus, immunization and boosting with the different forms of the 
immunogen commonly observed in the population might afford a broader and more effective 
protection.  
Accordingly, a successful prophylactic vaccine must have a dual capacity; the capacity 
to induce an effective immune response capable of surmounting the high mutational rate of 
HCV, and the capacity to generate high-quality memory immune cells capable of mounting a 
prompt recall response that outpaces HCV and prohibits it from producing enough viral 
proteins able to distort/antagonise the different arms of immune system.  
The definition of the correlates of protective immunity would enable the tailored 
design of a vaccine containing the optimum HCV epitopes/regions and the adjuvants that 
would ensure induction of adaptive responses that establish memory T cell populations with 
the phenotype, functionality and repertoire that would confer protective immunity upon 
exposure to different HCV variants. Moreover, this definition would enable the testing of the 
right determinants that could predict whether the vaccine in question would be protective upon 
viral exposure. All present vaccine trials could be considered empirical, since they do not 
measure defined correlates for the efficacy of protection. With the recent advances in 
immunological and molecular biology techniques, it is inevitable to revise our strategies for 
vaccine design based on lessons learned from successful vaccines on how to trigger an 
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efficient memory CMI and based on the correlates of protective immunity in the setting of a 
natural human reinfection defined in this thesis and its future continuation studies. 
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CHAPTER 6: 
PERSPECTIVES AND FUTURE DIRECTIONS 
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This study represents an initial effort to unravel the correlates of protective immunity 
and the characteristics that are associated with clearance of reinfection by a chronic virus. It 
enabled us to draw conclusions about the general determinants of protective immunity against 
HCV. Nevertheless, we still need to examine more patients to confirm the preliminary 
findings of this study. We also need to have a deeper insight into the underlying causes for 
failure of CD8 T cells recall responses in the non-protected group (transcriptome and 
individual-clonotype level), as well as a broader overview for the accompanying factors that 
could enhance/curtail such protection (roles for innate immunity, different CD4 T-cell subsets 
and nAbs). Another interesting group to be studied in parallel are patients who cleared a 
primary infection, but did not contract a second infection (exposed non-reinfected group) who 
could be privileged with a superior protection to that of the SR/SR group. 
Several gaps in our knowledge about protective immunity against chronic viral 
infections remain to be elucidated. First, we need to define the genomic signatures and 
molecular mechanism(s) underlying the enhanced/failed recall response upon re-exposure, and 
verify whether the mechanisms identified in mouse-models are valid in the more complex 
setting of human chronic viral infections such as HCV. Second, we need to define the role of 
each of the different subsets of CD4 T-cells in sustaining a protective memory immune 
response. Third, we must verify whether neutralizing Abs play a role in protective immunity 
against HCV. Fourth, we have to study the impact of the heterogeneity of the entire HCV-
genome sequence on the protective capacity of the memory immune response. Fifth, we need 
to monitor the specific contribution of individual TCR-clonotypes to protective immunity. 
Finally, we should verify whether there are differential elements affecting the migration of 
HCV-specific cells to the liver between the protected group and the un-protected group.    
Further studies are needed to enable answering these important questions, which would 
be crucial for the rational design of next-generation vaccines with the ability to fine-tune the 
early adaptive immune response to ensure the generation of memory T cells with optimal 
qualities that would confer protection upon exposure to chronic viruses. 
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6.1. Transcriptome analysis to dissect underlying causes of failure 
of protective immunity 
Transcriptional control of memory CD8 T cell differentiation has been shown to 
include an intricate interplay between different pairs of transcription factors. The balance 
between T-bet/EOMES and BLIMP1/Bcl-6 (among others) was shown to have a decisive role 
in the formation of short-lived terminally differentiated T cells versus long-lived memory T 
cells. Besides, the balance between different STATs (especially STAT3 and STAT4) is 
suggested to have a pivotal role in the differentiation of T cells and even biasing the formation 
of effector T-cell populations towards specific subsets (reviewed in [385]). A recent study also 
observed molecular and transcriptional profiles for exhausted CD4 T-cells that were distinct 
from those in their CD8 counterparts, and under the mixed control of both distinct and shared 
transcription factors [387]. 
Whether there are differential microenvironmental factors deriving the generation of 
high-quality versus low-quality memory through specific transcriptional and molecular 
mechanisms during the primary infection, thus favouring a specific fate in protected (SR/SR) 
versus non-protected (SR/CI) patients is important to be verified. The definition of these 
factors would be important to enable the adjustment of optimal conditions for generation of 
protective immunity using vaccination. 
We will examine the transcriptome profile of sorted HCV tetramer+ CD8 T cells at the 
baseline, peak and post infection and reinfection episodes. Upregulated genes will be validated 
by real-time PCR. Gene set enrichment analysis (GSEA) will be used for identification of 
significantly modulated pathways [388]. GSEA has already been successfully used to define 
important immune pathways during HIV infection and Yellow Fever (YF) vaccination studies 
[112, 389]. The profiles could be compared between the SR/SR group and the SR/CI group, 
and a control group of SR patients could be included, as well. 
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6.2. Defining the role of different CD4 T-cell subsets in protective 
immunity against HCV 
The help of CD4 T cells is essential to maintain efficient memory CD8 T cells [390, 
391] and prevent their exhaustion [43, 392, 393]. We have already studied the role of helper 
CD4 T cells during the multiple episodes of HCV infection. Nevertheless, the role of other 
CD4 T-cell subsets in the human reinfection setting needs to be defined. 
It has been previously shown that T-cell responses were differentially suppressed in 
patients infected with different strains of HCV, suggesting that T-cell responses are 
suppressed in a strain-specific fashion. Thus, even patients capable of clearing a primary 
infection, could develop persistent infection if reinfected by a heterologous strain of the virus, 
suggesting a role for virus-specific Tregs [394]. Tregs could be beneficial or detrimental 
during HCV infection, by either limiting immunopathology in the liver or suppressing 
protective T-cell responses [386]. Frequencies of CD25+ CD4+ T cells were higher in 
chronically infected patients, and exerted suppression on HCV-specific CD4 and CD8 T cells 
[267, 311]. Nevertheless, some studies suggested an immunomodulatory role preventing the 
apoptosis of highly activated CD8 T cells [363]. This is supported by a chimpanzee study 
showing that the frequency of Foxp3+ CD4+ CD25+ Tregs and the degree of suppression 
were similar in animals that spontaneously resolved and those that were persistently infected 
[395]. 
Our laboratory has already optimized the techniques for detection and measurement of 
the frequency and functions of different CD4 T-cell subsets. We were able to dissect the 
functions and ratio between two important CD4 T-cell subsets during acute primary HCV 
infection; Th17 and Tregs.  We demonstrated that acute resolving HCV is characterized by a 
strong Th1/Th17 response with specific expansion of IL-21 producing CD4 T cells and 
increased IL-21 levels in plasma, which correlated with the frequency of HCV-specific CD8 T 
cells. In contrast, viral persistence was associated with lower frequencies of IL-21 producing 
CD4 T cells, reduced proliferation and increased exhaustion of HCV-specific CD8 T cells. 
Furthermore, progression to chronic infection was accompanied by expansion of a specific 
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subset of highly suppressive CD39-expressing Tregs and a reversal in the Treg/Th17 ratio. 
However, the dynamics of Th17 cells and IL-21 and the plasticity of different CD4 T-cell 
subsets during the memory phase and reinfection episodes and their role in protective 
immunity remain to be elucidated and is one of our perspectives (Figure 14). 
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Figure 14: Plasticity of CD4 T-cell subsets in the context of viral infections. 
Reproduced with the permission of Macmillan Ltd: Nature Reviews in Immunology [396], 
author copyrights 2012. 
Legend: Following recognition of a specific antigen, naïve CD4 T cells become polarized into 
distinct effector T-cell subsets that differentially orchestrate the immune responses. The 
differentiation of polarized effector T cells is controlled by unique sets of transcription factors, 
the expression of which is determined by multiple signals during activation. Considerable 
plasticity exists within T-cell subsets in vivo, especially during responses to pathogens. 
Successful clearance of viruses in particular often depends on complex CD4 T-cell responses 
that encompass multiple T-cell subsets. Together, these subsets are capable of mediating direct 
antiviral functions, providing help for B cells and mediating cytotoxic killing of virus-infected 
cells. BCL-6, B cell lymphoma 6; EOMES, eomesodermin, FASL, FAS ligand; FOXP3, 
forkhead box P3; GATA3, GATA-binding protein 3; RORγt, retinoic acid receptor-related 
orphan receptor-γt; TCR, T cell receptor; TGFβ, transforming growth factor-β; TNF, tumour 
necrosis factor. 
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6.3. Defining the role of neutralizing antibodies in protective 
immunity against HCV 
The role of humoral immunity in spontaneous resolution of primary HCV infection 
remains controversial [248, 249, 279]. Even the recently described broadly-neutralizing 
antibodies against HCV are generated months to years into the chronic infection [248]. The 
role of humoral immunity during reinfection episodes is far less defined. A rechallenge study 
in chimpanzees showed that HCV-envelope antibodies remained undetectable regardless of 
the outcome of the reinfection episode [341]. Another study also showed that chimpanzees 
that previously cleared a primary HCV infection were able to clear HCV upon rechallenge 
without any evidence of neutralizing antibodies [338]. On the other hand, Osbourn et al. 
demonstrated in a human cohort that spontaneous resolution upon HCV reinfection correlates 
with generation of nAbs that were cross-reactive when tested against heterologous HCVpp. 
Unfortunately, this was in a group of reinfected patients that all resolved the reinfection, not 
allowing comparison with a control group of non-resolvers [354].  
We attempted to examine the neutralizing capacity of longitudinal plasma samples 
collected at different time points post reinfection (p.ri) against a panel of cell cultured HCV 
(HCVcc) representing the most common HCV genotypes in Canada (Genotypes 1a, 1b and 
3a). However, no distinct difference could be detected between the SR/SR and SR/CI group 
which may be due to the low number of patients in each group (data not shown). Further 
investigation of the role of nAbs in a larger cohort using custom HCVpp with the autologous 
E1/E2 viral sequences isolated during the various episodes of infection will be conducted and 
are expected to be more reflective of the real infection setting. 
6.4. Sequencing the HCV genome during the different episodes of 
infection 
It has already been shown in an HCV-cohort undergoing IFN-therapy that diversity in 
the whole viral genome sequence correlated with the response to treatment, and these 
correlations were still valid even when all T-cell epitope regions were excluded from the 
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analysis. This suggests that these variations could not be solely attributed to differential 
immune selection [211]. It has also been demonstrated in chimpanzees that the ability to clear 
consecutive homologous rechallenges was associated with fixed polyprotein sequences. In 
contrast, persistent infection was associated with numerous changes in the sequences of 
reinfecting virus [339].  
We have demonstrated that the changes in the sequences of the targeted epitopes in the 
unprotected group of patients (SR/CI) could be a probable cause of failure of the epitope-
specific CD8 T-cell recall response. Nevertheless, it does not explain the diminished 
proliferative capacity and functionality in response to peptide pools. It also does not explain 
the failure in expansion in the general magnitude and breadth of the general immune response 
measured by ELISPOT. We will use deep sequencing techniques to sequence entire regions of 
the HCV genome during reinfection episodes, especially the immunodominant non-structural 
regions. 
6.5. Dissecting the qualities of individual clonotypes associated 
with protection  
It has been shown before within the context of HIV infection that certain epitope-
specific clonotypes possess a higher avidity and flexibility in response to different variants of 
the epitope [89, 376]. The interplay between the virus and the immune system induces the 
mobilization of CD8 T-cell clonotypes with slightly lower avidity, but higher flexibility to 
cope with changes in the targeted epitope. Unfortunately, not all patients possess these 
clonotypes and are therefore unable to keep the mutated virus under check [375, 376]. 
We will generate cell-lines from individual epitope-specific clonotypes by sorting 
single tetramer+ CD8+ T cells and then expanding them [89]. We will test the avidity and 
polyfunctionality of the individual clonotypes against the different variants of the epitope, and 
verify the association between their avidity, functionality and flexibility. 
This would enable us to identify the presence of specific clonotypes correlating with 
protection and clonotypes having higher flexibility in response to different variants of an 
epitope. It would also help us extend previous findings in cytochrome-c mouse model and 
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HIV about the link between the kinetics of the TCR-repertoire and the affinity of the pMHC-
TCR binding [89, 372, 376]. 
6.6. Determining whether specific public clonotypes associate with 
protection 
Analysis of the TCR repertoire of epitope-specific CD8 T cells in HIV controllers 
compared to progressors showed that their repertoires included public TCR sequences shared 
between different patients among the controllers’ cohorts [371, 375]. 
We will perform clonotypic analysis of tetramer+ CD8+ T-cell populations targeting 
specific immunodominant epitopes from more patients to verify the recurrent usage of specific 
TCR-clonotypes in protected patients that could represent public protective clonotypes. 
6.7. Concluding remarks 
Successful control and eradication of smallpox, polio and yellow fever viruses causing 
infections with high rates of morbidity and mortality was achieved through the discovery of 
vaccines that provide protection upon exposure. Millions of humans are at risk of being 
infected with chronic viruses as HCV, HIV, HSV and CMV due to the lack of prophylactic 
vaccines against them. The main hindrance preventing the development of such vaccines is the 
lack of definition of the characteristics of a protective memory immune response against 
chronic viruses. 
The work presented in this thesis provides a significant advancement in the 
understanding of the protective immune response as it provides a primary insight towards 
dissecting the correlates of the adaptive immune response associated with the protection. 
These results would have an important significance for the development of vaccines against 
HCV and other similar chronic viruses. 
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APPENDIX I: The candidate’s contribution to the articles 
Author’s contribution to the first manuscript “Signatures of Protective Memory Immune 
Responses during HCV Reinfection” 
Mohamed S. Abdel-Hakeem (MSA) participated in the design of the study. Experiments were 
planned under the supervision and guidance of the research supervisor Naglaa Shoukry (NS). 
MSA generated all the data represented in the figures, performed all the analysis and prepared 
all the figures/tables. MSA contributed with NS to the writing of the article. Nathalie Bédard 
shared in the optimization of experiments and preliminary tetramer screening for the patients. 
Donald Murphy performed HCV genotyping assays and viral quantification. Julie Bruneau 
recruited and provided clinical follow-up for study participants, as well as participated and 
gave opinion for the study design, data analysis and writing the manuscript. NS supervised the 
whole study including design, data analysis and writing the manuscript. The data and results 
presented in this article were all generated during the Ph.D. studies of the candidate (MSA). 
This article is in revisions at Gastroeneterology. 
 
Author’s contribution to the second manuscript “Dynamics of Virus-Specific CD8 T-cell 
Repertoire during HCV Reinfection” 
Mohamed S. Abdel-Hakeem (MSA) participated in the design of the study. Experiments were 
planned under the supervision and guidance of the research supervisor Naglaa Shoukry (NS). 
MSA generated all the data represented in the figures, performed all the analysis and prepared 
all the figures/tables. MSA contributed with NS to the writing of the article. Julie Bruneau 
recruited and provided clinical follow-up for study participants, as well as participated and 
gave opinion for the study design, data analysis and writing the manuscript. Hugo Soudeyns 
provided support in the study design, data analysis and writing the manuscript. NS supervised 
the whole study including design, data analysis and writing the manuscript. The data and 
results presented in this article were all generated during the Ph.D. studies of the candidate 
(MSA). This article is to be submitted to the journal Blood. 
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APPENDIX II: Review article 
Author’s contribution to the review article “Protective Immunity against Hepatitis C; 
many Shades of Gray” 
Mohamed S. Abdel-Hakeem (MSA) participated in the design of the general structure of the 
review article under the supervision of the research supervisor Naglaa Shoukry (NS). MSA 
contributed with NS to the writing of the article. MSA prepared all the figures. 
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The majority of individuals who become acutely infected with hepatitis C virus (HCV)
develop chronic infection and suffer from progressive liver damage while approximately
25% are able to eliminate the virus spontaneously. Despite the recent introduction of new
direct-acting antivirals, there is still no vaccine for HCV. As a result, new infections and rein-
fections will remain a problem in developing countries and among high risk populations
like injection drug users who have limited access to treatment and who continue to be
exposed to the virus. The outcome of acute HCV is determined by the interplay between
the host genetics, the virus, and the virus-specific immune response. Studies in humans
and chimpanzees have demonstrated the essential role of HCV-specific CD4 and CD8 T
cell responses in protection against viral persistence. Recent data suggest that antibody
responses play a more important role than what was previously thought. Individuals who
spontaneously resolve acute HCV infection develop long-lived memoryT cells and are less
likely to become persistently infected upon reexposure. New studies examining high risk
cohorts are identifying correlates of protection during real life exposures and reinfections.
In this review, we discuss correlates of protective immunity during acute HCV and upon
reexposure.We draw parallels between HCV and the current knowledge about protective
memory in other models of chronic viral infections. Finally, we discuss some of the yet
unresolved questions about key correlates of protection and their relevance for vaccine
development against HCV.
Keywords: hepatitis C, acute infection, HCV reinfection, innate immunity, adaptive immunity, NK cells, T cells,
antibodies
INTRODUCTION
Hepatitis C virus (HCV), a member of the family Flaviviridae, is a
non-cytopathic hepatotropic virus transmitted primarily through
contaminated blood (1). TheWorld Health Organization (WHO)
estimates that there are 185million individuals infected withHCV
worldwide (2, 3). The prevalence is higher in developing countries,
the highest being in Egypt where it is estimated that 15–20% are
seropositive forHCV(4,5). These numbers are probably anunder-
estimate, since many HCV-infected individuals have not been
tested and thus remain undiagnosed.
The acute phase of hepatitis C is empirically defined as the first
6months following infection. Approximately, 20–30% of infected
individuals are able to clear the virus spontaneously without any
therapeutic intervention during this phase while 70–80% become
persistently infected (1). As the virus continues to replicate in the
liver of chronically infected individuals, they develop a variety of
liver diseases over a period of 5–30 years including hepatic fibro-
sis, end-stage cirrhosis, and hepatocellular carcinoma (HCC) (6).
Such patients represent 25%of the cirrhosis andHCCcasesworld-
wide (7),making hepatitis C themost common indication for liver
transplantation in North America (8, 9).
Despite the progress in understanding immunity against HCV
infection and its pathogenesis and, the development of highly
effective direct-acting antivirals (DAAs), a prophylactic anti-HCV
vaccine is still lacking. In absence of such a vaccine, two mil-
lion new HCV infections are estimated to occur every year (10).
Such cases are highly prevalent among marginalized populations
like injection drug users (IDUs), men who have sex with men
(MSM), and individuals living in developing countries with lim-
ited access to screening and treatment (11, 12). Vaccine develop-
ment against HCV is hampered by our limited knowledge of what
constitutes an effective and protective immune response against
HCV, as well as protection in real life exposure settings. Many
shades of gray remain and constitute active areas of the current
research on hepatitis C. In the following pages, we will attempt to
review the correlates of protection against HCV and identify these
outstanding questions and the ongoing efforts to address them.
THE VIRUS
The HCV genome consists of an uncapped positive single-
stranded RNA (+ssRNA) of approximately 9.6 kb-pairs (13). The
genome represents an uninterrupted open reading frame (ORF)
encoding a polyprotein precursor of approximately 3000 amino
acids (13). The viral genome includes 50 and 30 untranslated
regions (UTRs) that contain secondary RNA structures essential
for viral replication. The 50 UTR harbors an internal ribosome
www.frontiersin.org June 2014 | Volume 5 | Article 274 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abdel-Hakeem and Shoukry Protective immunity against hepatitis C
entry site (IRES) where protein translation is initiated. The HCV
polyprotein is processed co- and post-translationally by a combi-
nation of cellular and viral proteases into three structural proteins
(Core, E1, and E2) and seven non-structural (NS) proteins (P7,
NS2, NS3, NS4A, NS4B, NS5A, and NS5B) (Figure 1). Core is the
building unit of the viral nucleocapsid. The envelope glycoproteins
E1 and E2 interact with the viral receptors on permissive cells and
mediate viral entry. E2 also contains hypervariable regions (HVR)
that are targeted by neutralizing antibodies (nAbs). P7 acts as a
viroporin or ion channel. NS2 possesses an autoprotease activity
necessary for the polyprotein cleavage between NS2 and NS3. NS3
acts as serine protease in combination with NS4A that acts as a
cofactor to catalyze the processing of the HCV polyprotein. NS3
also harbors RNA helicase/NTPase activity that unwinds RNA–
RNA substrates and is essential for viral replication [reviewed in
Ref. (14, 15)]. The functions of NS4B and NS5A are poorly char-
acterized. However, studies show that NS4B induces the formation
of a membranous web compartment where viral replication takes
place (16), and cell-culture adaptive mutations mapped to the
NS5A enhance RNA replication suggesting its importance for viral
replication (17, 18). NS5A was also shown to harbor a region
that may determine response to alpha interferon (IFN-a) ther-
apy known as interferon sensitivity determining region (ISDR)
(19). NS5B is the viral RNA-dependent RNA-polymerase (RdRp)
responsible for HCV–RNA replication (14). As with other RNA
viruses, the HCV RdRp enzyme lacks proof-reading activity and
is highly error prone, leading to the emergence of different viral
populations circulating in the blood of an individual patient as a
mosaic of highly related sequences termed “quasispecies” (14).
Hepatitis C virus is classified into seven genotypes (1–7) and
up to 67 different subtypes based on the nucleotide sequences
of the Core/E1 and NS5B regions (20). The different genotypes
show marked differences in geographic distribution, response to
therapy, and pathogenesis (15).
VIRAL REPLICATION AND LIFE CYCLE
Hepatitis C virus replicates primarily in human hepatocytes. The
first described receptors for HCV were CD81 (21) and scav-
enger receptor class B type I (SR-BI) (22). The LDL receptor and
glycosaminoglycans (GAG) mediate initial binding to suscepti-
ble cells prior to interaction with CD81 and SR-BI (15). Tight
junction proteins claudin-1 (CLDN1) and occludin (OCLN) act
as receptors/co-receptors for HCV at cell junctions (23, 24). It
was recently reported that the cholesterol absorption receptor
Niemann–Pick C1-like 1 (NPC1L1) is an essential entry factor
(25) and that the epidermal growth factor receptor (EGFR) and
ephrin receptor type A2 are also required for HCV entry and pos-
sibly modulate the interaction between CD81 and CLDN1 (26).
Human CD81 and OCLN are the minimally required receptors to
render mouse hepatocytes susceptible to HCV entry (24). Binding
of HCV to its receptors is followed by fusion of the viral enve-
lopewith the cellularmembrane by clathrin-mediated endocytosis
then fusion with the endosomal membrane and the viral genome
is released into the cytosol (27). Cap-independent IRES-mediated
translation of the HCV ORF generates a large polyprotein that is
subsequently processed into mature structural and NS proteins
(Figure 1). Junctions between structural proteins are processed by
host signal peptidases from the endoplasmic reticulum. The viral
NS proteins are processed by the NS2/3 autoprotease (14) and the
NS3/4A serine protease (28). Replication takes place within ER
derived structures known as themembranousweb and ismediated
by NS5B through a negative strand intermediate in a replica-
tion complex. Viral assembly occurs within lipid raft like struc-
tures. HCV nucleocapsid is built from units of the core protein
with RNA, surrounded by a membrane derived from the human
cell with embedded heterodimers of the envelope glycoproteins
E1 and E2 [reviewed in Ref. (15)]. The virions associate with
low-density and very-low-density lipoproteins (LDL and VLDL)
forming lipoviroparticles (LVPs) that are pleomorphic (29).
FIGURE 1 | HCV genome and polyprotein.The HCV genome is
composed of an open reading frame (ORF) flanked by 5’ and 3’
untranslated regions (UTRs). IRES-mediated translation of the ORF leads
to the formation of a polyprotein that is processed into 10 viral proteins.
Cleavage of the core protein from E1 involves cellular signal peptidases,
which also cleave E1, E2, and p7 from the polyprotein (pink arrows). The
NS2–NS3 protease auto-cleaves itself (green arrow). The NS3 protease
located in the first one-third of NS3, assisted by its membrane-bound
cofactor, NS4A, cleaves the remaining proteins NS3, NS4A, NS4B, NS5A,
and NS5B (violet arrows).
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MODELS FOR STUDYING HCV INFECTION AND IMMUNITY
IN VITRO MODELS
Hepatitis C virus replicates poorly in tissue culture. Earlier surro-
gate models to study HCV protein functions, virus–host interac-
tion, and viral entry included vaccinia virus (VV) vectors express-
ing HCV proteins, direct transfection of HCV RNA, subgenomic,
and full length replicons and viral pseudoparticles carrying HCV
envelop glycoproteins on a capsid backbone of vesicular stom-
atitis virus or lentiviruses (HCVpp). It was not until 2005 that
the first in vitro replicating strain was isolated from a Japanese
patient with fulminant hepatitis termed JFH-1 virus, a genotype
2a isolate (30–32). Even with the development of this system, very
few cell lines are permissive for its replication, often involving
adaptive mutations within the viral genome and/or impairment
in some of the cellular antiviral mechanisms [reviewed in Ref. (15,
33)]. These models have been instrumental in studying the innate
antiviral response against HCV on a cellular level and identifica-
tion of many of the underlying viral evasion mechanisms. The
development of new cell lines or methods that allow HCV replica-
tion in primary human or mouse hepatocytes is an area of intense
research.
IN VIVO MODELS
Humans and chimpanzees are the only two species that are sus-
ceptible to HCV infection. The chimpanzee model has been
instrumental in the early studies of immunity against HCV where
timing of the infection and infecting viral strains were known
and it was possible to examine intrahepatic immune responses.
Research on chimpanzees is now restricted (34) and the search
for an alternate animal model is ongoing. Although considerable
progress has occurred in developing humanized mice susceptible
to HCV infection, these mice are generated on immune deficient
backgrounds that preclude studying adaptive immune responses.
Cotransplantation of human CD34+ human hematopoietic stem
cells and hepatocyte progenitors in mice with inducible liver dam-
age demonstrated good engraftment of human leukocytes and
hepatocytes. These mice became infected with HCV and demon-
strated some HCV-specific immune responses and liver fibrosis
(35). These data are preliminary and the model remains techni-
cally challenging. It will likely be a few more years before we have
a suitable alternative to the chimpanzee model for studying HCV-
specific immunity and preclinical testing of vaccine candidates
[reviewed in Ref. (36)].
Due to the asymptomatic nature of HCV, a limited number of
individuals present to the clinic with acute symptomatic infection.
In that situation, it is usually difficult to determine the exact date of
infection or exposure and the infecting viral strain(s). Most of our
early knowledge about acute HCV came from studies of experi-
mental infection of chimpanzees, or individuals infected following
high risk exposures like needle stick injuries in health care workers,
blood transfusions, as well as the few cases presenting with symp-
tomatic acute HCV. Recent studies relied upon monitoring high
risk individuals, in particular IDUs who currently represent the
main population of novel HCV infection in developed countries.
It is noteworthy that in these situations the definition of acute
HCV can vary from one cohort to another and is dependent on
the follow-up interval, where the date of infection is estimated at
best. It is also ethically impossible to obtain liver biopsies during
acute infection and our knowledge of acute intrahepatic responses
is derived from the chimpanzee model.
CLINICAL COURSE OF HCV INFECTION
Hepatitis C virus RNA can be detected in the peripheral blood of
infected individuals within oneweek following infection. Despite
this high level of viral replication,HCV-specific immune responses
remain undetectable inmost infected individuals for several weeks
suggesting that the virus outpaces the immune system and impairs
its responses (37).Nevertheless, interferon stimulated genes (ISGs)
are detected early in the liver and some mediators of innate
immunity like natural killer (NK) cells are activated and can
be detected in peripheral blood (discussed below). At approxi-
mately 4–8weeks, HCV-specific CD4 and CD8 T cells become
detectable in the liver and peripheral blood and are often but not
always associated with an increase in liver transaminases in the
blood (38, 39). Most individuals who are able to spontaneously
clear HCV do so within the first 6months and a smaller pro-
portion may clear their infection within 12months. The outcome
of HCV infection is determined by a “ménage-à-trois” between
host genetics, the virus and HCV-specific immunity. Other host
factors that influence the outcome of infection include ethnicity,
female sex, and accompanying co-morbidities (e.g., co-infection
with human immunodeficiency virus (HIV), alcohol abuse, renal
disease, obesity, or liver fibrosis) (40).
GENETIC FACTORS THAT INFLUENCE THE OUTCOME OF
ACUTE PRIMARY HCV
Several genetic factors,mostly in genes related to innate and adap-
tive immune functions, influence the outcomeof acuteHCV infec-
tion. Individuals homozygous for the killer inhibitory receptor
(KIR) gene KIR2DL3 and its ligandHLA-C1 alleles are more likely
to clear HCV infection than individuals with other KIR2DL:HLA-
C combinations (41). KIRs interact with their cognate MHC class
I ligands and regulate the activation and function of NK cells.
KIR2DL3 has a lower affinity for HLA-C1 than other KIR2DL
alleles, so HLA-C1-mediated inhibition of NK cells is thought to
be weaker in individuals homozygous for KIR2DL3 and HLA-
C1 thus enhancing their capacity to inhibit HCV replication or
kill virally infected hepatocytes (42). The same KIR/HLA-C com-
bination was consistently more frequent in IDUs with high risk
exposure to HCV who remain seronegative/aviremic as compared
to those with chronic infection (43).
Genome-wide association studies (GWAS) demonstrated a cor-
relation between several single-nucleotide polymorphisms (SNPs)
near the IL28B (IFNl3) gene locus and the spontaneous reso-
lution of infection, as well as response to IFN therapy (44–47).
Although several SNPs were identified, the rs12979860 SNP has
become the most relevant (48). The favorable allele was iden-
tified as CC and the non-favorable allele CT or TT for het-
erozygous or homozygous individuals, respectively. These alleles
were found to be unequally distributed among individuals of dif-
ferent ethnicities (Asians, Caucasians, and African Americans)
and correlated with their differential response to IFN therapy
(44, 47). Recent data have reported a novel transiently induced
region that carries a dinucleotide variant ss469415590 (TT or
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DG), which is in high linkage disequilibrium with rs12979860.
This resulted in a frameshift variant that created a novel gene,
designated IFNL4, encoding the interferon-l4 protein (49). This
mutation was also associated with higher levels of induction of
IL28B and interferon gamma-induced protein 10 (IP-10) thus
providing a potential mechanism for its enhanced role in viral
clearance (50).
It is not yet clear howpolymorphism in the IL28B and/or IFNL4
gene influences immune responses and the capacity to sponta-
neously eliminate HCV. Given that the IL28B and IL29 (IFNl1)
genes are in opposite orientation, this SNP is up stream of the
two genes and may influence expression of both. The responder
genotype was linked to higher expression of the IL28A/B as mea-
sured by qRT-PCR in PBMCs or protein levels in plasma and
lower HCV viral load, but results were not consistent among dif-
ferent studies (45, 51, 52). IL-29 was upregulated during acute
and chronic HCV and its expression correlated with induction
of ISGs but not acute infection outcome (52, 53). The non-
favorable IL28B genotype was associated with higher expres-
sion of ISGs in the liver (54–56), considered a predictor of
non-response to IFN therapy. Interestingly, ISGs were differ-
entially expressed in liver versus macrophages, where the non-
responder genotype was associated with lower ISG expression in
macrophages (56).
It was also suggested that IL28B polymorphism may influence
NK cell function or the cross-talk between innate and adaptive
immunity. Dring et al. have demonstrated that KIR2DS3 syn-
ergizes with IL28B to predict chronic evolution of HCV (57).
Suppiah et al. have demonstrated that polymorphism in IL28B,
HLA-C, and KIRs additively and interactively predict response to
therapy in chronic HCV infection (58). However, functional data
supporting this possibility are still lacking.
A more recent GWAS study demonstrated that in addition
to IL28B, another SNP near the gene for the HLA class II mol-
ecule DQB1*03:01, was independently associated with sponta-
neous resolution of HCV infection (59). Indeed, several HLA
HLA class I and class II alleles were previously associated with
the outcome of HCV [reviewed in Ref. (60)]. The HLA class
I alleles HLA-A*03, HLA-B*27, and HLA*B57 were associated
with spontaneous clearance [reviewed in Ref. (60)]. Interest-
ingly, the HLA-B*27 and -B*57 alleles are also associated with
better viral control in HIV infected individuals (61). The HLA
class II alleles HLA-DRb1*0101, -DRB1*0401, -DRB1*1101, and
DQB1*0301were strongly associatedwithHCVclearance,whereas
HLA-DRb1*0701 was associated withHCV persistence (62–64). It
is suggested that suchHLA class I and II alleles favor the generation
of immune responses targeting conserved epitopes or epitopes that
are less likely to mutate because of the high fitness cost associated
with such mutations and viral replication (65).
Other genetic factors that were associated with spontaneous
clearance of HCV include: ISGs, toll-like receptors (TLRs),
chemokines, cytokines, and their receptors [reviewed in Ref. (60)],
as well as tapasin associated with peptide loading on MHC class I
(66). Finally, HCV was also shown to exploit “holes” in the T cell
repertoire to facilitate its escape from detection by virus-specific
CD8 T cells (67).
INNATE IMMUNE RESPONSES DURING ACUTE PRIMARY
HCV
VIRAL SENSING AND INTRACELLULAR INNATE IMMUNITY
Foreign RNA molecules are recognized by pattern recognition
receptors (PRRs) including TLRs and/or intracellular nucleic acid-
binding proteins (68, 69). In hepatocytes, TLR3, protein-kinase R
(PKR), and retinoic-acid-inducible gene I (RIG-I) are the main
PRRs recognizing HCV upon entry and replication. PKR and
RIG-I activation signals are relayed via themitochondrial antiviral
signaling protein (MAVS), while TLR3 signals are relayed via the
TIRdomain-containing adapter inducing IFN-b (TRIF) [reviewed
in Ref. (70)]. Downstream of these adaptor proteins signaling cas-
cades are activated culminating in the secretion of type I IFNs
(70). Binding of auto- and paracrine type I IFNs to their receptors
activates signaling along the JAK–STAT signaling pathway. This
induces the expression of hundreds of ISGs in the infected cells
and neighboring cells (71) and creates a general antiviral state in
the liver that limits HCV RNA replication and cell-to-cell spread
(72). ISGs expressed in response to HCV infection include several
proteins with known antiviral effects, as well as some others that
were shown to promote HCV replication in vitro, as ISG15 and
USP18 (73, 74).
Upregulation of ISGs is detected in the liver early after HCV
infection irrespective of the outcome, suggesting that most HCV
isolates are resistant to the antiviral effects of this early innate
response (75–78). Nevertheless, the pro- and anti-viral roles of
the different ISGs would suggest differential induction of specific
ISGs in patients with different outcomes of HCV infection. Recent
work on primary hepatocytes infected with HCV demonstrated
that type III IFNs (IFNls) could be the earliest responders and
that they lead to induction of ISGs shared with type I IFNs, as
well as other distinct ISGs (79, 80). Preliminary studies suggest
that although similar ISGs are induced by type I and type III IFNs,
they may signal through two distinct pathways (81), have differ-
ent kinetics (82) maybe cell type specific (56) and/or IFNl allele
dependent (83).
Infected hepatocytes are not the only source of type I and type
III IFNs but liver resident Kupffer cells (84), BDCA3+ myeloid
dendritic cells (mDCs) (85), and plasmacytoid DCs (pDCs) (86,
87) can detect HCV RNA and produce type I and type III IFNs,
thus contributing to the intrahepatic antiviral state and inducing
inflammatory cytokines and chemokines like IP-10 that recruit
virus-specific T cells to the liver.
Despite the rapid viral sensing and induction of antiviral
responses, HCV is able to persist as it has devised several mech-
anisms to evade recognition and inhibit IFN-signaling pathways.
NS3/4A was shown to use its serine protease activity to act as the
viral “Swiss army knife” to disrupt viral sensing pathways at early
steps by splicing MAVS and TRIF downstream of the major sen-
sors of HCV–RNA [reviewed in Ref. (70)]. Other HCV proteins as
core, E2, andNS5A interfere with various early and late steps along
the JAK–STAT signaling pathway that is induced by type I and III
IFNs further contributing to inhibiting the IFN response (88–90).
However, ISGs remainhighly expressed in individualswhodevelop
chronic infection and their level of expression correlates inversely
with the response to IFN based therapies (91). This suggests that
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sustained viral replication and induction of ISGs induce a state of
tolerance within hepatocytes that become refractory to external
IFN stimulation.
NATURAL KILLER CELLS
Natural killer cells are one of the earliest lines of innate immune
defense. They exert their function by killing virally infected cells
via secretion of cytotoxicmolecules like granzymes andperforin or
through tumor necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL)-mediated killing. They also secrete cytokines that
can regulate innate and adaptive immunity like IFNg, TNFa, IL-
10, and IL-21. NK activity is governed by the balance between
activating and inhibitory signals. One of the major determinants
of such activity is the strength of the interaction between the
inhibitory KIRs expressed on NK cells and their MHC class I lig-
ands expressed on target cells (92). NK cells are highly enriched
in the liver and are expected to play a major role in controlling
hepatotropic infections (93, 94). NK cells were activated early in
healthcare workers following accidental percutaneous exposure
to HCV and may have contributed to protection from infection
in 11/12 individuals in this group who remained aviremic (95).
NK cells were also activated in high risk IDUs and expression of
the NK cells activating receptor NKp30 correlated with protec-
tion from HCV infection (96). Hyperactivation of NK cells was
observed during acute HCV infection irrespective of the outcome
(97–99). Increased IFNg production was enriched in KIR2DL3
expressing NK cells as suggested by genetic studies demonstrating
that this allele was associated with spontaneous resolution of HCV
potentially due to less NK cell inhibition (98). Reduced expres-
sion of NKp30 could predict the outcome of acute HCV (97).
Notably, NK cells fromHCV acutely infected individuals and dur-
ing chronic infection were biased toward cytotoxicity rather than
cytokine production (99, 100) and NK cell degranulation, a sur-
rogate marker of cytotoxicity, correlated with the magnitude of
HCV-specific T cells (99). This suggests that NK cell cytotoxic
activity may kill infected hepatocytes and facilitate the transfer of
HCV antigens to the draining lymph nodes as they are picked up
and presented by DCs.
During chronicHCV infection, intrahepaticNK cells are gener-
ally highly activated and this activation correlates with the degree
of liver inflammation (101, 102). Peripheral NK cells express vari-
able levels of the NK activation markers NKp30, NKp44, NKp46,
NKG2C, and NKG2D and increased expression of the inhibitory
receptor NKG2A as compared to healthy individuals [reviewed
in Ref. (103–105)]. NK cell numbers and functions, especially
cytotoxic activity, were shown to be lower in chronic hepati-
tis C patients as compared to healthy donors but results varied
from one study to another probably reflecting various experimen-
tal designs and patient cohorts (106–109). Recombinant HCV
E2 protein was reported to directly bind CD81 on the surface
of NK cells and inhibit its functions (110, 111). HCV-infected
hepatocyte cell lines but not purified virions reproduced a similar
phenomenon (112, 113).
Recent data from the lymphocytic choriomeningitis virus
(LCMV) model has demonstrated that NK cells may act as rheo-
stat to control CD4-mediated help for CD8T cell functions during
chronic infection (114). Similarly, in the hepatitis B virus (HBV)
model, it was shown that NK cells can selectively eliminate acti-
vatedT cells expressing theTNF-related apoptosis-inducing ligand
death receptor 2 (TRAIL-R2) and thus, negatively regulate antivi-
ral immunity (115). NK cells also interact with DCs and this
cognate interaction regulates both innate and adaptive immu-
nity. NK cells produce IFNg and TNFa that induce maturation
of DCs and enhance their capacity to prime virus-specific T cells.
In return,DCs produce IL-12 and IL-15 that enhance activation of
NK cells (116). It would be interesting to examine if such cross talk
exists during acute HCV infection and cross-regulates adaptive
immunity.
DENDRITIC CELLS
Dendritic cells are one of the major antigen-presenting cells
(APCs) in the body. They bridge innate and adaptive immu-
nity andmay impact priming of HCV-specific immune responses.
DCs rapidly differentiate into mature DCs in response to vari-
ous “danger” signals like activation through pathogen associated
molecular patterns (PAMPs) in particular TLR ligands, interac-
tion with innate lymphocytes (NK and NKT cells), cytokines, and
inflammatorymediators (117). There are twomain subsets of DCs,
mDCs representing the majority of DCs and mostly associated
with antigen processing and presentation and pDCs that can sense
viral infections and are the main producers of type I and type
III IFNs. pDCs can detect HCV RNA in a TLR-7 specific manner
when presented as part of an infected cell (86). This activation can
be mediated by transfer of exosomes containing HCV–RNA from
infected cells to pDCs (87). As such, DCs are considered a main
orchestrator of the HCV innate and adaptive immune response.
The role and function of DCs during acute and chronic HCV
infection remain highly controversial. The frequencies of mDCs
and pDCs were shown to correlate with the outcome of infection,
where reduced frequencies were associated with chronic infection
(118–121). Our group has recently demonstrated that sustained
hyperresponsiveness of DCs was associated with resolution of
HCV infection suggesting better priming of HCV-specific T cells
(122). Various groups have reported that DCs are defective in
chronic HCV, in particular, in response to TLR ligands (123–126),
may be infected (123–126), and may induce proliferation of Tregs
(127) while others have demonstrated that they are functional
(118, 120, 128, 129). How do DCs influence priming of HCV-
specific immune responses? Is it through a direct effect on antigen
presentation or through better NK–DC interaction? Are DCs pre-
senting HCV antigens more tolerogenic or targets for elimination
by NK cells? These remain as some of the gray areas in the HCV
field.
ADAPTIVE IMMUNE RESPONSES DURING ACUTE PRIMARY
HCV
The importance of cell-mediated immunity in HCV clearance is
demonstrated by the correlation between specific HLA class I and
class II alleles and spontaneous resolution and underscored by
depletion studies in the chimpanzee model showing that both
CD4 and CD8 T cells are required for viral clearance and that
they have complementary rather than exclusive roles. The role of
nAbs is slowly being unraveled. In the following sections, we will
summarize the current state of knowledge on this topic.
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ONSET OF ADAPTIVE IMMUNE RESPONSES
HCV-specific CD8 and CD4 T cell responses appear late around
6–8weeks following primary HCV infection despite high levels of
viral replication. This delay in the onset of virus-specific T cells
could be attributed to the tolerogenic nature of the liver environ-
ment and the time required for viral antigens to reach the draining
lymph nodes to be presented by professional APCs (38, 94). It
might also be indicative of the capacity of the virus to evade the
innate immune system, interferewithmaturationof DCsor impair
their capacity for antigen processing and presentation. Onset of
HCV-specific CD8 T cells in blood and/or liver and the detection
of IFNg, CD3,CD4, and CD8 transcripts in the liver are kinetically
linked to decline in viral loads (76, 77).
CD8 T CELL RESPONSES DURING ACUTE PRIMARY HCV
The breadth of the CD8 T cell response is a key determinant of
spontaneous resolution. Up to nine different epitopes were rec-
ognized simultaneously in chimpanzees and humans with acute
resolving HCV while much fewer epitopes were recognized in
individuals developing chronic infection (130, 131). Responses
targeting the NS proteins were immunodominant and correlated
with spontaneous clearance (132), but the individual epitopes tar-
geted were different, even among individuals with shared HLA
alleles (133, 134).
Escape mutations within targeted CD8 T cell epitopes are
associated with viral persistence and represent a major immune
evasion mechanism used by the virus. They typically occur early
and becomefixed in the viral quasispecies (135–137).Mutated epi-
topes are mostly associated with loss of binding to the restricting
MHC and are thus not recognized or poorly induce a new T cell
response (135, 136). Escape mutations are also dependent on the
interplay between the virus and host genetics. The hostHLA alleles
enforce selective pressure on their cognate epitopes. This is evident
as these mutations revert to their wild type sequences when trans-
mitted to an individual not carrying the sameHLAallele andwhere
the epitope is no longer under selection pressure (138). Host HLA
may also induce selection pressure on a population level resulting
in viral adaptation within a specific genetically related population
(139). Finally, viral fitness limits the variability within some epi-
topes (140, 141). CertainHLA-alleles likeHLA*B27 are considered
protective as they prime responses to highly constrained epitopes
that are less likely to mutate because of the high fitness cost (65,
142, 143).
The epitope-specific CD8 T cell receptor (TCR) repertoire may
also limit escape mutations. One study in the chimpanzee model
suggested that generation and maintenance of a repertoire with
higher diversity was associated with resolution of HCV infection
and limited the emergence of escape mutations in the targeted
epitopes (144). Another study correlated a specific mutation in an
MHC class I restricted epitope (NS31406) to the scarcity of spe-
cific TCRs that could recognize the mutant, thus exploiting this
“hole” in the T cell repertoire (67). Several studies in HIV cohorts
demonstrated an association between the ability to control HIV
replication and progressing to AIDS with the presence of specific
CD8 T cell clonotypes that possessed superior functional avidity,
as well as cross-reactivity to the different variants of the targeted
epitope (145). Additional studies examining the dynamics of the
TCR repertoire, functionality, and escape mutations during acute
and chronicHCV in relation to changes in viral quasispecieswould
be of interest.
The magnitude of responding CD8 T cells also correlates with
spontaneous resolution. Studies using MHC class I tetramers
demonstrated that T cells specific for one single epitope can reach
up to 8% of CD8 T cells in spontaneous resolvers (131, 146). The
frequency of HCV-tetramer positive population was several folds
higher in the liver than in peripheral blood of chimpanzees during
acute resolving HCV with elevated expression of CD69, a marker
of T cell activation (147).
The use of MHC class I tetramers allowed direct ex vivo phe-
notypic characterization of the HCV-specific CD8 T cells. Early
expression of the IL-7 receptor alpha (CD127) on virus-specific
CD8 T cells emerged as a major predictor of spontaneous resolu-
tion while its loss was associated with viral persistence (148, 149).
CD8 memory T cell populations generated following clearance of
primary HCV infection were CD127hi and Bcl-2hi (146). This is
consistent with data from the LCMV model showing that CD127
is a marker of cells destined to become long-lived memory T cells
(150). On the other hand, HCV-specific CD8 T cells express vari-
able levels of PD-1 during acute infection suggesting that PD-1
acts more as an activation rather than an exhaustionmarker (151–
153). Other exhaustion markers like the T cell immunoglobulin
and mucin domain 3 (Tim-3), cytotoxic T lymphocyte associated
antigen-4 (CTLA-4), CD160, KLRG-1, and 2B4 are differentially
expressed during acute and chronicHCV suggesting a spectrumof
exhaustion that correlated with function and persistent infection
(154, 155). TheTim-3 ligand galectin-9 (Gal-9)was upregulated in
the plasma during acute infections progressing to chronicity (155,
156) and in the liver of chronic individuals (156), thus contribut-
ing to T cell exhaustion. Blockade of PD-1, Tim-3, and CTLA-4
separately or in combination rescued HCV-specific CD8 T cells
fromexhaustion suggesting that they act synergistically (157–159).
In vitro supplementation of IL-21, a mediator of CD4 T cell help,
also rescued HCV-specific T cells from Tim-3/Gal-9-mediated
apoptosis (155).
HCV-specific CD8 T cells become difficult to detect in the
peripheral blood of individual who develop chronic infection
but are readily detectable in the liver and continue to express
a highly activated and exhausted phenotype (160, 161). HCV-
specific intrahepatic CD8 T cells from chronic HCV patients
expressed TIM-3, PD-1, and 2B4, while CD8 T cells from patients
who had cleared the virus following IFN therapy (i.e., in absence
of active viral replication) and T cells specific for cytomegalovirus
lacked TIM-3 and expressed higher levels of LAG-3; these cells
also exhibited different memory phenotypes and proliferative
responses (162).
HCV-specific T cells in the peripheral blood might be slightly
impaired in their proliferative and cytokine producing capacity
when they first appear in blood suggesting a “stunned”phenotype
(163).Analysis of multiple effector functions simultaneously iden-
tified the presence of a polyfunctional population of virus-specific
CD8 T cells that correlated with spontaneous clearance of HCV
(146), similar to what was observed during control of HIV infec-
tion (164) and in the LCMVmodel (165). The functions analyzed
included secretion of the effector cytokines IFNg, the T cell growth
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factor IL-2 and the degranulation marker CD107a, a surrogate
marker of cytotoxicity (146). Assays on sorted cells demonstrated
that polyfunctionality was localized within the CD127+ HCV-
tetramer reactive CD8 T cells providing further evidence to the
importance of this T cell subset inmediating viral clearance (146).
Differences in CD8 T cell functions become increasingly appar-
ent as the infectionprogresses and are associatedwith loss of helper
CD4 response, as well (discussed below). In patients who become
chronically infected T cells show progressive loss of function,
reduced polyfunctionality and diminished proliferative capacity
(146, 166). CD8 T cells detected in chronic HCV patients were
arrested in an early maturation stage, impaired in cytokine pro-
duction, cytotoxicity, and/or proliferative capacity (167–169). The
loss in function also correlates with the degree of exhaustion as
described above and were reversible in vitro upon blockade of the
PD-1, CTLA-4, and/or Tim-3 pathways (170). However, in vivo
blockade of the PD-1 pathway in chronically infected humans and
chimpanzees had limited efficacy suggesting that a threshold of
functional HCV-specific T cells is required for such immunother-
apeutic strategies to work (171, 172). Functional exhaustion could
be attributed to the persistence of the antigen, where it was shown
in the LCMV model that prolonged exposure to viral antigens is
the main cause for reduced frequency and impaired effector func-
tions of virus-specific CD8 T cells (173, 174). Confirming this
hypothesis are data demonstrating that HCV-specific CD8 T cells
detected in chronic patients where the respective cognate epitope
was mutated (i.e., no longer stimulated by the cognate epitope)
were functional and expressed lower levels of PD-1 and increased
CD127, a marker of long-lived memory cells and a predictor
of spontaneous resolution (175–177). Similarly, early therapeu-
tic intervention and sustained virologic response to IFN therapy
rescued CD127+ long-lived memory T cells (146, 176).
In summary, spontaneous resolution of acute HCV correlates
with early emergence of CD127+ HCV-specific CD8 T cells. The
response is also broad, of high frequency and polyfunctional in
nature. Several factors contribute to failure of this response in indi-
viduals who become persistently infected. First, escape mutations
in targeted epitopes facilitate viral evasion of the immune system.
Second, loss of CD4 help or a switch to an immunoregulatory
profile further compromises the antiviral capacity of virus-specific
CD8 T cells (discussed below). Third, continued viral replication
contributes to exhaustion of HCV-specific T cells through persis-
tent antigenic stimulation leading to progressive loss of function
and diminished survival of virus-specific CD8 T cells. Fourth,
exhaustion is exacerbated by increased expression of the ligands
to the inhibitory receptors like Gal-9.
CD4 T CELL RESPONSES DURING ACUTE PRIMARY HCV
The importance of CD4 T cells in clearance of primary acute HCV
was first demonstrated by the correlation between CD4 prolifera-
tive responses targeting the HCV NS proteins and viral clearance
(178, 179), whereas the loss of such responses was associated with
viral recurrence (37, 131, 180). The breadth and vigor of the CD4
response also correlated with spontaneous resolution (179, 180).
CD4 T cell responses targeting up to 14 different epitopes were
detected in individuals with acute resolving HCV (181) and some
of these epitopes were identified as promiscuous epitopes that
can be presented by multiple HLA-DR alleles (182, 183). Unlike
CD8 epitopes, escape mutations were uncommon in MHC class
II restricted CD4 T cell epitopes suggesting that this is an unlikely
mechanism of CD4 T cell failure (184, 185).
Despite the development of MHC class II tetramers and multi-
mers,direct ex vivo detection and characterizationof HCV-specific
CD4 T cells has been limited due to the low frequency of tetramer
reactive T cells, very often requiring enrichment. In addition, the
restricted number of epitopes and tetramers that are available
limited such analysis. Direct ex vivo studies have demonstrated
that HCV-specific CD4 T cells are detectable by tetramers mostly
during the acute phase. The frequency declines and they remain
detectable inhumanswho resolve the infectionduring thememory
phase but require enrichment where they were shown to express
markers of central memory T cells (CCR7+CD45RA CD27+)
(186, 187). Nevertheless,HCV-specific CD4T cells were detectable
directly ex vivo by MHC class II tetramers in one chimpanzee at
7 years post resolution of acute primary HCV (152). The use of
tetramers also revealed that broad virus-specific CD4 T cells were
present early in most individuals acutely infected with HCV irre-
spective of the outcome, but rapidly lost the proliferative capacity
and cytokine production, specifically IL2, and disappeared from
the periphery with the establishment of chronic infection (188,
189). This challenged the prevailing hypothesis that HCV persis-
tence is the result of a failure to prime virus-specific CD4 T cells
and suggested that it is rather T cell exhaustion and the failure to
sustain such CD4 T cell responses that leads to chronicity. Indeed,
in vitro blockade of the PD-1, IL-10, and TGF-b pathways rescued
the proliferative and cytokine producing capacity of CD4 T cells
from individuals with chronic HCV (190).
The importance of CD4 T cell help in maintaining a func-
tional CD8 T cell response during HCV infection was clearly
demonstrated byCD4depletion studies in chimpanzees,where the
frequency of virus-specific CD8 T cells and their cytokine produc-
ing capacity gradually declined resulting in accumulationof escape
mutations in the targeted CD8 epitopes (191). So how do HCV-
specific T cells provide help for CD8 T cells? Our group recently
demonstrated that expansion of CD161hiCCR6+CD26+CD4+
Th17 T cells correlated with spontaneous resolution of HCV.
These cells produced large amounts of IL-17A and IL-21 and
this correlated with the increased plasma concentration of these
two cytokines and spontaneous resolution of HCV (155). Specifi-
cally, increased plasma levels of IL-21 during the late acute phase
correlated with the frequency of virus-specific CD8 T cells and
rescued them from Tim-3/Gal-9-mediated apoptosis (155). This
underscored the role of IL-21 as a major helper cytokine similar
to previous observations on the LCMV model and HIV (192).
Other sources of IL-21 like NK cells and follicular helper T cells
(Tfh) remain unstudied and may play an active role in mediating
CD4 help.
Virus-specific Th17 and regulatory T cells (Tregs) were detected
during acute and chronic HCV (193–195) and Th17-like CD4 T
cells were enriched in the livers of individuals with chronic HCV
(196). The preferential expansion of Tregs with viral persistence
may represent another level of inhibition of HCV-specific CD4
and CD8 T cells. CD39+CTLA4+ Tregs were expanded during
acute HCV infections progressing to chronicity with a shift in the
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Th17/Treg balance (155). Such Tregs can be a source of Gal-9 fur-
ther contributing to the inhibition/exhaustion of CD4 and CD8 T
cells expressing Tim-3 (155). Tregs are also expanded in chronic
HCV but it is not yet clear if expansion of Tregs is a cause or an
effect of HCV persistence as a feedback mechanism to limit virus
induced immunopathology and inflammation. A recent report
suggested that subinfectious exposures to HCV in the chimpanzee
model may predispose to the development of Tregs that can later
suppressHCV-specific responses upon subsequent infection (197)
suggesting that elevated Tregs can be a cause of persistence. Finally,
the flexibility and reversible nature among the different T-helper
subsets is a domain of intense research (198) and whether HCV-
specific CD4 T cells are endowed with such plasticity and the
pathways involved remain to be seen.
In summary, broad HCV-specific CD4 T cell responses are
primed during most acute HCV infections. However, contraction
of this CD4 T cell population and its failure in sustaining a robust
CD8 T cell effector response is a hallmark of HCV persistence.
Early induction of IL-21 producing Th17 cells is critical tomediate
help and limit exhaustion of virus-specific CD8 T cells. However,
CD4 T cell exhaustion, leads to sequential loss of IL-2 produc-
tion, proliferative capacity, and IFNg production in addition to an
imbalance in the Th17/Treg ratio. Tregs may contribute to exhaus-
tion and inhibition of CD4 and CD8 T cells through production
of the Tim-3 ligand Gal-9 and the regulatory cytokines IL-10 and
TGF-b.
HUMORAL RESPONSES DURING ACUTE PRIMARY HCV
Although, HCV RNA reaches high serum titers by week 2 post
infection, anti-HCV antibody response (seroconversion) is usu-
ally not detected before week 8 (199, 200). Early studies showed
that antibodies (Abs) targeting the HVR-1 region of the E2 gly-
coprotein of HCV are neutralizing in vitro and in vivo (201, 202),
but select formutations in the envelope region (203). Chimpanzee
studies showed that generation of Ab responses was not necessarily
associatedwith viral clearance (204,205). In humans,Ab responses
were delayed,were of low titers and declined rapidly in individuals
who cleared HCV spontaneously (206–208). One study showed
that nAbs appeared in patients after HCV has already established
chronic infection and were unable to clear the virus and selected
for escape mutants (209). However, another study showed that
early induction of nAbs was associated with spontaneous reso-
lution of HCV primary infection (210). Broadly nAbs that could
protect against heterologousHCV infectionwere recently reported
(211, 212). Similar broadly nAbs confer protection against most
pathogens, yet, they did not necessarily correlate with the control
of infection or protection against superinfection in some chronic
viral infections like HIV (213).
One of the major limitations for understanding humoral
immunity against HCV is the lack of proper tools to measure
precisely the levels of nAbs. The current method measures neu-
tralization of HCVpp or infectious virions carrying HCV E1–E2
envelope glycoproteins corresponding to a limited number of
HCV genotypes reference sequences, and thus do not necessarily
represent the autologousE1/E2 sequences circulating in thepatient
(214, 215). AnHCVpp library comprised of 19 genetically-distinct
sequences that represent the natural variability of genotype 1
E1/E2 was recently used to demonstrate the evolution of the HVR-
1 sequences in response to nAbs (216). A recent study using this
HCVpp library demonstrated that resolution of HCV infection
was associated with a broad nAb response generated early during
the infection (217).
Another antiviral role for anti-HCV Abs could be through
induction of antibody-dependent cellular cytotoxicity (ADCC).
ADCC is a mechanism whereby the variable region of Abs binds
to infected cells while the constant region (Fc) is recognized by Fc
receptors expressed by various innate immune cells including NK
cells. Binding to the FcgR3a (CD16) triggers cytokine production
and degranulation of NK cells, resulting in lysis of the targeted cell.
Several studies suggest that ADCC plays a role in controlling viral
replication during HIV infection (218, 219) and may have con-
tributed to the success of the HIV RV144 vaccine trial performed
in Thailand (220). So far, only one study has demonstrated the
presence of ADCC-inducing antibodies specific for the E2 envelop
protein in several HCV patients during acute and chronic HCV
infection, as well as after spontaneous clearance (221). Further
studies will be required to confirm these results and determine if
ADCC-inducing antibodies play a role in the spontaneous clear-
ance of HCV infection and in the protection againstHCV infection
and reinfection.
Some major challenges exist for generating protective humoral
immunity against HCV. First, the envelope proteins are not highly
immunogenic, causing theAb response to be slow andweak during
primary infection (216). Second,Absmostly target theHVR of E2,
a region with highmutation rates, which facilitates the selection of
viral sequences that are highly resistant to Ab neutralization (222).
This selection was shown to take place as the cellular immunity
collapsed and the infection progressed to chronicity (223). Third,
the epitopes targeted by nAbs are shielded by heavy glycosyla-
tion and complexation with host lipoproteins, which limits their
efficacy in vivo (224).
In summary, recent data suggest that nAbs are induced earlier
than what was previously thought and may play an active role in
spontaneous resolution but these results remain inconclusive and
further investigation using autologous E1/E2 sequences is required
to understand this role. The recent elucidation of the crystal struc-
tures of E2 (225) and E2 bound to the broadly nAbAR3C (226), as
well as structuralmutational studies should provide better insights
into how E1/E2 interact with their receptors and nAbs. In addi-
tion, the role of CD4 T cells, in particular Tfh cells, in providing
help for antibody production by B cells remains undefined.
SUMMARY OF ACUTE PHASE IMMUNE RESPONSES AND
MECHANISMS OF IMMUNE EVASION
Hepatitis C virus infection of hepatocytes activates innate immune
sensing mechanisms like TLRs, RIG-I, and PKR that activate sig-
naling cascades resulting in production of type I and type III IFNs
and induction of several antiviral ISGs in infected hepatocytes.
HCV can also be transferred to DCs or Kupffer cells via exosomes
leading to activation of innate pathways and additional secretion
of IFNs. Intrahepatic NK cells are activated by IFNs and recognize
and kill HCV-infected hepatocytes generating apoptotic bodies
containing HCV antigens. These apoptotic bodies are taken up
by APCs like Kupffer cells and DCs that process and present HCV
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antigens as peptides bound toMHC class I and II and primeHCV-
specificCD8andCD4 responses, respectively. Infectedhepatocytes
also present processed HCV antigens in the context of MHC class
I and prime virus-specific CD8 T cells that contribute to killing
and generation of additional apoptotic bodies containing viral
antigens. The transfer of HCV antigens from the liver to drain-
ing lymph nodes via migratory DCs is thought to be critical for
priming of efficient immune responses. Several populations of
HCV-specific CD4 helper T cells are primed including Th1 cells
that provide help forCD8-mediated killing of infected hepatocytes
via production of IFNg and TNFa, Th17 cells that produce IL-21
that limits exhaustion of HCV-specific CD8 T cells and rescues
them from apoptosis and Th2 cells that provide help for antibody
producing B cells and generation of nAbs via IL-4 and IL-6. The
role of Tfh cells and their support for development of nAbs remain
undefined during acute HCV, as well as the potential contribution
of ADCC to viral control. Similarly, cross-talk between NK cells
and DCs and how this interaction influences priming of virus-
specific T cells and regulates their function are unknown. HCV
can evade innate immunity by interfering with the IFN-signaling
pathway, inhibiting NK cells’ functions (even transiently), escape
mutations of targeted CD8 T cell epitopes, or exhaustion of virus-
specific CD4 and CD8 T cells through upregulation of exhaustion
molecules like PD-1, Tim-3, CTLA-4, and others. Tregs are also
induced and they can dampen HCV-specific responses directly
through secretion of the immunoregulatory cytokines IL-10 and
TGF-borproductionof Gal-9 that can induce apoptosis of Tim-3+
virus-specific Th1, Th17, and CD8 T cells (Figure 2).
PROTECTIVE IMMUNITY AGAINST HCV
HCV-specificmemory CD4 andCD8 T cells were detectable in the
peripheral blood of humans who have spontaneously resolved pri-
mary acute HCV for up to 20 years following viral clearance while
antibody responseswaned (227). Similarly,memoryCD4 andCD8
T cells were detectable in the peripheral blood and liver of HCV-
resolved chimpanzees at 7 years following resolution of primary
infection (147). Virus-specific CD4 and CD8 T cells were also
detectable in individuals with potential occupational, household
contact, or high risk behavior like injection drug use, in absence
of detectable antibody responses or history of infection suggest-
ing subclinical exposure, and priming of HCV-specific memory T
cells (228–231).
The frequency of HCV-specific memory T cells was stable for
several years after the resolution of primary infection in chim-
panzees (147). Rechallenge studies demonstrated no sterilizing
immunity but were characterized by a shorter duration of viremia
and lower viral loads and were associated with protection from
virus persistence in most (147, 232–235), but not all studies (236).
Expansion of HCV-specific memory CD4 and CD8 T cells in
peripheral blood and the liver was associated with rapid control of
HCV infection upon rechallenge. IFNg producing CD4 and CD8
T cells were detected at a higher frequency andmuch earlier during
secondary infection as compared to primary infection in the same
chimpanzees (147, 191, 232–235). The hierarchy of CD4 helper T
cell epitopes was preserved during secondary infection years later
(182). Control of viral replication in animals challengedwithHCV
following experimental vaccination was associated with priming
of CD127+ PD-1lo CD8+ T cells that persisted at high levels for
prolonged periods and were bifunctional, producing both IFNg
and TNFa (237). Another study demonstrated that clearance of
HCV reinfection upon heterologous rechallenge involved the acti-
vation of both innate and adaptive immune responses. Higher
intrahepatic gene expression of CD56, CD8, type I and II IFN, and
ISGs were observed in one out of two chimpanzees who were able
to clear the rechallenge virus (238). This response correlated with
expansion of HCV-specific CD4 and CD8 T cells in the peripheral
blood in absence of nAbs (238).
The protective role of memory CD4 and CD8 T cells was con-
firmed using antibody-mediated depletion. CD4 T cell depletion
was associated with low level viremia. Although memory CD8
T cells initially provided some control for viral replication, they
rapidly waned in absence of CD4 T cell help leading to accumula-
tion of escape mutations in targeted epitopes and viral persistence
after more than 1 year of follow-up (191). In contrast, memory
CD8T cell depletion led to a significant delay in control of viremia,
and this control coincided with the recovery of HCV-specific T
cells in blood and liver (147). Altogether, these data demonstrate
a protective role for memory T cells upon reexposure to HCV but
the role of nAbs was not sufficiently analyzed due to lack of the
proper tools and the generally weak anti-HCV antibody response
induced in chimpanzees.
As described above, HCV-specific memory CD4 and CD8 T
were detectable 20 years post-clearance of the virus, whereas anti-
bodies were barely detectable (227). Phenotypic characterization
of HCV-specific CD4 T cells in spontaneously resolved cases
showed they were CCR7+, CD45RA , and CD27+, characteristic
of central memory T cells (186). Spontaneous resolution from a
primaryHCV infectionwas associatedwith the generationof poly-
functional HCV-specific memory population expressing CD127hi
Bcl-2hi profile (146,148,149) consistentwith a profile of long-lived
memory CD8 T cells (150). It is not clear howHCV-specificmem-
ory CD4 and CD8 T cells are maintained for prolonged periods.
Apart fromtheir intrinsic long-livedproperties and transcriptional
profile, memory T cells can be maintained through homeostatic
proliferation in response to the g-chain cytokines IL-7, IL-15, and
IL-21 (239, 240). They may also be maintained through periodic
restimulation with cross-reactive viral or self-antigens. Finally, it
is possible that minor quantities of HCV RNA are maintained for
a prolonged period following viral clearance and contribute to
periodic restimulation of such memory T cells (241, 242).
The protective role of HCV-specific immunological memory
is difficult to address in humans. Nevertheless, epidemiological
studies demonstrated that high risk IDUs who have spontaneously
resolved one HCV infection were less likely to be reinfected than
HCV-naïve individuals despite repeated high risk exposures (243–
246), but the reported rate of incidence of reinfectionswas variable
because of the different HCV RNA testing interval where rein-
fections of shorter duration or accelerated viral clearance may
have been missed (247). Other factors include differences in the
characteristics of individual subjects, as age, ethnicity, and risk
behaviors (247). Nevertheless, the rate of spontaneous clearance
of reinfectionwas higher than that for primary infection (243, 245,
248). This provided preliminary evidence of protective immunity
against HCV. Osburn et al. monitored a group of high risk IDUs at
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FIGURE 2 | Summary of innate and adaptive immunity during primary
HCV infection. (1) HCV entry and replication inside hepatocytes induces the
production type I and type III IFNs that are also secreted by pDCs and
create an antiviral state in infected hepatocytes and neighboring cells and
stimulate NK cells that kill infected hepatocytes. (2) Liver resident and
migratory APCs (Kupffer cells and DCs) uptake apoptotic bodies from
destroyed HCV-infected hepatocytes and present HCV-derived epitopes to
both CD4 and CD8T cells in the context of MHC class II and MHC class I,
respectively. (3) The cross-talk between DCs and NKs regulates the function
of both cells enhancing antigen presentation and priming, as well as
NK-mediated killing. (4) CD4 helper T cells support responses of CD8T cells
and B cells through production of Th1 andTh2 cytokine, respectively. (5)
Whether Abs produced from B cells during primary infection have an
essential role in viral clearance by directly neutralizing the virus or by
mediating ADCC is not fully understood, and the role of Tfh cells in this
process is still unknown. (6) CD8T cells eliminate HCV-infected cells
through direct cytotoxic mechanisms (cytolytic granules, as perforin and
granzyme) or non-cytolytic mechanisms through secretion of the antiviral
cytokines IFNg andTNFa. (7) CD8T cell functions are sustained and
enhanced by IL-21 mainly produced byTh17 cells. IL-21 is also essential to
rescue virus-specific T cells from exhaustion caused by persistent exposure
to HCV antigens. Reduced IL-21 production or Th17 cell numbers results in
an increased exhaustion status and expression of exhaustion markers like
PD-1, Tim-3, CTLA-4, and others. (8) Regulatory T cells might be a cause in
the failure of the primary immune response by secreting the regulatory
cytokinesTGFb, IL-10, or secretion of Gal-9 that enhances apoptosis of
Tim-3+ CD4 and CD8T cells. ADCC, antibody-dependent cellular
cytotoxicity; APC, antigen-presenting cell; CTLA-4, cytotoxic T lymphocyte
antigen-4; DC, dendritic cell; FcR, receptor for the constant fragment of the
antibody; Gal-9, galactin-9; Gz, granzyme; HCV, hepatitis C virus; IFN,
interferon; IL, interleukin; NK, natural killer; PD-1, Programed death-1; pDC,
plasmacytoid DC; Tfh, T follicular helper cells; TGF, transforming growth
factor; Th17, T-helper 17 cell; Tim-3, T cell immunoglobulin and mucin domain
3; TNF, tumor necrosis factor; Treg, regulatory T cell.
monthly intervals and observed a rate of reinfection at almost 50%
(11/22). Spontaneous clearance of reinfection was associated with
broadened T cell responses and generation of cross-reactive Ab
responses (248). However, phenotypic and polyfunctional char-
acterization of HCV-specific memory CD4 and CD8 T cells was
not performed. In this study, 10/11 subjects examined resolved
the second infection, thus a control group of unprotected patients
that would enable the definition of the exact correlates of protec-
tion was lacking. Preliminary work from our group suggests that
protection fromHCV persistence upon reinfection is variable and
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associated with expansion of HCV-specific memory CD8 T cells
that are polyfunctional in nature with expansion of a CD127lo
population consistent with effector memory T cells (249).
Early treatment of HCV could rescue long-lived HCV-specific
memory CD4 and CD8 T cells (146, 176, 189) but the protective
role of natural T cell memory generated after viral clearance versus
treatment induced memory generated after therapeutic-mediated
clearance remains to be evaluated. An equally protective memory
immune response would argue in favor of early treatment of high
risk individuals as this will provide them with long-term protec-
tion if they are reexposed. Comparison of the capacity of the new
DAAs and/or IFN free regimens to rescue such protective memory
responses should also be evaluated.
In summary, long-lived T cell memory responses are generated
following spontaneousHCVclearance anddata fromchimpanzees
and limited human studies suggest that they canprovide somepro-
tection. However, the signatures of a protective immune response
upon reexposure are far less defined, especially in terms of the
phenotype and functionality of HCV-specific protective mem-
ory immune responses. We propose a model inferred from our
current knowledge of protective immunity during acute primary
HCV infection (Figure 3). We hypothesize that protection upon
reexposure is associatedwith themaintenance of higher frequency,
breadth, and polyfunctionality of HCV-specificmemory CD4 and
CD8 T cells. Such long-lived memory T cells are likely main-
tained through homeostatic proliferation in response to g-chain
cytokines. Upon reexposure, these memory T cells expand rapidly
and eliminate the infecting virus. Similar to murine models of
viral infections, repeated exposure will select for the virus-specific
memory T cells with the highest proliferative capacity and func-
tional avidity (250). It is likely that such long-livedmemory T cells
will acquire a genomic signature that will facilitate their capac-
ity to expand rapidly and effectively upon reexposure. Individuals
who cannot maintain such long-lived, broad, and polyfunctional
memory T cells because of reduced homeostatic cytokine or pro-
liferation or predisposition to generation of Tregs and increased
T cell exhaustion are less likely to be protected upon reexpo-
sure. Host genetics, nAbs and homology between the infecting
viral strains during primary and secondary infection can tip
the balance toward viral clearance or persistence of the second
infection.
Protective immunity in the context of real life exposure remains
the most understudied area of HCV due to the limited number
of organized high risk cohorts suitable for such studies and the
need for follow-up at close intervals to detect multiple infection
episodes (247). Concerted efforts to study such response on a
large scale in matched cohorts with different ethnic backgrounds
are underway and should yield important knowledge in the future
(251, 252). In addition, the organization and characterization of
such cohorts provides the perfect setup to evaluate vaccine can-
didates. Use of novel genomic and proteomic tools should yield
better insights about the pathways involved in protective immu-
nity. Comparative analysis of virus-specific cellular and humoral
responses in relation to variations in the infecting viral strain
is essential to understand the interplay between the virus and
immune system and cross-protective immunity.
IMPLICATIONS FOR VACCINE DEVELOPMENT
The need of a prophylactic HCV vaccine to prevent viral transmis-
sion remains an urgent need to reduce the future disease burden
worldwide (11). The plethora of data suggesting that cellular
immunity is the major armmediating spontaneous clearance dur-
ing primary HCV infection led to the assumption that it should be
the target for vaccine development. Nevertheless, the recent data
on the role of nAbs in resolution of primary infection suggest a
possible contribution of humoral immunity in both primaryHCV
clearance and prophylaxis.
There are two challenges facing the development of HCV vac-
cines. First, the genetic diversity of HCV sequences and its high
rate of mutability. Second, the ability of HCV proteins to dis-
rupt and evade the different arms of the immune system. This
necessitates the design of an effective vaccine that generates mem-
ory immune cells capable of mounting a prompt recall response
upon reexposure to diverse HCV strains in a fashion that out-
paces the virus and prohibits it from crippling the immune
system.
Three major approaches have been adopted for vaccine design
againstHCV. The traditional approach uses recombinant envelope
proteins to induce nAbs. It has gained more potential recently
with the discovery of broadly nAbs. Vaccination with recombi-
nant E1/E2 proteins was shown to induce cross-reactive nAbs that
might contribute to protective immunity upon exposure to HCV
(253–255). The second approach uses virus-like particles (VLPs)
that express HCV structural proteins to induce both humoral and
cellular immunity, but it failed to induce humoral responses when
tested in chimpanzees. Furthermore, upon homologous rechal-
lenge 2/4 vaccinated chimpanzees demonstrated sporadic very low
levels of viremia during 1 year of follow-up (256). The third and
most promising approach is designing anHCV vaccine that would
induce a potent T cell immune response. Replication-defective
recombinant viral vectors [e.g., adenovirus (Ad), vaccinia virus
(VV),modified vacciniaAnkara (MVA)]were used to deliverHCV
antigens to prime T cell responses. Another promising vector that
was successful in the simian immunodeficiency virus (SIV)model,
but has not yet been tested inHCV is cytomegalovirus (257). HCV
proteins could also be deliveredusingDNAvaccines,where recom-
binant plasmids expressing various proteins could be injected into
the host [reviewed in Ref. (11)].
A combination of viral vector prime and DNA or recombi-
nant protein boost is preferred to prevent neutralization of the
subsequent boosts by vector-specific antibodies that could have
been generated during priming. Two candidate vaccines using
this strategy showed promising preliminary results and are at an
advanced stage of development. The first vaccine uses heterolo-
gous prime/boost regimens with chimpanzee adenovirus Ad3Ch3
and a rare strain of human adenovirus (Ad6) expressing the entire
NS region of genotype 1b BK strain (NS3-5B). This vaccine was
tested in a phase I clinical trial in humans (ClinicalTrials.gov
NCT01436357). Both vectors primed broad CD4 and CD8 T cell
responses that were capable of responding to heterologous strains
of HCV genotypes 1a and 3a. Polyfunctional HCV-specific T cells
(IL-2+ IFNg+ TNFa+) could be sustained for at least a year
after boosting with the heterologous vector (258). This vaccine
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FIGURE 3 | Hypothetical model for protective and non-protective
immunity upon HCV reinfection. Individuals who spontaneously clear
primary HCV infection develop long-lived virus-specific memory CD4 and
CD8T cells. Such memoryT cell populations are maintained by the action of
homeostatic cytokines like IL-7, IL-15, and IL-21. Upon HCV reinfection,
some individuals will be protected against viral persistence while others will
be unprotected. (A)The protected individuals will be able to spontaneously
clear the second infection with a shorter period of viremia and reduced peak
viremia. Viral clearance will be accompanied by an accelerated memoryT
cell recall response detectable in both liver and blood. The exact
characteristics of a protective response are yet to be defined in terms of
breadth and quality. (B) In unprotected individuals, reinfection will be
associated with a weak or late recall response and incomplete T
cell-mediated control of viremia. The underlying causes of failure to resolve
the reinfection despite the ability to spontaneously resolve a prior infection
maybe low levels of homeostatic cytokines affecting the maintenance of
memory T populations, reduced breadth, or quality of the recall response
upon reinfection and increased frequency of Tregs leading to dampening of
the immune response, viral persistence, and rapid exhaustion of
HCV-specific T cells. Neutralizing antibodies, host genetics, and homology
between the infecting viral sequences at different episodes may play a role
in protection upon reinfection.
is currently in a phase II trial in high risk IDUs. The second vac-
cine uses a regimen of priming with Ad6 encoding NS3-5B of
genotype 1b BK strain and boosting with NS3-5B-encoding plas-
mid DNA. A study in chimpanzees that received this vaccine then
challenged with HCV demonstrated that control upon HCV chal-
lenge following vaccination was associated with CD127+ PD-1lo
CD8 T cells that persisted at high levels for prolonged period and
were bifunctional (IFNg+ TNFa+). Nevertheless, three out of five
chimpanzees were not protected suggesting that a more efficient
immune response may be required (237, 259).
Correlates of protective immunity against HCV need to be
clearly defined so that they could be monitored following vac-
cination to predict the degree of protection that may be con-
ferred. This should involve characterization of the genomic and
proteomic pathways involved and identification of biomarkers
that can be used as benchmarks to monitor vaccine success in
a non-invasive way. Strategies targeting both cellular and humoral
immunity are likely to be more successful (260). The use of
immune modulators like PD-1 blockers, TLR agonists, or mod-
ulators of biological pathways like transcription factors involved
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in memory T cell generation may be useful as vaccine adjuvants
to enhance immunogenicity and favor the development of the
desirable immune response (250).
FUTURE RESEARCH DIRECTIONS
There is a general misconception that this is the end of HCV and
that the new treatments will completely eliminate HCVwithin the
next few years. Unfortunately, this is highly unlikely since the new
DAAs remain expensive and are associated with a fair number of
side effects. Moreover, their use in special populations like indi-
viduals with advanced liver disease or HIV coinfection remains
experimental and limited at this point. Most importantly,many of
the individuals infected with HCV have not been tested and con-
tinue to infect others. Future research should focus on the many
shades of gray that still cloud our understanding of what consti-
tutes a long-term protective immune response and the interaction
between the virus and the host. This requires the use of orga-
nized and well characterized cohorts and standardized methods
to evaluate immunity on a large scale with sufficient statistical
power. Areas of interest involve better understanding of the role of
genetic predictors of HCV outcome like IL28B and IFNL4 in viral
clearance and long-term protection; understanding the nature of
CD4 T cell help for both CD8 T cells and antibody producing B
cells; elucidation of the role of neutralizing and non-nAbs during
primary and secondary HCV infections; development of better
small animal models for preclinical testing of vaccines and the
use of novel genomics and proteomics tools to identify implicated
pathways and non-invasive markers of efficient immune response.
Collaboration with other fields, including research on vaccines for
other viruses like yellow fever virus and HIV, as well as work with
more physiologically relevant in vitro models like primary hepa-
tocytes should provide a clearer image of the protective immunity
against HCV and better success for ongoing and future vaccine
development strategies.
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AWARDS AND PRIZES: 
July 2014  Travel Award  21st International Symposium on HCV &  
Related Viruses. Banff, Canada. Sept, 2014 
 
      
Mar 2014  Oral Presentation Prize  Journée Dépt. Microbiologie et 
Immunologie, Université de Montréal 
 
      
Mar 2013  Basic Research Award 
 
 Canadian Association for the Study of 
the Liver (CASL) 
 
      
Dec 2012  Poster Presentation Prize  Journée de Recherche, CRCHUM  
      
Nov 2012  Oral Presentation Prize  Journée du Réseau SIDA/MI du FRSQ  
      
Aug 2012  Bill & Melinda Gates 
Foundation Global Health 
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 Keystone Symposium for Immunological 
Mechanisms of Vaccination. Ottawa, 
Canada. Dec, 2012. 
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Mar 2010  Basic Research Award  CASL  
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 Egyptian Cultural and Educational 
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 16th International Symposium on HCV & 
Related Viruses. Nice, France. Oct, 2009. 
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 Egyptian Student Association of North 
America (ESANA) 
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graduating at the top 2% 
 The Arab Co. for Pharmaceutical and 
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HONOURS AND CREDENTIALS: 
 
Jun  2010  Dean’s Honours list  
(M.Sc. graduation) 
 Faculté des études superieur et postdoctorales, 
Université de Montréal 
     
Jun 2010  Dean’s Honours list  
(M.Sc. graduation) 
 Faculté de médecine,  
Université de Montréal 
     
April 2009  M.Sc. thesis chosen as one of   
the top 10% in the discipline 
 Jury of the M.Sc. thesis 
 
     
July 1999  Licence of practicing pharmacist  Egyptian Pharmacists Syndicate 
     
May 1999  Dean’s Honours list  
(B.Pharm. graduation) 
 Faculty of Pharmacy,  
Cairo University 
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CONTRIBUTION TO SCIENTIFIC NOTES: 
 
1. Participating in the preparation of the scientific notes for the practical studies in the 
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Microbiology and Immunology, Faculty of Pharmacy, Cairo University, 2006.  
 
REVIEWING ACTIVITY: 
1. Member of the reviewing committee for the 2nd Canadian HCV Symposium, 2013. 
 
TECHNICAL EXPERTISE AND TRAINING: 
 
• Cell biology techniques: Tissue culture, working with human patients’ samples, 
working with infectious material under BSL2 and BSL3 conditions.  
• Immunological flow cytometry techniques: Intracellular staining (ICS), proliferation 
assays (CFSE dilution), tetramer staining and cell-sorting techniques using BD LSR II 
multiparameter flow cytometer, and analysis using FlowJo® and SPICE® software. 
Other Immunological techniques: Enzyme linked immunospot (ELISpot) assays and  
Immune Flourescence (IF).   
• Virological techniques: viral RNA extraction, culturing infectious virion particles in 
vitro and design of chimeric plasmids.  
• Molecular biology techniques: PCR, Real-time PCR, DNA sequencing, cloning, 
protein separation, immunoblotting, using Lasergene® software for the analysis of 
mutations, design of cloning strategies and primers.  
• Basic bacteriological techniques: bacterial culture, bacterial counting, bacterial 
identification, biochemical reactions and assessment of antimicrobial activity. 
 
• Training on viral neutralization techniques at the laboratory of Dr. Michael Houghton, 
Li Ka Shing Institute of Virology, University of Alberta. April, 2013. 
• Training on viral culture techniques at the laboratory of Dr. Arash Grakoui, Emory 
Vaccine Centre, Emory University, Atlanta, GA, USA. February, 2011. 
 
 
 
 
 
 
 
 
